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General introduction
Background
Diabetes	mellitus	(DM)	is	the	most	common	endocrine	disease	worldwide,	and	is	pri-
marily	defined	by	the	level	of	hyperglycemia.	Current	diagnostic	criteria	for	the	presence	
of	DM	as	recommended	by	the	American	Diabetes	Association	are:
1:		fasting	(no	caloric	 intake	for	at	 least	8	hours)	venous	plasma	glucose	concentration	
≥ 7.0 mmol/l, or 
2:	symptoms	of	hyperglycemia	and	a	casual	plasma	glucose	≥	11.1	mmol/l,	or	
3:		two	hour	plasma	glucose	≥	11.1	mmol/l	after	an	oral	glucose	tolerance	test.1
Recent	estimates	indicate	that	there	were	171	million	people	in	the	world	with	diabetes	
in the year 2000, and this was projected to increase to 366 million by 2030.2 In 2005, an 
estimated	1.1	million	people	died	from	the	complications	of	DM of which almost half of 
the	deaths	occurred	in	people	under	the	age	of	70	years.	55%	of	DM	related	deaths	were	
in women.3	The	estimated	prevalence	of	diabetes	in	the	Netherlands	in	2030	is	5.1%,	
based	on	an	estimated	population	of	12.5	million	people	aged	between	20-79	years.4 
The	total	amount	of	healthcare	costs	for	patients	with	DM	in	2005	in	the	Netherlands	
was 814 million euro, 1.2% of the total healthcare costs.5 
DM	can	be	classified	into	DM	type	1	and	DM	type	2.	DM	type	1	(also	called	type	1	dia-
betes,	T1D,	T1DM,	insulin-dependent	DM,	juvenile	diabetes)	is	an	autoimmune	disease,	
which	results	in	the	destruction	of	insulin-producing	ß	cells	of	the	pancreas.	Lack	of	insu-
lin	causes	an	increase	in	fasting	blood	glucose,	which	begins	to	appear	in	the	urine	once	
above	the	renal	threshold.	Glycosuria	or	glucose	in	the	urine	causes	the	patient	to	uri-
nate	more	frequently,	and	drink	more	than	normal	(polydipsia).	Classically,	these	were	
the	characteristic	symptoms	which	prompted	the	discovery	of	the	disease.	DM	type	2	
(formerly	called	non-insulin-dependent	or	adult-onset	DM)	results	from	the	body’s	inef-
fective	use	of	insulin,	and	is	characterized	by	high	blood	glucose	in	the	context	of	insulin	
resistance	and	relative	insulin	deficiency.	DM	type	2	comprises	90%	of	all	diabetic	people	
worldwide,	and	is	largely	the	result	of	excess	body	weight	and	physical	inactivity.	While	
it	is	initially	often	managed	by	increasing	exercise	and	dietary	modification,	medications	
are	usually	needed	as	the	disease	progresses.	Furthermore,	DM	type	2	is	often	associ-
ated	with	 obesity,	 hypertension	 and	 elevated	 cholesterol	 (combined	hyperlipidemia),	
often	 termed	as	 the	metabolic	 syndrome.	 Symptoms	may	be	 similar	 to	 those	of	DM	
type	1,	but	are	often	less	marked.	Long	term	complications	of	DM	include	microvascular	
damage	(the	eyes,	kidneys	and	peripheral	nerves)	and	macrovascular	injuries	(ischemic	
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heart	disease,	stroke	and	peripheral	vascular	disease).	These	complications	reduce	life	
expectancy	and	quality,	and	significantly	 increase	morbidity.	Due	to	the	often	masked	
symptoms	of	DM	type	2,	the	disease	may	only	be	diagnosed	several	years	after	onset	
when	complications	have	already	occurred.	Often,	 the	prognosis	of	patients	with	DM	
depends	on	 the	presence	of	 cardiovascular	disease.	Coronary	artery	disease	 (CAD)	 is	
the	 leading	cause	of	morbidity	and	mortality	 in	 individuals	with	DM	type	2.6 The 10-
year	mortality	rate	in	patients	with	known	CAD	and	diabetes	exceeds	70%.7 Some stud-
ies	suggested	that	the	risk	for	future	cardiac	death	in	patients	with	DM	without	known	
CAD	is	similar	to	that	in	nondiabetic	patients	with	overt	clinical	CAD.7	In	addition,	early	
and	late	outcomes	of	diabetic	patients	with	acute	coronary	syndromes	are	worse	than	
those	of	their	nondiabetic	counterparts.	To	compound	the	problem,	CAD	is	frequently	
in	 an	advanced	 state	 in	diabetic	patients	when	 it	manifests	 clinically,	 and	myocardial	
ischemia	is	often	asymptomatic	in	these	patients.8, 9	The	aforementioned	adverse	clini-
cal	outcomes	in	patients	with	DM	underscore	the	need	to	develop	practical	approaches	
to	detect	CAD	in	an	earlier	stage	before	clinical	symptoms	occur.	Early	detection	of	CAD	
and myocardial ischemia may be important to reduce the burden of cardiovascular dis-
ease,	morbidity	and	mortality	in	asymptomatic	patients	with	DM	type	2.	Identification	
of	these	asymptomatic	diabetic	patients	is	important	as	early	intervention	may	improve	
long	term	survival.	From	a	clinical	perspective,	patients	with	high	risk	characteristics	on	
testing	for	myocardial	 ischemia	may	benefit	from	coronary	revascularization.	With	re-
gard	to	pharmacological	therapy,	the	knowledge	that	a	patient	with	diabetes	has	CAD	
may	 indicate	the	need	to	 initiate	or	 intensify	pharmacological	treatment	with	aspirin,	
statins	and	ACE	 inhibitors.	A	number	of	noninvasive	tests	are	now	available	to	detect	
myocardial	ischemia,	coronary	atherosclerotic	disease,	cardiac	nervous	innervation	and	
left	ventricular	dysfunction.	In	this	thesis,	several	cardiac	imaging	techniques	were	used	
for	risk	stratification	of	asymptomatic	patients	with	DM	type	2.
Myocardial perfusion imaging by single photon emission computed tomography
Myocardial	perfusion	imaging	(MPI)	is	a	functional	cardiac	imaging	method	used	to	diag-
nose	ischemic	heart	disease.	The	underlying	principle	is	that	under	conditions	of	stress,	
diseased	myocardium	receives	less	blood	flow	than	normal	myocardium.	A	cardiac	spe-
cific	radiopharmaceutical	(Technetium-99m,	99mTc)	is	administered.	Thereafter,	the	heart	
rate is increased either by exercise or pharmacologically with adenosine, dobutamine or 
dipyridamole to induce myocardial stress. Pharmacological stress can be used for diabet-
13
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ic	patients,	who	cannot	achieve	maximal	cardiovascular	stress	because	of	polyneuropa-
thy or peripheral artery disease. Single photon emission computed tomography (SPECT)	
is	a	nuclear	medicine	tomographic	imaging	technique	that	uses	gamma	rays	emitted	by	
the	injected	radiopharmaceutical.	SPECT	imaging	is	performed	by	using	a	gamma	cam-
era	to	acquire	multiple	2-dimensional	images	from	multiple	angles.	A	computer	is	used	
to	apply	a	tomographic	reconstruction	algorithm	to	the	multiple	projections,	yielding	a	
3-dimensional dataset. This dataset may then be manipulated to show thin slices along 
any	chosen	axis	of	 the	body.	To	acquire	SPECT	 images,	 the	gamma	camera	 is	 rotated	
around	the	patient.	Projections	are	acquired	at	defined	points	during	the	rotation,	typi-
cally	every	3	to	6	degrees.	In	most	cases,	a	full	360	degree	rotation	is	used	to	obtain	an	
optimal	reconstruction.	The	time	taken	to	obtain	each	projection	 is	also	variable,	but	
15	till	20	seconds	are	typical.	This	gives	a	total	scan	time	of	15	until	20	minutes.	SPECT	
imaging	performed	after	stress	reveals	the	distribution	of	the	radiopharmaceutical,	and	
therefore	the	relative	blood	flow	to	the	different	regions	of	the	myocardium.	Diagnosis	
is made by comparing stress images to a set of images obtained at rest. Homogeneous 
myocardial uptake of the tracer indicates normal myocardium and perfusion. Absence of 
the	tracer	means	clinically	significant	infarction	or	coronary	stenosis.	A	defect	at	stress	
images	that	normalizes	at	the	rest	images	indicates	an	inducible	perfusion	abnormality,	
and	it	corresponds	to	a	significant	coronary	stenosis.	A	defect	both	at	stress	and	rest	im-
ages	(a	fixed	defect)	indicates	an	area	with	loss	of	viable	myocardium,	such	as	secondary	
to	myocardial	 infarction.	Cardiac-gated	acquisitions	are	possible	with	SPECT.	Triggered	
by	the	electrocardiogram	to	obtain	differential	 information	about	the	heart	 in	various	
parts	of	its	cycle,	gated	myocardial	SPECT	can	be	used	to	obtain	quantitative	informa-
tion	about	myocardial	perfusion,	thickness,	and	contractility	of	the	myocardium	during	
various	parts	of	the	cardiac	cycle.	 It	also	allows	calculation	of	 left	ventricular	ejection	
fraction,	stroke	volume,	and	cardiac	output.10
Multislice computed tomography coronary angiography and calcium scoring
Multislice	computed	tomography	(MSCT)	coronary	angiography	is	a	noninvasive	imag-
ing	technique	which	can	visualize	the	coronary	arteries	and	detect	significant	stenoses.	
The	 latest	generation	64-slice	computed	 tomography	scanner	allows	high	 resolution	
and	nearly	motion-free	coronary	 imaging.	Coronary	stenoses	are	detected	with	high	
sensitivity	and	a	normal	scan	accurately	rules	out	the	presence	of	significant	coronary	
stenoses.11	To	achieve	images	of	good	quality,	patients	need	to	be	prepared	with	an	in-
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travenous	cannula	for	contrast	injection.	Also	one	hour	before	the	scan,	beta-blockers	
may	be	needed	 to	 slow	 the	heart	 rate	 and	 improve	 image	quality.	 An	optimal	 scan	
protocol	has	to	be	performed	to	result	in	a	high	spatial	resolution	and	a	high	temporal	
resolution	scan	with	low	radiation	exposure	to	the	patient.12	First,	a	calcium	score	with-
out	contrast	 can	be	obtained,	using	prospective	electrocardiographic	 triggering.	The	
presence	of	calcium	serves	as	a	marker	for	the	presence,	location	and	extent	of	calci-
fied	plaque	in	the	coronary	arteries.	Because	calcium	is	a	marker	for	CAD,	the	amount	
of	calcium	detected	on	a	cardiac	CT	scan	is	a	helpful	prognostic	tool.	Coronary	artery	
calcium	(CAC)	can	be	identified	as	a	dense	area	at	the	location	of	a	coronary	artery	ex-
ceeding	the	threshold	of	130	Hounsfield	units.	The	amount	of	calcification,	expressed	
as	the	calcium	score,	may	help	to	predict	the	likelihood	of	a	myocardial	infarction.	An	
overall	 (Agatston)	 score	 for	each	coronary	artery	and	each	patient	can	be	 recorded,	
grading	the	extent	of	CAD.	The	CAC	score	scan	can	be	followed	by	64-slice	MSCT	coro-
nary	angiography	performed	during	electrocardiographic	gating	and	the	administration	
of	non-ionic	contrast	(50-100	ml).	The	whole	scanning	process	is	completed	after	10-15	
minutes.	Large	amounts	of	data	are	obtained	and	transferred	to	a	remote	workstation	
for	post	processing	and	subsequent	evaluation.	The	MSCT	coronary	angiography	 im-
ages	can	be	evaluated	visually	for	the	presence	of	luminal	stenoses	and	plaque	char-
acterization.13    
123I‑metaiodobenzylguanidine myocardial scintigraphy
123I-metaiodobenzylguanidine	(123I-mIBG)	is	a	neurotransmitter	and	analogue	of	norepi-
nephrine. 123I-mIBG	myocardial	scintigraphy	is	an	imaging	modality	that	allows	evalua-
tion	of	cardiac	sympathetic	innervation	in	vivo.	It	enables	both	the	assessment	of	global	
as	well	 as	 regional	 cardiac	 sympathetic	 innervation	by	visualization	of	 the	uptake	and	
storage	of	radiolabeled	neurotransmitters	to	presynaptic	nerve	terminals.	After	blocking	
thyroid uptake, 123I-mIBG	is	intravenously	injected	at	rest.	Fifteen	minutes	post	injection;	
anterior	planar	images	of	the	chest	are	acquired	and	stored	in	a	256	x	256	matrix.	There-
after,	a	360	°	SPECT	study	is	acquired	using	a	gamma	camera	(4˚/step,	35	seconds/pro-
jection,	128	x	128	matrix).	Repeated	planar	and	SPECT	studies	are	acquired	at	approxi-
mately	4	hours	post-injection.	Early	(15	minutes	post-injection)	and	late	(4-hour	delayed)	
planar	images	are	processed	to	determine	the	heart-to-mediastinum	ratio	(HMR).	The	
planar mIBG	images	are	analyzed	using	regions	of	interest	(ROI)	to	calculate	the	uptake	
ratios	and	washout	percentages.	Therefore,	a	ROI	is	drawn	manually	over	the	left	ven-
15
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tricle.	A	second	rectangular	ROI	is	drawn	over	the	upper	mediastinum	and	the	opposite	
arm	and	used	as	a	reference	background	region.	The	HMR	of	average	counts	per	pixel	
is	calculated	for	the	early	and	delayed	images.	After	correcting	for	the	physical	decay	of	
123I,	early	and	delayed	HMR	values	are	then	used	to	compute	the	myocardial	washout	
ratio	 (WR)	of	mIBG	as	 follows:	WR=	 [early	heart	 counts-early	mediastinum	counts]	 –	
[delayed	heart	counts-delayed	mediastinum	counts]	 /	 [early	heart	counts-early	medi-
astinum	counts]	x	100%.	Polar	map	formats	 (normalized	to	100%)	are	used	 for	visual	
interpretation	and	semi-quantitative	analysis.	
Global left ventricular strain
Global	left	ventricular	longitudinal	strain	using	automated	functional	imaging	(AFI),	pro-
vides	a	new	imaging	technique	based	on	two-dimensional	strain	imaging.14	The	software	
analyzes	motion	by	tracking	speckles	(natural	acoustic	markers)	in	the	ultrasonic	image	
in two dimensions. The frame-to-frame changes of the speckles are used to derive mo-
tion	and	velocity.	For	 this	purpose,	one	single	cardiac	cycle	 is	needed	 from	each	api-
cal	view	(apical	long	axis,	four-	and	two-chamber	views).	First,	the	end-systolic	frame	is	
defined	in	the	apical	long-axis	view.	The	closure	of	the	aortic	valve	is	marked,	and	the	
software	measures	the	time	interval	between	R-wave	and	aortic	valve	closure.	This	in-
terval	is	used	as	a	reference	for	the	four-	and	two-chamber	view	loops.	After	defining	the	
mitral	annulus	and	the	left	ventricular	apex	with	three	index	points	at	the	end-systolic	
frame in each apical view, the automated algorithm traces three concentric lines on the 
endocardial	border,	the	mid-myocardial	layer	and	epicardial	border,	including	the	entire	
myocardial wall. The tracking algorithm follows the endocardium from this single frame 
throughout the cardiac cycle, and allows for a further manual adjustment of the region 
of interest to ensure that all myocardial regions are included throughout the cardiac 
cycle.	The	left	ventricle	is	divided	in	6	segments	in	each	apical	view	and	the	tracking	qual-
ity	is	validated	for	each	segment.	Then,	the	myocardial	motion	is	analyzed	by	speckle-
tracking	within	the	ROI.	Finally,	 the	automated	algorithm,	using	a	17-segment	model,	
provides	the	peak	systolic	longitudinal	strain	for	each	left	ventricular	segment	in	a	“bull‘s	
eye” plot, with the average value of peak systolic longitudinal strain for each view and 
the	averaged	global	 longitudinal	peak	systolic	strain	for	the	complete	left	ventricle.	 In	
general,	 longitudinal	 strain	values	are	presented	as	negative	values;	a	 larger	negative	
value	indicates	more	longitudinal	shortening.	For	strain	analysis,	digital	cine-loops	are	
processed	off-line	using	commercially	available	software.
16
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Study population
From	May	2005,	DM	type	2	patients	who	were	asymptomatic	for	CAD	and	had	≥1	risk	
factor	for	CAD	were	referred	from	an	outpatient	diabetic	clinic	in	The	Hague	(Diabetes	
Zorg	Haaglanden)	to	the	Leiden	University	Medical	Center	for	cardiac	risk	stratification.	
First,	the	patients	were	seen	at	the	outpatient	cardiology	clinic	and	were	confirmed	as	
being	asymptomatic	using	the	Rose	questionnaire.15	Furthermore,	a	physical	examina-
tion,	 blood	 analysis	 and	 standardized	 2-dimensional	 transthoracic	 echocardiography	
were	performed.	Every	eligible	patient	underwent	MPI	by	SPECT,	MSCT	coronary	angi-
ography	and	CAC	scoring.	In	patients	with	normal	MPI,	123I-mIBG	myocardial	scintigra-
phy	was	performed.	Depending	on	the	results	of	these	investigations,	pharmacological	
therapy	was	started.	If	necessary,	the	patients	were	referred	for	invasive	coronary	an-
giography,	possibly	followed	by	percutaneous	coronary	intervention	or	coronary	artery	
bypass	grafting.	After	the	initial	investigations,	all	patients	were	seen	at	the	outpatient	
cardiology	clinic	every	year.	These	visits	included	an	ECG	and	physical	examination.	Two	
years	after	the	initial	visit,	a	second	MPI	by	SPECT,	transthoracic	echocardiography	and	
blood	analysis	were	performed.	All	data	were	systematically	and	prospectively	entered	
in a database. The extensive database formed the basis for the studies presented in this 
thesis.	At	the	time	of	writing	this	thesis,	patients	are	still	followed-up.						
aim and outline of this thesis
The	aim	of	this	thesis	was	to	investigate	the	role	of	noninvasive	cardiac	imaging	modali-
ties	to	identify	asymptomatic	DM	type	2	patients	with	increased	cardiovascular	risk.	For	
this	purpose	we	used	the	data	obtained	from	the	earlier	mentioned	database.
In chapter 2,	we	focused	on	the	potential	roles	of	stress	MPI	and	computed	tomography	
CAC	 scoring	 as	 two	 complementary	 approaches	 for	 screening	 asymptomatic	 patients	
with	diabetes.	 In	addition,	on	the	basis	of	the	available	evidence	in	the	literature,	we	
proposed	a	potential	algorithm	for	this	purpose.
Chapter 3 describes an	observational	study	that	prospectively	evaluated	the	compara-
tive	prevalence	of	the	presence	of	coronary	atherosclerosis	by	stress	SPECT,	CAC	scoring	
and	MSCT	coronary	angiography,	and	their	diagnostic	interrelationships	in	asymptom-
atic	patients	with	DM	type	2.
The	prevalence	of	CAD	in	a	large	cohort	of	asymptomatic	patients	with	DM	type	2	us-
ing MSCT coronary angiography was evaluated in chapter 4.	Furthermore,	the	plaque	
17
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composition	of	the	coronary	lesions	was	also	evaluated,	and	the	relationship	between	
calcium scoring and noninvasive angiography was explored.
The purpose of the study in chapter 5 was to evaluate the prevalence of an abnormal 
stress	MPI	study	in	a	cohort	of	truly	asymptomatic	patients	with	DM	type	2	using	MPI	by	
SPECT.	Secondly,	we	determined	which	clinical	characteristics	may	predict	an	abnormal	
stress	MPI	study	in	this	population,	indicating	the	presence	of	cardiovascular	disease.
In chapter 6,	the	difficulty	of	adequate	risk	stratification	for	patients	with	asymptomatic	
diabetes	was	illustrated	in	a	case	report	of	an	asymptomatic	DM	type	2	patient,	who	suf-
fered	a	silent	myocardial	infarction	after	the	initial	screening.
The aim of the study described in chapter 7	was	 to	evaluate	whether	 subclinical	 left	
ventricular	systolic	dysfunction	was	independently	related	to	coronary	atherosclerosis.	
Furthermore,	it	was	investigated	whether	it	could	provide	incremental	information	over	
baseline	characteristics	to	identify	patients	with	coronary	atherosclerosis.	
In chapter 8 we describe the prevalence of cardiac autonomic neuropathy in a cohort 
of	truly	asymptomatic	patients	with	DM	type	2	using	heart	rate	variability	and	123I-me-
taiodobenzylguanidine	myocardial	scintigraphy.
Chapter 9 contains the summary and conclusions of the results of this thesis.
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Screening of asymptomatic patients 
with type 2 diabetes mellitus for silent 
coronary artery disease. Combined use of 
stress myocardial perfusion imaging and 
coronary calcium scoring
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abstract
Diabetes	mellitus	and	coronary	artery	disease	constitute	an	ominous	clinical	combina-
tion.	Rates	of	morbidity	and	mortality	as	a	 result	of	 cardiovascular	 complications	are	
high	in	patients	with	type	2	diabetes	mellitus.	Screening	for	silent	coronary	artery	dis-
ease,	to	detect	the	disease	in	an	early	stage	and	to	be	able	to	initiate	early	appropriate	
treatment,	has	recently	become	an	important	focus	of	clinical	investigation.	Recent	pro-
spective	studies	have	shown	that	the	overall	prevalence	of	silent	coronary	artery	disease	
in	truly	asymptomatic	 individuals	with	diabetes	 is	about	20%	to	25%.	 It	 is	of	practical	
and	clinical	importance	to	explore	ways	to	“enrich”	the	target	screening	population.	In	
this	editorial	point	of	view	the	relative	roles	of	stress	radionuclide	myocardial	perfusion	
imaging and coronary calcium scoring are examined. The two methodologies appear to 
have	complementary	values	for	the	screening	of	asymptomatic	individuals	with	diabetes	
mellitus.	A	screening	algorithm	involving	sequential	use	of	coronary	calcium	scoring	and	
subsequent	stress	radionuclide	myocardial	perfusion	imaging	is	proposed.
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Introduction
The	prevalence	of	diabetes	mellitus	has	reached	epidemic	proportions	and	constitutes	
a	major	public	health	problem.	Worldwide,	it	affects	almost	200	million	individuals,	and	
this	number	 is	expected	to	 increase	exponentionally	as	the	population	ages	and	obe-
sity	and	sedentary	life	style	become	increasingly	ubiquitous.	In	the	United	States	almost	
1.3 million individuals are diagnosed with diabetes each year.16 
Cardiovascular	complications,	including	coronary	artery	disease	(CAD),	are	the	leading	
causes of morbidity and mortality in individuals with type 2 diabetes mellitus.6 The over-
all	prevalence	of	CAD	has	been	reported	to	be	as	high	as	60%	in	patients	with	diabetes	
referred	for	stress	testing.17	The	10-year	mortality	rate	in	patients	with	known	CAD	and	
diabetes exceeds 70%.7 Some studies suggest that the risk for future cardiac deaths in 
patients	with	diabetes	without	known	CAD	is	similar	to	that	in	non-diabetic	patients	with	
overt	clinical	CAD.7	In	addition,	early	and	late	outcomes	of	diabetic	patients	with	acute	
coronary	syndrome	are	worse	than	those	of	their	nondiabetic	patient	counterparts.
To	compound	the	problem,	myocardial	ischemia	is	often	asymptomatic	in	patients	with	
diabetes	mellitus,	and	CAD	is	frequently	in	an	advanced	state	when	it	becomes	clinically	
manifest.8, 9	Coronary	artery	bypass	grafting	in	patients	with	diabetes	has	been	shown	
to improve the survival rate and may be superior to percutaneous coronary interven-
tion,	possibly	due	to	the	presence	of	more	diffuse	atherosclerosis.9 Moreover, the need 
for	repeated	percutaneous	coronary	intervention	or	coronary	artery	bypass	grafting	is	
significantly	greater	in	patients	with	diabetes	as	compared	to	nondiabetic	patients.18
The	previously	described	adverse	clinical	outcomes	in	patients	with	diabetes	underscore	
the	need	to	develop	practical	approaches	for	detecting	CAD	in	an	early	stage	before	clini-
cal	complications	have	occurred.	A	number	of	noninvasive	tests	are	available	to	detect	
myocardial ischemia: exercise electrocardiography, stress myocardial perfusion imaging 
(MPI),	and	stress	echocardiography.	Other	noninvasive	techniques	may	be	able	to	detect	
the	generalized	process	of	atherosclerotic	disease,	such	as	imaging	of	the	vessel	wall	of	
carotid	arteries	 via	high-resolution	ultrasound	or	 coronary	 artery	 calcium	 (CAC)	 scor-
ing	via	computed	tomography	(CT).	It	is	currently	unclear	whether,	for	the	purpose	of	
screening,	detection	of	these	early	markers	of	CAD	is	preferred	over	the	actual	visualiza-
tion	of	myocardial	ischemia.	In	this	editorial	point	of	view	we	will	focus	on	the	potential	
roles of stress MPI and CT CAC scoring as two complementary approaches for screening 
asymptomatic	patients	with	diabetes.	In	addition,	on	the	basis	of	the	available	evidence	
in	the	literature,	we	propose	a	potential	algorithm	for	this	purpose.
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MPI in symptomatic patients with diabetes mellitus
Although	the	role	of	stress	MPI	for	risk	stratification	is	well	established	in	the	general	
population,	similar	data	are	relatively	scarce	in	patients	with	diabetes	mellitus.	Several	
studies	in	the	literature	suggest	a	high	prevalence	of	abnormal	MPI	studies	in	diabetic	
patients	(Table	1).	Zellweger	et	al	noted	that	this	high	prevalence	was	dependent	of	the	
clinical	presentation:	i.e.	angina	or	shortness	of	breath.	Patients	with	diabetes	who	pre-
sented	with	shortness	of	breath	had	a	significantly	higher	incidence	(51%)	of	abnormal	
MPI	than	patients	who	complained	of	angina	(44%).19	Symptomatic	patients	with	diabe-
tes	in	addition	had	a	significantly	higher	hard	and	total	cardiac	event	rate	than	patients	
without	diabetes.	Giri	et	al	observed	 that	 the	cardiac	events	 rate	 in	diabetic	patients	
was	8.6%,	as	 compared	 to	4.5%	 in	non-diabetic	patients.20 As in the general popula-
tion,	stress	MPI	is	able	to	stratify	patients	with	diabetes	in	high-	and	low-risk	prognostic	
groups	 (Table	1).	The	cardiac	event	 rate	 for	any	given	MPI	abnormality	was	higher	 in	
diabetic	patients	than	in	nondiabetic	patients,	ranging	from	3.6	%	to	13.2,	and	diabetic	
women	had	the	worst	outcome.	Moreover,	patients	with	diabetes	and	normal	MPI	had	
a	higher	cardiac	event	rate	than	non	diabetic	patients,	ranging	from	0.7	%	to	3.6	%.	Not	
only	is	the	outcome	of	patients	with	diabetes	and	normal	MPI	not	as	favourable	as	in	
patients	without	diabetes	(<	1%),	the	“warrantee”	period	of	normal	MPI	appears	also	
to be shorter than 2 years.20	It	is	conceivable	that	his	may	be	attributed	to	accelerated	
progression	of	atherosclerosis	in	the	diabetic	state.
MPI in asymptomatic patients with diabetes mellitus
Nesto	et	al	reported	in	1990	that	57%	of	asymptomatic	patients	with	diabetes	mellitus	
and	peripheral	vascular	disease	had	evidence	of	silent	CAD	on	stress	MPI.26 A number 
of	subsequent	studies	have	confirmed	the	presence	of	silent	ischemia	in	asymptomatic	
patients	with	diabetes.	19, 25-38 The reported prevalence of silent ischemia, however, var-
ied markedly between studies, from 6% to 59%.19, 30, 34, 36, 38-40 This wide range in the 
prevalence	of	silent	 ischemia	 is	most	 likely	 related	to	differences	 in	patient	selection,	
stress	methodology,	imaging	techniques	and	interpretive	definitions.	
Reviewing	the	available	literature	on	stress	testing	in	asymptomatic	patients	with	diabe-
tes,	one	can	distinguish	3	types	of	studies	(Table	2):	(A)	retrospective	database	analyses	
of	patients	referred	for	stress	testing	who	had	diabetes,	(B)	retrospective	database	anal-
yses	of	known	asymptomatic	patients	with	diabetes	referred	for	stress	testing,	and	(C)	
prospective	studies	in	truly	asymptomatic	patients	with	diabetes.	Because	of	selection	
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bias,	the	first	type	of	study	in	the	literature	(section	A,	Table	2)	typically	showed	a	high	
prevalence	(41%-58%)	of	abnormal	stress	MPI	results	and	a	high	cardiac	event	rate.20, 22, 38 
It	 is	likely	these	patients	were	referred	for	stress	testing	because	of	typical	or	atypical	
symptoms and/or perceived clinical high risk. No details with regards to the type of dia-
betes	mellitus	or	its	treatment,	duration,	or	comorbidity	were	generally	available.	The	
second	type	of	studies	in	the	literature	(section	B,	Table	2)	showed	a	lower	prevalence	
of abnormal stress MPI and cardiac event rate.19, 25, 34, 37	Nevertheless,	these	patients	
may	not	be	representative	of	asymptomatic	patients	with	diabetes	in	the	larger	popula-
tion,	because	they	were	referred	for	stress	MPI,	for	example,	before	noncardiac	surgery.	
The mean prevalence of silent ischemia ranged from 26%-39%, although Miller et al 
reported	abnormal	MPI	in	59%	of	presumably	asymptomatic	patients.25 Because of the 
retrospective	nature	of	these	two	types	of	studies,	there	remains	uncertainty	about	the	
true	prevalence	of	silent	ischemia	in	asymptomatic	patients	with	diabetes.
Prospective studies in asymptomatic patients with diabetes mellitus
Several	prospective	studies	have	been	performed	in	truly	asymptomatic	patients	with	
diabetes	mellitus	 (section	C,	Table	2).30, 31, 36, 40-42 In general, these studies showed a 
lower	prevalence	of	silent	CAD,	ranging	from	6%	to	22%.	However,	there	were	important	
differences	in	design	and	stress	testing	methodology.	These	methodological	differences	
table 1. MPI	in	symptomatic	patients	with	diabetes
year author (ref) nr pts tracer stressor abnor-
mal mpi 
(%)
mean 
f/u 
(m)
he in ab-
normal 
mpi
 (%/yr)
he in 
normal 
mpi 
(%/yr)
1987 Felsher21  123 201TL Exercise	 56 36 4.8 1.3
1999 Kang22 1271 201TL,MIBI Exercise,	Adenosine	 41 24±8 3.9-7.9 1.2
2002 Schinkel23  207 MIBI Dobutamine 64 49±29 6.6* 0.7*
2002 Giri20  929 201TL,MIBI Exercise,	Adenosine	 48 36±18 5.0-6.4 3.6-3.9
2003 Berman24 5333 201TL,MIBI Adenosine 37-62 27±9 4.7-9.0* 1.8-2.5
2004 Zellweger19  911 201TL,MIBI Exercise,	Adenosine 44-51 24 5.6-13.2 2.0-3.3
2004 Miller25 2998 201TL,MIBI Exercise,	Adenosine,	
Dipyridamole,	
Dobutamine
60 70±42 3.6-5.9 NA
F/U,	 follow-up;	HE,	 hard	 events	 (cardiac	 death	 or	 non-fatal	myocardial	 infarction);	MIBI,	 technetium-99m	 sestamibi;	MPI,	
myocardial	perfusion	imaging;	NA,	not	available;	201TL, thallium-201 chloride. *=	only	cardiac	death.
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may	explain	the	variation	in	observed	prevalence	of	silent	CAD.	For	example,	in	the	Milan	
Study	on	Atherosclerosis	and	Diabetes	(MiSAD)	asymptomatic	patients	with	diabetes	had	
exercise	electrocardiography	as	the	first	diagnostic	test.30 Only if this test was abnormal, 
stress	MPI	was	performed.	It	is	possible	that,	because	of	the	insensitivity	of	exercise	elec-
trocardiography,	the	overall	observed	prevalence	of	observed	silent	CAD	was	low	(6%).	
Moreover,	fatal	cardiac	event	rate	was	low	as	well.	Janand-Delenne	et	al	and	Cosson	et	al	
performed either exercise electrocardiography or thallium-201 imaging, whereas Penfor-
nis et al used exercise electrocardiography, stress MPI or stress echocardiography.31, 40, 41 
Currently,	2	prospective	studies	in	asymptomatic	patients	with	diabetes	are	still	ongoing.	
Only	in	the	Detection	of	Ischemia	in	Asymptomatic	Diabetics	(DIAD)	study	was	the	same	
stress	test	(adenosine	Tc-99m	Sestamibi	MPI)	consistently	performed	in	all	522	random-
ized	patients.36	In	the	DIAD	study	22%	of	patients	had	abnormal	MPI	results.	In	the	study	
by	Anand	et	al,	510	asymptomatic	patients	with	diabetes	had	pre-screening	performed	
using	electron-beam	CT	(EBCT).	If	the	EBCT	CAC	score	was	100	Agatston	units	or	greater,	
stress MPI was performed.43	The	 imputed	prevalence	of	silent	CAD	 in	their	study	was	
13%.	These	2	recent	prospective	studies	indicated	that	the	prevalence	of	silent	CAD	in	
truly	asymptomatic	patients	is	considerably	lower	than	was	suggested	by	retrospective	
database	analyses.	Thus,	in	order	for	screening	to	be	cost-effective,	one	should	find	ways	
to	“enrich”	the	target	population	of	asymptomatic	patients	with	diabetes.
Value of CAC scoring in patients with diabetes mellitus
CT	techniques	(EBCT,	multislice	CT)	allow	for	noninvasive	detection	and	quantification	of	
CAC,	an	early	marker	of	CAD.44	Various	studies	have	recently	demonstrated	the	prognos-
tic	significance	of	CAC	scores	in	the	general	population.45-48 Because of the previously 
mentioned	ominous	association	between	CAD	and	diabetes	mellitus,	the	prevalence	of	
CAC	has	been	explored	in	patients	with	diabetes	without	known	CAD.49 In a cohort study 
of	30,904	asymptomatic	 individuals,	 including	1,075	diabetics,	 the	median	CAC	 score	
was	 in	 general	 higher	 in	 patients	with	diabetes	 than	 in	 patients	without	diabetes.	 In	
addition,	 the	 likelihood	of	having	a	CAC	score	 in	 the	highest	age/gender	quartile	was	
70%	greater	for	patients	with	diabetes.	Raggi	et	al	investigated	the	prognostic	value	of	
CAC in subjects with and without diabetes mellitus.50 In a cohort of 10,377 asymptom-
atic	individuals,	which	included	903	diabetics,	the	mean	CAC	score	and	death	rate	were	
significantly	higher	in	subjects	with	diabetes	than	in	those	without	diabetes.	Moreover,	
for	every	 increase	 in	CAC	score,	there	was	a	greater	 increase	 in	mortality	for	diabetic	
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patients	than	for	patients	without	diabetes.	In	contrast,	patients	with	diabetes	and	no	
evidence of CAC had a similar survival compared to that of individuals without diabetes 
and no detectable CAC. Qu et al noted that subjects with diabetes and low CAC score had 
a	four-fold	increase	in	hard	cardiac	event	rate	compared	with	nondiabetic	subjects	with	
a low CAC score.51	On	the	other	hand,	the	prognostic	value	of	CAC	as	a	continuum	was	
weaker	in	patients	with	diabetes	than	in	patients	without	diabetes.	
Elkeles	et	al	found	a	close	relationship	between	waist-hip	ratios,	systolic	blood	pressure	
and CAC score.52 Thus, CAC scoring may be linked to the metabolic syndrome in type 2 
diabetics.	In	asymptomatic	individuals,	Moser	et	al	noted	that	the	prevalence	of	CAC	was	
significantly	increased	when	more	than	3	cardiac	risk	factors	were	present.53 Thus, the 
presence	of	multiple	cardiac	risk	factors	could	be	used	as	a	justification	for	CAC	screen-
ing.	Furthermore,	an	Agatston	score	of	400	or	greater	appeared	to	be	a	logical	threshold	
for	initiating	further	testing	with	stress	MPI.53 These data suggest that CAC scoring may 
have	value	as	an	approach	to	enrich	target	population	of	asymptomatic	patients	with	
diabetes for screening.
Relative values of CAC score and ischemia on MPI for detecting CAD
Currently,	only	limited	data	are	available	on	the	relative	values	of	CAC	and	MPI	for	detec-
tion	silent	CAD	and	prognostication.	He	et	al	prospectively	examined	3,895	asymptomat-
ic	subjects	with	EBCT;	411	of	these	underwent	stress	MPI.54 Only 6.8% of these subjects 
had known diabetes mellitus. The likelihood of stress-induced myocardial ischemia on 
MPI	increased	in	parallel	to	the	CAC	score,	in	particular	at	CAC	scores	of	400	or	greater.	
Of	patients	with	CAC	score	400	or	greater,	46%	had	demonstrable	stress-induced	myo-
cardial ischemia on MPI. 
Berman	et	al	evaluated	1,195	patients	without	known	CAD,	including	51%	asymptomatic	
individuals	and	11.6	%	patients	with	diabetes.55 The authors noted that the likelihood 
of	stress-induced	myocardial	ischemia	on	MPI	was	very	low	(<2%)	if	the	CAC	score	was	
lower than 100 Agatston units. However, when the CAC score exceeded 400 Agatston 
units,	 a	 relatively	high	percentage	of	patients	had	abnormal	MPI	 studies.	 These	data	
suggested	a	 role	 for	CAC	 scoring	 as	 a	 gatekeeper	 for	patients	who	may	benefit	 from	
further	risk	stratification	with	stress	MPI.	Alternatively,	56%	of	patients	with	normal	MPI	
had	CAC	scores	of	100	and	greater,	indicating	that	absence	of	stress-induced	myocardial	
ischemia does not exclude preclinical presence of atherosclerosis.
Wong	et	al	 similarly	explored	 the	 interaction	between	CAC	 scoring	and	 stress	MPI	 in	
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1,043	patients	without	 known	CAD.56	Of	 the	patients,	 313	had	metabolic	 abnormali-
ties,	including	140	patients	with	diabetes	mellitus	and	173	patients	with	metabolic	syn-
drome. Again, a CAC score lower than 100, which occurred in approximately 2 % of pa-
tients,	was	associated	with	absence	of	stress-induced	ischemia	on	MPI.	The	likelihood	
of stress-inducible ischemia increased in parallel with increasing CAC score. It was noted 
that	 the	presence	of	 diabetes	mellitus	 or	metabolic	 syndrome	 significantly	 increased	
the	 likelihood	of	 abnormal	MPI.	 For	 instance,	 of	 patients	with	CAC	 score	of	 400	 and	
greater,	13.6%	of	patients	without	metabolic	abnormalities	had	stress	induced	ischemia,	
whereas	this	occurred	in	23.4%	of	those	with	metabolic	abnormalities.	
As	mentioned	previously,	one	recent	study	explored	the	combined	use	of	CAC	assess-
ment	with	EBCT	and	MPI	in	patients	with	asymptomatic	diabetes.43 Anand et al evalu-
ated	510	asymptomatic	patients	with	type	2	diabetes	using	EBCT	to	assess	CAC.	Stress	
MPI	was	performed	in	127	(25%)	patients	with	a	CAC	score	greater	than	100	Agatston	
units.	For	comparison,	53	randomly	selected	patients	with	a	CAC	score	of	100	or	less	also	
underwent	stress	MPI.	None	of	the	patients	with	CAC	score	of	10	or	less	had	abnormali-
ties	on	MPI.	An	 increasing	prevalence	of	abnormal	MPI	studies	was	noted	 in	patients	
with	higher	CAC	score.	Specifically,	18.4%	of	patients	with	a	CAC	score	between	11	and	
100	had	ischemia,	whereas	71.4%	of	patients	with	a	CAC	score	greater	than	1000	had	
ischemia. It should be noted that the incidences of abnormal MPI again are higher than 
those	observed	in	the	nondiabetic	cohorts.55	These	observations	suggest	that	sequential	
use	of	EBCT	and	MPI	may	optimize	screening	of	asymptomatic	diabetic	patients	and	that	
EBCT	may	be	used	as	gatekeeper	for	stress	MPI.	The	clinical	relevance	of	these	findings	
is	further	underlined	by	the	prognostic	data	in	the	study	by	Anand	et	al.	During	a	mean	
follow-up	of	18±5	months,	no	events	occurred	in	patients	with	a	CAC	score	of	10	or	less;	
as	compared	with	82%	of	events	occurring	in	patients	with	a	CAC	score	greater	than	400.	
Of	note,	the	CAC	score	and	the	extent	of	abnormalities	on	MPI	were	the	only	predictors	
of future cardiac events.
Conclusion
Stress-induced	abnormalities	on	MPI	and	positive	CAC	scores	 represent	 two	different	
aspects	of	CAD.	The	first	one	reflects	the	pathophysiologic	consequences	of	luminal	ob-
structive	CAD,	whereas	 the	 second	one	 indicates	 the	presence	of	 the	atherosclerotic	
process	with	calcium	deposition	in	the	vessel	wall.
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The	recent	findings	of	truly	prospective	studies	in	asymptomatic	patients	with	diabetes	
mellitus,	 suggest	a	 relatively	 low	prevalence	of	 silent	CAD	as	evidenced	by	abnormal	
MPI.	Although	in	most	patients	the	MPI	abnormalities	were	relatively	modest,	a	signifi-
cant	number	of	patients	had	markedly	abnormal	test	results.
CAC	may	occur	in	patients	with	and	without	abnormal	MPI,	but	with	increasing	severity	
of	CAC	scores,	the	prevalence	and	severity	of	stress-induced	MPI	abnormalities	increase.
The	screening	of	populations	predisposed	to	CAD	is	performed	to	rule	out	(presumably	
indicating	good	prognosis)	as	well	as	to	rule	in	(and	treat)	disease.	At	this	time,	it	is	not	
entirely	clear,	although	presumed,	that	early	detection	of	silent	CAD	and	its	treatment	
improves	long-term	outcome	of	asymptomatic	individuals.	Because	of	the	relatively	low	
overall	prevalence	of	silent	CAD	(approximately	22%)	 it	appears	 that	screening	all	as-
ymptomatic	 patients	with	 diabetes	mellitus	 by	 stress	MPI	may	 not	 be	 cost	 effective.	
Moreover,	only	a	small	number	of	patients	may	have	severe	MPI	abnormalities.	Thus	it	
is	important	to	device	ways	to	enrich	the	target	population.	It	has	been	suggested	that	
conventional	 cardiac	 risk	 factors,	duration	of	diabetes,	macro	and	microvasculopathy,	
circulating	markers	such	as	C-reactive	protein	or	plasminogen	activator	inhibitor-1	might	
be	helpful	to	construct	a	“high-risk	profile”	for	asymptomatic	patients	with	diabetes	mel-
litus.	In	the	DIAD	study	none	of	these	variables	was	associated	with	MPI	abnormalities.	
Only	male	gender,	body-mass-index	and	marked	cardiac	autonomic	dysfunction	were	
statistically	associated	with	markedly	abnormal	MPI.	The	study	by	Anand	et	al	suggests	
that	CAC	scoring	might	be	an	approach	to	identify	an	“enriched”	asymptomatic	patient	
population.	
We	propose	an	algorithm	for	the	screening	of	asymptomatic	diabetics	(Figure	1).	The	
first	step	of	screening	consists	assessment	of	the	CAC	score	by	CT	scanning.	If	the	Ag-
atston score is lower than 100, the yield of stress MPI is likely to be low and may not 
be indicated. If the Agatston score is between 100 and 400 and any of the following is 
present:	metabolic	syndrome,	age	greater	than	65	years,	duration	of	diabetes	greater	
than	10	years,	microalbuminuria,	retinopathy,	autonomic	cardiac	neuropathy,	stress	MPI	
appears	justified.	If	the	Agatston	score	is	greater	than	400,	stress	MPI	is	definitely	indi-
cated. If stress MPI shows evidence of myocardial ischemia, coronary angiography is 
indicated.	If	stress	MPI	is	normal,	aggressive	medical	treatment	should	be	instituted	and	
stress MPI has to be repeated within two years. 
Prospective	studies	may	be	conducted	to	evaluate	the	effectiveness	of	such	a	screening	
approach	and	answer	the	following	questions:	Does	the	stepwise	approach	outlined	in	
the	algorithm	yield	higher	prevalence	of	 silent	CAD?	 Is	 the	outcome	 in	patients	with	
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low	CAC	 score	 indeed	 favourable?	Whether	 screening	and	early	detection	of	disease	
ultimately	result	in	improve	outcome	can	only	be	evaluated	in	a	large	randomized	treat-
ment	 trial.	 It	 is	 conceivable	 that	 the	BARI-2	 trial	will	 provide	a	partial	 answer	 to	 this	
pertinent	question.
Figure 1.		Algorithm	for	screening	of	asymptomatic	patients	with	diabetes	mellitus.
MPI,	myocardial	perfusion	imaging;	DM,	diabetes	mellitus	
Asymptomatic type 2 diabetes mellitus
-Metabolic syndrome
-DM	duration	>	10	yrs
-Microalbuminuria
-Retinopathy
-Autonomic neuropathy
-Age	>	65	years
Coronary Calcium Score
<	100 100 - 400
No MPI MPI
neg pos
Coronary 
angiography
Risk	factor	reduction
Repeat	MPI	<2	yrs
>	400
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abstract
Background
We	sought	to	assess	prospectively	evidence	for	silent	coronary	artery	disease	(CAD)	in	
asymptomatic	patients	with	type	2	diabetes	mellitus	by	stress	single-photon	emission-
computed	tomography	(SPECT)	myocardial	perfusion	imaging,	coronary	artery	calcium	
(CAC)	scoring	and	multislice	computed	tomographic	(MSCT)	coronary	angiography.
Methods
One	hundred	asymptomatic	patients	(aged	30	to	72	years)	with	type	2	diabetes	mellitus	
and	one	or	more	risk	factors	for	CAD	were	prospectively	recruited	from	an	outpatient	
diabetes	clinic.	All	patients	underwent	adenosine	technetium-99m	sestamibi	SPECT	im-
aging, CAC scoring and 64-slice MSCT coronary angiography. 
Results
Twenty-three	patients	(23%)	had	abnormal	stress	SPECT	imaging	consistent	with	induc-
ible	myocardial	 ischemia,	whereas	60	patients	(60%)	had	positive	CAC	scoring	(18 pa-
tients	[18%]	with	significant	CAC	>401),	and	70	patients	(70%)	had	abnormal	MSCT	coro-
nary	angiography	(24	patients	[24%]	with	significant	≥50%	stenosis).	
Of	77	patients	with	normal	SPECT, 44	had	a	positive	CAC	score	(10	patients	[13%]	>401)	
and	54	showed	CAD	on	MSCT	angiography	(16	patients	[21%]	≥50%	stenosis).	Of	23 pa-
tients	with	an	abnormal	SPECT,	16	patients	had	a	positive	CAC	score	(8	patients	[35%]	
>401)	and	16	patients	had	CAD	on	MSCT	angiography	(8	patients	[35%]	≥50%	stenosis).	
Overall,	17	patients	(17%)	had	>2	significantly	abnormal	diagnostic	test	results,	and	5 pa-
tients	having	three	tests	significantly	abnormal.
Conclusion
In	this	cohort	of	asymptomatic	patients	with	type	2	diabetes	mellitus,	different	modali-
ties	visualized	different	aspects	of	silent	coronary	atherosclerosis.	Anatomical	evidence	
of	coronary	atherosclerosis	(CAC	and	MSCT)	occurred	more	frequently	than	functional	
evidence	(stress	SPECT).	However,	clinically	significant	manifestations	of	CAD	were	ob-
served	 in	about	one-quarter	 to	one-fifth	by	each	modality,	either	 separately	or	 com-
bined.	The	relative	prognostic	value	of	each	modality	needs	to	be	determined	by	a	fol-
low-up of this cohort.
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Introduction
Diabetes	mellitus	has	become	a	worldwide	healthcare	problem	and	its	prevalence	contin-
ues to increase.2, 16	Cardiovascular	complications	are	the	most	common	causes	of	mortal-
ity	and	morbidity	 in	patients	with	type	2	diabetes	mellitus.7 Moreover, life expectancy 
is	significantly	affected	by	the	presence	or	absence	of	cardiovascular	disease	in	patients	
with diabetes mellitus.57	Early	identification	of	patients	with	diabetes	and	coronary	artery	
disease	(CAD)	is	essential	for	early	initiation	of	appropriate	treatment,	which	may	affect	
favourably	an	otherwise	poor	outcome.	However,	the	detection	of	CAD	in	patients	with	
diabetes	remains	a	challenge,	because	CAD	is	often	without	symptoms.	
In	 the	DIAD	study	 the	overall	prevalence	of	 silent	myocardial	 ischemia	by	single-photon	
emission	computed	tomography	 (SPECT)	was	22%.	This	 included	stress-induced	regional	
myocardial	 perfusion	 abnormalities	 (16%)	 as	 well	 as	 ischemic	 electrocardiogram	 (ECG)	
changes	during	adenosine	infusion	or	abnormal	left	ventricular	function	(6%).36 Anand et al 
suggested	that	the	diagnostic	yield	of	screening	by	stress	SPECT	imaging	could	be	enhanced	
by	coronary	artery	calcium	(CAC)	scoring	as	first	test.43 In recent years, direct noninvasive 
visualization	of	CAD	has	become	feasible	with	multislice	computed	tomographic	 (MSCT)	
coronary	angiography.	This	technique	allows	for	evaluation	of	the	degree	of	luminal	steno-
sis	and	noncalcified	plaque	in	addition	to	calcifications.58, 59	At	the	present	time,	it	is	unclear	
which	of	these	three	noninvasive	diagnostic	techniques	is	most	effective	for	the	detection	
of	clinically	important	silent	CAD	in	asymptomatic	patients	with	type	2	diabetes	mellitus.	
The	current	observational	study	was	designed	to	evaluate	prospectively,	in	asymptom-
atic	patients	with	type	2	diabetes,	the	comparative	prevalence	of	evidence	for	coronary	
atherosclerosis	by	stress	SPECT,	CAC	scoring	and	MSCT	coronary	angiography	and	their	
diagnostic	interrelationship.
 
methods
Patients and study protocol
Consecutive	asymptomatic	patients	with	type	2	diabetes	mellitus	were	recruited	in	one	
outpatient	diabetes	clinic	from	May	2005	until	January	2006.	Inclusion	criteria	consist-
ed	of:	(1)	type	2	diabetes	mellitus;	(2)	no	angina	or	angina-equivalent	symptoms;	(3)	a	
normal	resting	ECG.	Exclusion	criteria	were:	(1)	known	or	suspected	CAD;	(2)	history	of	
coronary	revascularization;	 (3)	 treatment	with	anti-anginal	medication;	 (4)	ventricular	
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and	supraventricular	arrhythmias;	(5)	contraindications	for	the	use	of	iodinated	contrast	
media	(allergy	and/or	glomerulal	filtration	rate	<	60	ml/min/1.73m2).	Asymptomatic	sta-
tus	was	determined	using	the	questionnaire	of	Rose	et	al	for	angina.15	The	Framingham	
risk	score	of	Wilson	et	al	was	used	to	calculate	low,	intermediate	and	high	10-year	risk	
for coronary heart disease.60 
Vasodilator stress SPECT myocardial perfusion imaging
Electrocardiogram-gated	technetium-99m	sestamibi	(99mTc-sestamibi;	30	mCi)	SPECT	myo-
cardial	perfusion	imaging	was	performed	using	a	2-day	stress	and	rest	protocol.	All	patients	
were	instructed	to	abstain	from	caffeine-containing	products	from	24	hour	before	testing.	
Vasodilator	stress	was	performed	by	intravenous	infusion	of	adenosine	(140 µg/kg/minute 
for	6	minutes)	with	 simultaneously	handgrip	exercise.	During	adenosine	 infusion,	blood	
pressure	and	12-lead	ECG	were	recorded	every	minute	and	during	recovery.	Ischemic	ECG	
changes	were	defined	as	greater	than	1-mm	flat	or	downsloping	ST-segment	depression	
in	two	or	more	leads	during	adenosine	infusion.	SPECT	imaging	commenced	120	minutes	
after	radiopharmaceutical	injection	using	a	triple-head	SPECT	gamma	camera	(GCA	9300/
HG,	Toshiba	Corporation,	Tokyo,	Japan).	Image	acquisition	was	performed	in	concordance	
with	the	American	Society	of	Nuclear	Cardiology	(ASNC)	guidelines	using	a	circular	180°	or-
bit,	64	projections	and	20	seconds/projection.61, 62	No	attenuation	correction	was	applied.	
One	experienced	observer	(FJTW),	blinded	to	clinical	data	and	results	of	CAC	scoring	and	
MSCT angiography, interpreted reconstructed stress-rest short- and long-axis slices by visu-
al	analysis.	Images	were	categorized	as	either	normal	or	abnormal.	When	abnormal,	defect	
reversibility and stress defect severity were assessed using 17-segment colour-coded polar 
maps	with	normal	 reference	files.	 Left-ventricular	 perfusion	 abnormalities	were	 catego-
rized	on	the	basis	of	quantification	as	small	(0	to	5%	of	the	left	ventricle),	moderate	(≥5	and	
<10%),	or	large	(≥10%),	as	previously	described.36	Ischemic	ECG	changes	during	adenosine	
infusion	are	highly	specific	for	CAD	and	were	interpreted	as	abnormal	stress	SPECT	result.63
Multislice computed tomography
MSCT	was	performed	using	a	64-slice	Toshiba	multislice	Aquilion	system	(Toshiba	Medi-
cal	Systems,	Tokyo,	Japan).	First,	a	coronary	calcium	scan	without	contrast	was	obtained	
using	prospective	triggering,	followed	by	64-slice	MSCT	angiography	performed	during	
electrocardiographic	gating	and	the	administration	of	non-ionic	contrast	at	5	mL/s	ac-
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cording to the protocols as described previously.64, 65 If the heart rate was greater than 
or	equal	to	65	beats/minute	additional	oral	b-blockers	(metoprolol,	50	or	100	mg,	single	
dose,	1	hour	before	examination)	were	provided	as	tolerated.	Axial	data	sets	were	trans-
ferred	to	a	remote	workstation	(Vitrea	2,	Vital	Images,	Plymouth,	Minnesota,	USA)	for	
post	processing	and	subsequent	evaluation.
Coronary artery calcium score
The	CAC	was	assessed	by	two	experienced	observers	(JWJ,	JDS)	using	dedicated	software	
(Vitrea	2,	Vital	Images).	The	CAC	was	identified	as	a	dense	area	at	the	location	of	a	coro-
nary	artery	exceeding	the	threshold	of	130	Hounsfield	units	(HU).	An	overall	Agatston	
score	was	recorded	for	each	coronary	artery	and	per	patient.	Standard	categorization	of	
Agatston	scoring	was	applied:	less	than	10,	minimal;	11	to	100,	mild;	101	to	400,	moder-
ate;	401	to	1000,	severe;	and	greater	than	1,000,	extensive. 
Coronary angiography
The MSCT coronary angiograms were evaluated by the same two experienced observers 
(JWJ,	JDS),	who	were	unaware	of	the	results	of	SPECT	imaging.	Coronary	arteries	were	
divided	 into	17	segments	according	to	the	modified	American	Heart	Association	clas-
sification	and	determined	to	be	evaluable	or	not	by	visual	 inspection.66	Subsequently,	
interpretable segments were evaluated for the presence of luminal stenoses, both by 
scrolling	through	the	axial	images	and	by	inspecting	curved	multiplanar	reconstructions.	
Significant	coronary	obstruction	was	defined	as	 the	presence	of	at	 least	1	stenosis	of	
greater	than	50%	luminal	narrowing,	as	assessed	visually.	Nonobstructive	CAD	was	de-
fined	by	the	presence	of	atherosclerosis	but	not	exceeding	50%	luminal	narrowing.	Nor-
mal	arteries	were	defined	as	the	absence	of	any	evidence	of	coronary	atherosclerosis.	
 
Statistical analysis
Categorical	baseline	characteristics	are	expressed	as	numbers	and	percentages.	Continu-
ous	variables	are	expressed	as	mean	 (±	 standard	deviation).	 Statistical	 analyses	were	
performed	using	SPSS	software	(version	12.0,	SPSS,	Inc.,	Chicago,	Illinois,	USA)	and	SAS	
software	(SAS	system,	release	6.12,	SAS	Institute,	Inc.,	Cary,	North	Carolina).	P	<	0.05	was	
considered	statistically	significant.
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results
Patient characteristics
In	total,	176	consecutive	patients	were	screened.	Sixty-nine	(39%)	patients	were	ineli-
gible	for	the	study.	Twenty-five	(14%)	patients	had	an	abnormal	resting	ECG,	including	4	
patients	with	atrial	fibrillation.	Nineteen	(11%)	patients	were	on	anti-anginal	medication	
for	chest-pain	symptoms.	Seven	(4%)	patients	had	contraindications	for	the	use	of	iodin-
ated	contrast	media.	Eighteen	(10%)	patients	had	a	questionnaire	of	Rose	et	al	that	was	
positive	for	angina.
Consequently,	107	(61%)	patients	were	eligible	for	the	study.	Four	patients	refused	to	
participate;	one	patient	was	 later	excluded	because	of	uninterpretable	SPECT	 images,	
and	2	patients	because	of	 an	uninterpretable	MSCT.	 Thus,	 the	final	 study	population	
consisted	of	100	patients	(65	men;	age,	53	±	10	years).	The	patient	characteristics	are	
shown in Table 1.
The	mean	duration	of	diabetes	mellitus	was	9.4	±	7.0	years.	Most	of	the	patients	were	
on	oral	anti-diabetic	therapy	(61%).	Statins	were	used	by	54%	of	the	patients.	Thirty-sev-
en	patients	had	complications	of	diabetes	mellitus,	such	as	peripheral	vascular	disease	
(n=14),	peripheral	neuropathy	and	retinopathy.
SPECT myocardial perfusion imaging 
Twenty	patients	(20%)	had	regional	perfusion	abnormalities	(Figure	1).	Eighteen	of	these	
perfusion	abnormalities	were	reversible	defects.	Most	regional	perfusion	abnormalities	
were	 relatively	 small;	only	3	patients	had	moderate-sized	perfusion	defects.	 Ischemic	
ECG	changes	during	adenosine	infusion	occurred	in	6	patients.	Three	of	these	patients	
had	also	regional	perfusion	abnormalities:	two	were	small	and	one	was	moderate	in	size.	
The	other	three	patients	had	normal	perfusion.	In	total,	23	patients	(23%)	had	abnormal	
stress	perfusion	studies	(Figure	1).
CAC scoring 
No	CAC	was	present	in	40	patients	(40%).	Sixty	patients	(60%)	had	evidence	of	CAC.	By	
Agatston	scoring	the	amount	of	calcium	was	minimal	in	5	(5%)	patients,	mild	in	21	(21%)	
patients,	moderate	in	16	(16%)	patients	and	severe	in	18	patients	(18%).	Of	18	patients	
with	Agatston	score	greater	than	401,	7	patients	had	a	score	greater	than	1,000	(Figure 1).
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MSCT coronary angiography 
MSCT	 coronary	 angiography	was	normal	 in	30	patients	 (30%).	 The	 remaining	70	pa-
tients	 (70%)	 showed	 luminal	narrowing	of	one	or	more	 coronary	arteries	 (Figure	1).	
Forty-six	had	nonobstructive	atherosclerosis,	11	had	single-vessel	 involvement	(24%),	
16	 had	 two-vessel	 involvement	 (35%)	 and	 19	 had	 three-vessel	 involvement	 (41%).	
Twenty-four	patients	 (24%)	had	 significant	 luminal	narrowing	greater	 than	50%,	 and	
none	had	single-vessel	involvement,	8	(33%)	had	two-vessel	involvement	and	16	(67%)	
with	three-vessel	 involvement.	One	patient	had	greater	than	50%	left	main	coronary	
artery stenosis.
table 1.	Clinical	characteristics	of	100	asymptomatic	patients	with	type	2	diabetes.
Gender	(M/F) 65/35
Age	(yrs) 53 ± 10
Diabetes-related	risk	factors
Diabetes	duration	(yrs) 9.4 ± 7.0
Age	at	time	of	diagnosis	of	diabetes	(yrs) 44 ± 12.0
HbA1C	(%) 7.3 ± 1.6
Treatment
Diet	only 0	(0%)
Oral 61	(61%)
Insulin and oral agent 16	(16%)
Insulin 23	(23%)
Retinopathy 12	(12%)
Peripheral vascular disease* 14	(14%)
Body	mass	index	(kg/m2) 29 ± 5.0
Waist	circumference	(cm) 102 ± 13.0
Microalbuminuria 45	(45%)
Hypertension 51	(51%)
Hypercholesterolemia 53	(53%)
Family	history	of	CAD^ 51	(51%)
Smoking
Past 24	(24%)
Current 12	(12%)
Medication
Aspirin 21	(21%)
ACE-inhibitors/ARB 35	(35%)/20	(20%)
Statins 54	(54%)
Values	are	presented	as	number	(ratio	in	%)	or	mean	±	standard	deviation.
ACE,	 angiotension	 converting	 enzyme;	ARB,	 angiotensin	 receptor	 blockers;	HbA1c, haemoglobin A1c;	 CAD,	 coronary	 artery	
disease;	yrs,	years;	kg,	kilogram;	m2,	square	meter.
* Peripheral vascular disease was determined based on clinical history
^	A	positive	family	history	was	defined	by	the	diagnosis	of	CAD	in	parents	or	siblings	before	the	age	of	50	years
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Framingham risk score and abnormal test results
The	relationship	between	Framingham	risk	score	and	abnormal	findings	on	stress	SPECT,	
CAC	and	MSCT	coronary	angiography	is	shown	in	Table	2.	No	relation	between	risk	score	
and	abnormal	imaging	findings	was	observed.	
SPECT imaging and CAC
The	relationship	between	CAC	scoring	and	stress	SPECT	imaging	is	shown	in	Figure	2.	Of	
77	patients	with	normal	SPECT	imaging,	33	(43%)	had	no	CAC,	but	CAC	was	present	in	44	
(57%).	The	mean	CAC	score	in	these	44	patients	was	278	±	394.	The	CAC	score	was	mini-
mal	in	4	patients	(9%),	mild	in	15	patients	(33%)	and	moderate	in	15	patients	(33%).	Ten	
patients	(13%)	with	normal	SPECT	had	a	CAC	score	greater	than	401,	which	was	severe	
in	8	patients,	and	extensive	(greater	than	1,000)	in	2	patients.	
Of	23	patients	with	abnormal	SPECT	imaging,	7	patients	(30%)	had	no	evidence	of	CAC.	
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Figure 1.  Distribution	(%)	of	diagnostic	findings	on	stress	single-photon	emission	com-
puted	 tomography	 (SPECT),	 coronary	 artery	 calcium	 (CAC)	 scoring	 and	mul-
tislice	 computed	 tomography	 (MSCT)	 angiography	 in	 100	 asymptomatic	 pa-
tients	with	type	2	diabetes.	
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In	the	16	remaining	patients	(70%)	with	abnormal	SPECT	images,	the	mean	CAC	score	
was	1,581	±	2,469	(P	=	NS	compared	to	patients	with	normal	SPECT).	The	CAC	score	was	
minimal	in	1	patient,	mild	in	6	patients	and	moderate	in	1	patient.	Eight	patients	(35%)	
had	a	CAC	score	greater	than	or	equal	to	401.	Fourteen	of	66	patients	(21%)	with	CAC	
less	than	or	equal	to	100	had	abnormal	stress	SPECT,	compared	to	9	of	34	patients	(26%)	
with	CAC	greater	than	100	(P =	0.7).	Of	note,	two	of	three	patients	with	ischemic	ECG	
changes	without	perfusion	abnormalities	had	CAC	score	greater	than	or	equal	to	401	
(954	and	8,730,	respectively).
table 2.	Relation	between	abnormal	SPECT,	CAC	score	greater	than	or	equal	to	401	AU,	
MSCT	coronary	angiography	indicating	stenosis	greater	than	or	equal	to	50%	and	Fram-
ingham	risk	score	in	100	asymptomatic	patients	with	type	2	diabetes.
low risk
 n=39
intermediate risk 
n=42
High risk 
n=19
Abnormal	SPECT 12	(31%) 6	(14%) 5	(26%)
CAC	score	≥	401	AU 5	(13%) 8	(19%) 5	(26%)
MSCT	coronary	angiography	≥	50%	stenosis 4	(10%) 14	(33%) 6	(32%)
AU,	Agatston	units;	CAC	score,	coronary	artery	calcium	score;	MSCT,	multislice	computed	tomography;	SPECT,	single-photon	
emission computed tomography. 
Figure 2.  Coronary	Artery	Calcium	(CAC)	score	and	number	of	patients	with	normal	and	
abnormal	single-photon	emission	computed	tomography	(SPECT)	imaging.
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SPECT imaging and MSCT coronary angiography
Of	the	77	patients	with	a	normal	SPECT,	23	(30%)	had	a	normal	MSCT	coronary	angio-
gram.	However,	in	the	remaining	54	patients	(70%)	with	normal	SPECT,	MSCT	angiogra-
phy	was	abnormal,	38	had	nonobstructive	(less	than	50%)	luminal	narrowing	and	16 pa-
tients	had	stenoses	greater	than	or	equal	to	50%	stenoses.
Of	23	patients	with	abnormal	SPECT	imaging,	7	patients	(30%)	had	a	normal	MSCT	coro-
nary	angiogram.	Of	the	remaining	16	patients	 (70%)	with	abnormal	SPECT,	8	patients	
had	nonobstructive	luminal	narrowing	and	8	patients	had	stenosis	greater	than	or	equal	
to	50%.	Of	note,	all	3	patients	with	 ischemic	ECG	changes	during	adenosine	 infusion,	
without	perfusion	abnormalities	on	SPECT,	had	nonobstructive	CAD	on	MSCT.
SPECT imaging, CAC and MSCT coronary angiography
Figure	3	shows	the	interrelationship	of	clinically	significant,	abnormal	diagnostic	test	re-
sults.	Seventeen	patients	(17%)	had	more	than	2	abnormal	diagnostic	tests,	whereas	in	
5	patients	all	3	tests	were	abnormal.	Figure	4	shows	the	interrelationship	for	3	patients	
with	moderate	myocardial	perfusion	defects.	Two	of	3	patients	had	also	other	abnormal	
test results.
speCt
Abnormal
n=23
msCt
CAD>50%
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Figure 3.  	Ven	 diagram	 showing	 the	 interrelationship	 between	 abnormal	 stress	 SPECT,	
CAC	score	greater	than	or	equal	to	401	and	obstructive	(≥50%)	CAD	on	MSCT.	In	
17	patients	(17%)	more	than	2	diagnostic	tests	were	abnormal;	5	patients	had	
three abnormal test results.
CAC	score,	coronary	artery	calcium	score;	CAD,	coronary	artery	disease,	MSCT,	multislice	computed	tomography;	SPECT,	sin-
gle-photon emission computed tomography.
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Different manifestations of CAD 
Referral for invasive angiography
In	total,	7	patients	were	referred	for	invasive	angiography.	Three	of	7	patients	had	both	
abnormal	MSCT	and	SPECT.	Invasive	angiography	demonstrated	in	all	3	patients	signifi-
cant	multivessel	CAD,	requiring	percutaneous	coronary	 intervention	(PCI)	or	coronary	
artery	 bypass	 grafting	 (CABG).	 Three	 other	 patients	 underwent	 invasive	 angiography	
because	of	abnormal	MSCT	(but	normal	SPECT).	Invasive	coronary	angiography	showed	
nonobstructive	CAD	in	2	patients,	whereas	1	patient	had	significant	CAD	for	which	he	
underwent	CABG.	Finally,	1	patient	was	referred	because	of	abnormal	SPECT	in	combina-
tion	with	nonobstructive	CAD	according	to	MSCT.	Invasive	angiography	showed	signifi-
cant	single-vessel	disease,	which	was	subsequently	treated	with	PCI.
discussion
To	the	best	of	our	knowledge,	this	is	the	first	study	to	evaluate	the	prevalence	of	mani-
festations	of	coronary	atherosclerosis	in	asymptomatic	patients	with	type	2	diabetes	by	
three	distinctly	different	noninvasive	diagnostic	imaging	variables.	Anatomical	evidence	
of coronary atherosclerosis by CAC and MSCT coronary angiography occurred more fre-
Figure 4.  Ven	diagram	showing	the	 interrelationship	between	moderate-sized	myocar-
dial	perfusion	defects	on	SPECT,	extensive	(>1,000)	CAC	score,	and	three-vessel	
CAD	(stenosis	≥50%)	on	MSCT.
CAC	score,	coronary	artery	calcium	score;	CAD,	coronary	artery	disease;	MSCT,	multislice	computed	tomography;	3VD,	three-
vessel disease.
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quently	than	functional	evidence	of	CAD	by	abnormal	stress	SPECT	imaging.	However,	
when	 only	 clinically	 significant	 abnormalities	were	 considered,	 i.e.,	 stress	myocardial	
perfusion	defects	(including	ischemic	ECG	changes),	a	CAC	score	greater	than	401	and	
coronary	artery	stenosis	greater	than	or	equal	to	50%,	the	observed	prevalences	were	
rather	similar:	23%,	18%,	and	24%,	respectively.	Although	only	5%	of	patients	had	all	
three	tests	abnormal,	more	than	2	abnormal	tests	occurred	in	17%	of	patients.	These	
prevalences are in the range of 22% prevalence of silent ischemia recently reported in a 
similar	patient	population	in	the	DIAD	study.36 
Several	 recent	 studies	 evaluated	 the	 interrelationship	 between	 abnormal	 SPECT	 im-
aging, CAC scoring and MSCT coronary angiography, either separately or in combina-
tion.55, 67, 68	These	investigations	suggested	that	abnormal	findings	on	each	of	these	mo-
dalities	must	be	viewed	as	complementary.	In	a	study	from	our	own	institution,	compar-
ing	SPECT	with	MSCT	coronary	angiography,	anatomic	evidence	of	atherosclerosis	was	
frequently	not	associated	with	inducible	ischemia.	Conversely,	normal	stress	myocardial	
perfusion images did not exclude atherosclerosis.67 With	regards	to	CAC,	patients	with	
abnormal	SPECT	images	have	higher	likelihood	of	significant	CAC;	the	prevalence	of	an	
abnormal	 SPECT	 study	parallels	 the	 increasing	 severity	 of	 CAC	 score.55 However CAC 
(even	severe)	occurred	also	in	patients	with	normal	SPECT	images.55, 68 These observa-
tions	are	in	agreement	with	a	long-established	notion	that	no	tight	correlation	exists	be-
tween	apparently	anatomically	significant	CAD	and	stress-inducible	ischemia.	The	pres-
ent	 study	 illustrates	 similar	 inconsistent	 interrelationships	 in	Figure	3	and	4.	Possibly,	
plaque	extent,	 location	and	composition,	are	also	 important	predictors	of	 ischemia	 in	
addition	to	the	degree	of	stenosis	or	extent	of	coronary	artery	calcifications.	
The	studies	cited	above	were	performed	in	general	symptomatic	and	asymptomatic	pa-
tient	 cohorts	with	 known	or	 suspected	CAD.	How	 these	data	 apply	 to	 asymptomatic	
patients	with	diabetes	is	unclear.	Wong	et	al	showed	that	CAC	scores	greater	than	400	in	
patients	with	metabolic	syndrome	and	diabetes	indicated	markedly	increased	risk	for	in-
ducible myocardial ischemia.56 Anand et al suggested CAC scoring as a methodology for 
pre-screening	asymptomatic	patients	with	diabetes	to	enhance	the	yield	of	stress	SPECT	
myocardial perfusion imaging.43	The	authors	observed	that	few	patients	with	CAC	less	
than	100	had	stress	SPECT	myocardial	perfusion	abnormalities.	 In	our	study	however	
patients	with	CAC	 less	than	100	had	similar	prevalence	of	abnormal	SPECT	 images	as	
patients	with	CAC	greater	than	100.	In	addition	to	the	presence	of	microvascular	disease,	
a	possible	explanation	for	this	finding	could	be	a	relatively	high	proportion	of	patients	
with	noncalcified	atherosclerosis.	A	recent	study	comparing	computed	tomography	an-
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giography	to	CAC	observations	in	asymptomatic	patients	with	type	2	diabetes	showed	
that	CAD	was	present	in	55%	of	patients	with	CAC	<10,	indicating	the	presence	of	non-
calcified	rather	than	calcified	plaque	burden.69 Accordingly, it is conceivable that in our 
study,	the	presence	of	noncalcified	atherosclerosis	could	have	attributed	to	myocardial	
ischemia	in	patients	with	a	CAC	score	less	than	100.	
Thus,	the	three	diagnostic	imaging	variables	reflect	different	aspects	of	the	atherosclerot-
ic	process.	Myocardial	perfusion	defects	may	be	caused	by	flow-limiting	epicardial	coro-
nary	artery	stenoses,	but	also	by	microvascular	disease	and	endothelial	dysfunction,	and	
remains	at	present	the	only	technique	established	for	clinical	decision	making	with	regard	
to	medical	or	interventional	treatment.	CAC	indicates	calcium	accumulation	in	the	vessel	
walls	and	consequently	atherosclerosis	with	or	without	vascular	remodelling.	Coronary	
artery stenoses on MSCT coronary angiography indicate luminal narrowing, but the tech-
nique	cannot	distinguish	between	lesions	that	are	physiologically	relevant	and	not.	
Limitations
An	important	limitation	of	our	study	is	that	the	study	population	was	relatively	small.	Our	
observations	need	to	be	confirmed	in	a	larger	patient	cohort	of	asymptomatic	patients	with	
diabetes	mellitus.	Having	demonstrated	important	discrepancies	in	manifestations	of	ath-
erosclerosis	between	the	three	noninvasive	diagnostic	imaging	modalities,	the	significance	
of	this	observation	is	not	clear.	Is	one	modality	more	valuable	than	the	other?	Only	follow-
up	of	this	patient	cohort	and	outcome	data	on	future	hard	cardiac	events	will	provide	insight	
in	this	conundrum.	Indeed,	follow-up	data	of	these	patients	are	currently	being	acquired.
Conclusion
In	this	cohort	of	asymptomatic	patients	with	type	2	diabetes	mellitus,	different	nonin-
vasive	diagnostic	modalities	visualized	different	aspects	of	 silent	coronary	atheroscle-
rosis.	Anatomical	evidence	of	coronary	atherosclerosis	(CAC	and	MSCT)	occurred	more	
frequently	than	functional	evidence	(stress	SPECT).	However,	presumably	clinically	sig-
nificant	manifestations	of	CAD	were	observed	in	about	one-quarter	to	one-fifth	of	the	
cohort	by	each	modality,	either	separately	or	combined.	The	relative	prognostic	value	of	
each modality will be determined by follow-up in this cohort.
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abstract
Objective
The	purpose	of	the	study	was	to	evaluate	the	prevalence	of	CAD	as	well	as	plaque	mor-
phology	 in	asymptomatic	patients	with	type	2	diabetes	using	multislice	computed	to-
mography	(MSCT).	In	addition,	the	relation	between	calcium	score	and	MSCT	findings	
was explored.
Design
In	 70	patients,	 coronary	 calcium	 scoring	 and	noninvasive	 coronary	 angiography	were	
performed.	Angiograms	showing	atherosclerosis	were	further	classified	as	obstructive	
(≥50%	luminal	narrowing)	CAD	or	not.	Plaque	type	(noncalcified,	mixed	and	calcified)	
was	determined.	Finally,	the	relation	between	calcium	score	and	MSCT	findings	was	ex-
plored.
Results
A	calcium	score	<10	was	observed	in	31	(44%)	patients.	A	calcium	score	of	10-100	was	
observed	in	14	(20%)	patients	while	a	score	of	101-400	or	>400	was	identified	in	respec-
tively	12	(17%)	and	13	(19%)	patients.	Noninvasive	coronary	angiography	showed	CAD	
in	56	(80%)	patients.	
322	coronary	segments	with	plaque	were	identified,	of	which	132	(41%)	contained	non-
calcified	plaques,	65	(20%)	mixed	plaques	and	125	(39%)	calcified	plaques.	The	percent-
age	of	patients	with	obstructive	CAD	paralleled	increasing	calcium	score.	The	presence	
of	CAD	was	noted	in	17	(55%)	patients	with	no	or	minimal	calcium	(score	<10).
Conclusion
MSCT	angiography	detected	a	high	prevalence	of	CAD	 in	asymptomatic	patients	with	
type	2	diabetes.	A	 relatively	high	proportion	of	plaques	were	noncalcified	 (41%).	 Im-
portantly,	a	calcium	score	<	10	did	not	exclude	CAD	in	these	patients.	MSCT	might	be	
a	useful	technique	to	identify	CAD	in	asymptomatic	patients	with	type	2	diabetes	with	
incremental value over calcium scoring.
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Introduction
Diabetes	mellitus	 has	 reached	 epidemic	 proportions	 and	has	 become	 a	major	 public	
health problem. Almost 200 million individuals are known to have diabetes and this 
number	is	expected	to	increase	exponentionally.	In	the	USA	almost	1.3	million	new	sub-
jects are diagnosed with diabetes each year.16 
Cardiovascular	complications,	including	coronary	artery	disease	(CAD),	are	the	leading	
causes of morbidity and mortality in individuals with type 2 diabetes mellitus.6 The over-
all	prevalence	of	CAD	has	been	reported	to	be	as	high	as	60%	in	patients	with	diabetes	
referred	for	stress	testing.17	The	10-year	mortality	in	patients	with	known	CAD	and	dia-
betes exceeds 70%.7	The	poor	clinical	outcome	 in	patients	with	diabetes	underscores	
the	need	to	develop	practical	approaches	for	detecting	CAD	at	an	early	stage.	Moreover,	
in	patients	with	diabetes	mellitus,	CAD	has	frequently	progressed	to	an	advanced	state	
before it becomes clinically manifest.8, 9 
The	 role	 of	 single	 photon	 emission	 computed	 tomography	 (SPECT)	 in	 asymptomatic	
diabetics	 has	 recently	 been	 evaluated.	 The	 Detection	 of	 Silent	 Myocardial	 Ischemia	
in	Asymptomatic	Diabetics	 (DIAD)	 study	 is	 an	 ongoing	 randomized	 study	 using	 gated	
SPECT	 for	 risk	 stratification	 in	asymptomatic	patients	with	diabetes	 type	2.	 In	22%	of	
patients	(silent)	myocardial	ischemia	was	noted,	with	16%	showing	abnormal	perfusion	
on	SPECT.36
Recently,	multislice	computed	tomography	(MSCT)	has	been	proposed	as	an	alternative	
imaging	modality	for	the	evaluation	of	patients	with	known	or	suspected	CAD.59 MSCT 
allows	anatomic,	noninvasive	 imaging	of	 the	coronary	arteries,	 including	detection	of	
coronary	atherosclerosis	by	assessing	the	coronary	artery	calcium	burden	(calcium	scor-
ing)	 and	by	performing	noninvasive	 angiography.	 This	 technique	has	 the	potential	 to	
detect	CAD	at	an	early	stage.	With	the	recently	introduced	64-slice	MSCT,	high	sensitivity	
and	specificity	for	the	detection	of	significant	(≥50%	luminal	narrowing)	stenoses	have	
been	reported	and	this	technique	has	been	validated	against	conventional	coronary	an-
giography and intravascular ultrasound.65, 70-77 The purpose of this study was to evaluate 
the	prevalence	of	CAD	 in	a	 large	cohort	of	asymptomatic	type	2	diabetic	patients	us-
ing	MSCT	angiography.	The	plaque	constitution	of	the	coronary	artery	lesions	was	also	
evaluated,	and	the	relation	between	calcium	scoring	and	noninvasive	angiography	was	
explored.
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Design
Patients
Seventy-three	asymptomatic	patients	with	type	2	diabetes	mellitus	were	included.	All	
patients	were	referred	from	an	outpatient	diabetic	clinic	to	our	 institution	for	assess-
ment of cardiovascular risk. Inclusion criteria consisted of type 2 diabetes mellitus, no 
angina	 or	 angina-equivalent	 symptoms.	 Exclusion	 criteria	 were:	 known	 or	 suspected	
CAD;	 history	 of	 coronary	 revascularization;	 treatment	 with	 anti-anginal	 medication;	
ventricular	and	supraventricular	arrhythmias;	contraindications	for	the	use	of	iodinated	
contrast	media.	Patients	were	excluded	from	analysis	when	an	irregular	heart	rate	dur-
ing	MSCT	data	acquisition	rendered	the	MSCT	data	set	uninterpretable.	Asymptomatic	
status	was	confirmed	using	the	Rose	questionnaire	for	angina.15 The study was part of a 
clinical	study	for	patients	referred	to	the	MSCT	for	which	clinical	approval	was	obtained.
MSCT, data acquisition
Imaging	was	performed	using	a	64-slice	MSCT	scanner	(Aquilion	64,	Toshiba	Medical	Sys-
tems,	Japan).	If	the	heart	rate	was	≥	65	beats/min,	additional	oral	beta-blockers	(meto-
prolol	50	mg,	single	dose,	1	hour	before	scan)	were	provided	when	tolerated.	
First,	a	prospectively	triggered	coronary	calcium	scan	was	performed	before	MSCT	angi-
ography.	Accordingly,	data	were	acquired	with	a	collimation	of	64	x	0.5	mm	and	a	tube	
rotation	time	of	400	milliseconds,	and	tube	current	of	300	mA	at	120	kV	for	patients	
with	normal	posture	(BMI<	30	kg/m2).	In	case	of	patients	with	higher	body	mass	indexes	
(>30),	tube	current	was	increased	to	350	or	400	mA	at	135	kV.	The	temporal	window	
was	set	at	75%	after	the	R-wave	for	electrocardiographically	triggered	prospective	re-
construction.	80	to	110	ml	non-ionic	contrast	material,	depending	on	the	total	scan	time,	
was	administered	with	a	flow	rate	of	5	ml/sec	(Iomeron	400®,	Bracco	Atlanta	Pharma,	
Konstanz,	Germany).	Automated	detection	of	peak	enhancement	in	the	aortic	root	was	
used	for	timing	of	the	scan.	All	images	were	acquired	during	an	inspiratory	breath	hold	
of	approximately	10	seconds,	with	simultaneously	registration	of	the	patient’s	electro-
cardiogram.	 Subsequently,	 data	 sets	were	 reconstructed	and	 transferred	 to	a	 remote	
workstation	as	previously	described.75	Briefly,	images	were	initially	reconstructed	at	75%	
of	the	cardiac	cycle.	In	case	of	motion	artefacts,	a	representative	single	slice	was	recon-
structed throughout the cardiac cycle in steps of 20 milliseconds to determine the most 
optimal	additional	reconstruction	phases.	
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MSCT, data analysis
Coronary artery calcium score
The	coronary	artery	calcium	score	was	assessed	with	the	application	of	dedicated	soft-
ware	(Vitrea	2,	Vital	 Images,	USA).	Coronary	artery	calcium	was	 identified	as	a	dense	
area	in	the	coronary	artery	exceeding	the	threshold	of	130	Hounsfield	units.	An	overall	
Agatston	score	was	recorded	for	each	patient.
Coronary plaque assessment
All	angiograms	were	evaluated	by	two	experienced	observers	(JWJ,	JDS)	unaware	of	the	
clinical	history	of	the	patients.	In	case	of	disagreement,	a	joint	reading	was	performed	and	
a consensus decision was reached. Coronary arteries were divided into 17 segments ac-
cording	to	the	modified	American	Heart	Association	classification.66 Only segments with a 
diameter	>	1.5	mm	(as	measured	on	the	MSCT	coronary	angiogram)	were	included.	First,	
each	segment	was	classified	as	 interpretable	or	not.	Then,	 the	 interpretable	segments	
were	evaluated	 for	 the	presence	of	 any	 atherosclerotic	plaque	using	 axial	 images	 and	
curved	multiplanar	reconstructions.	Coronary	plaques	were	defined	as	structures	>	1	mm2 
within	and/or	adjacent	to	the	coronary	artery	lumen,	which	could	be	clearly	distinguished	
from	the	vessel	lumen	and	the	surrounding	pericardial	tissue,	as	described	previously.58
As	adequate	distinction	between	a	single	lesion	and	the	presence	of	diffuse	atheroscle-
rosis	extending	over	several	segments	may	be	difficult	in	some	cases,	it	was	chosen	to	
perform the analysis on a segmental basis, also in order to improve reproducibility of 
the	 results.	One	 coronary	 plaque	was	 assigned	 per	 segment.	 Subsequently,	 the	 type	
of	 plaque	was	 determined	 using	 the	 following	 classification:	 1)	 noncalcified	 plaques,	
plaques	having	 lower	density	 compared	with	 the	contrast-enhanced	vessel	 lumen;	2)	
calcified	plaques,	plaques	with	high	density;	and	3)	mixed	plaques,	plaques	with	noncal-
cified	and	calcified	elements	within	a	single	plaque.	Finally,	it	was	determined	whether	
the	lesion	was	obstructive	or	not,	using	a	threshold	of	50%	luminal	narrowing.	For	each	
patient	 the	number	of	 diseased	 vessels	 and	number	of	 each	 type	of	 plaque	was	de-
termined.	Patients	without	plaques	were	considered	normal;	an	abnormal	MSCT	was	
defined	in	the	presence	of	≥	1	coronary	plaque.	
Statistical analysis
Continuous	variables	were	expressed	as	mean	and	standard	deviation.	Proportions	were	
expressed	in	percentages.	Statistical	analysis	was	performed	using	SPSS	12.0	software.
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results
Patient Characteristics
In	 total	 73	patients	were	 referred	 from	 the	outpatient	diabetic	 clinic	 and	enrolled	 in	
the	present	study.	Three	patients	(4%)	were	excluded	from	the	analysis	because	of	an	
irregular	heart	rate	during	MSCT	data	acquisition,	which	rendered	the	MSCT	data	set	
uninterpretable.	Baseline	characteristics	of	the	70	analyzed	patients	are	provided	in	Ta-
ble 1.	The	majority	of	the	patients	were	male	(74%).	The	mean	duration	of	diabetes	was	
110 ± 88 months.
msCt
Coronary artery calcium score
As	shown	in	Figure	1,	coronary	calcium	was	absent	or	the	calcium	score	was	less	than	
10	in	31	(44%)	patients.	A	calcium	score	of	10-100	was	observed	in	14	(20%)	patients,	a	
score	of	101-400	in	12	(17%)	patients,	and	13	(19%)	patients	had	a	calcium	score	>400.	
Coronary angiography
MSCT	identified	14	(20%)	patients	without	CAD	and	56	(80%)	patients	with	CAD.
A	total	of	38	(54%)	patients	had	nonobstructive	CAD,	and	18	(26%)	patients	had	obstruc-
tive	CAD	(at	least	1	significant	(≥50%)	stenosis)	(see	Figure	2).
In	the	38	patients	with	nonobstructive	CAD,	10	(26%),	8	(21%),	and	20	(53%)	had	1-,	2-,	
Figure 1.		Bar	graph	showing	the	coronary	calcium	score	categories	in	the	study	population.
Calcium	score	(Agatston)
		<10																	10-100													101-400														>400
n=31                  n=14                  n=12                   n=13
50%
40%
30%
20%
10%
0%
pe
rc
en
ta
ge
	o
f	p
ati
en
ts
51
Prevalence of CAD and plaque morphology
and	3-vessel	disease,	respectively.	Regarding	the	18	patients	with	obstructive	CAD,	1,	2,	
and	3	vessels	were	significantly	diseased	in	0	(0%),	4	(22%),	and	14	(78%)	patients.
Plaque morphology
A	total	of	15	(1.3%)	of	1190	coronary	segments	were	not	interpretable	due	to	motion	
artefacts.	 In	the	56	patients	with	CAD,	322	coronary	segments	with	plaques	were	ob-
served.
Fifty-nine	(18%)	plaques	were	obstructive	and	263	(82%)	plaques	were	nonobstructive.	
132	(41%)	contained	noncalcified	plaques,	65	(20%)	mixed	plaques	and	125	(39%)	calci-
fied	plaques,	as	illustrated	in	Figure	2B.
table 1.	Characteristics	of	the	study	population	(n=70)
Clinical characteristics
Age	(yrs)  54 ± 11
Gender	(male) 	 52	(74%)
BMI(kg/m2)  29 ± 5
Circumferential	length	(cm) 101 ± 13
Age	at	diabetes	diagnosis	(yrs)  45 ± 12
DM	duration	(months) 110 ± 88
Hypercholesterolemia 	 36	(51%)
Hypertension 	 36	(51%)
Smoking 	 15	(21%)
Family	history	of	CAD 	 37	(53%)
Laboratory findings
Creatinine	(μmol/L)  84 ± 20
HbA1C	(%)   7.2 ± 1.6
Cholesterol	(mmol/l)   4.8 ± 1.1
Microalbuminuria/Creatinine	ratio	(>	3.5μg/μmol) 	 26	(37	%)
Medical therapy
Insulin 	 13	(19%)
Oral agent 	 44	(63%)
Insulin plus oral agent 	 11	(16%)
ACE	inhibitors 	 24	(34%)
AT-2 blockers 	 15	(21%)
Statins	 	 33	(47%)
Aspirin 	 16	(23%)
DM related complications 	 37	(53%)
(Peripheral vascular disease, polyneuropathy, retinopathy)
Data	are	means	±	SD	or	n	(%)	ACE,	angiotensin	converting	enzyme;	AT-2,	Angiotensin	2;	BMI,	body	mass	index;	CAD,	coronary	
artery	disease;	DM,	diabetes	mellitus.
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Figure 2. 	Prevalence	of	CAD	in	70	patients	with	asymptomatic	type	2	diabetes	mellitus.	
(A)	Only	20%	of	patients	showed	normal	coronary	arteries.	Plaque	morphology	
in	322	diseased	coronary	segments	showing	a	relative	high	proportion	of	non-
calcified	plaques.(B)
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Figure 3.		Bar	graph	demonstrating	the	distribution	of	both	obstructive	and	nonobstructive	
coronary	artery	disease	(CAD)	per	coronary	artery	calcium	(CAC)	score	category.	
Obstructive	CAD	
Nonobstructive	CAD
Normal MSCT
<10	 10-100	 101-400	 >400
pe
rc
en
ta
ge
	o
f	p
ati
en
ts
100
80
60
40
20
0
53
Prevalence of CAD and plaque morphology
Coronary calcium score versus coronary angiography
Comparison of the coronary artery calcium score and MSCT angiography showed that 
the	percentage	of	patients	with	obstructive	CAD	paralleled	the	increasing	calcium	score;	
increasing	 from	10%	 in	patients	with	minimal	 calcium	 (score	<10)	 to	54%	 in	patients	
with	calcium	score	>400	(Figure	3).	Still,	 in	patients	with	minimal	calcium	(score	<10),	
the	presence	of	CAD	was	detected	on	noninvasive	coronary	angiography	in	55%	(n=17)	
of	the	patients.	In	these	patients,	CAD	was	nonobstructive	in	82%	(n=14)	and	obstructive	
in	18%	(n=3)	patients.
discussion
The	main	findings	of	this	study	can	be	summarized	as	follows.	First,	MSCT	could	detect	
CAD	in	80%	of	asymptomatic	patients	with	type	2	diabetes.	In	addition,	in	56%	of	pa-
tients	an	elevated	calcium	score	(>10)	was	observed.	Although	most	patients	presented	
with	nonobstructive	CAD,	in	26%	of	the	patients	at	least	1	significant	coronary	artery	ste-
nosis	was	detected.	Furthermore,	in	the	majority	of	patients	with	nonobstructive	CAD,	
diffuse	disease	was	noted	involving	the	entire	coronary	tree.	
Second,	coronary	plaque	composition	was	explored	and	revealed	a	relatively	high	pro-
portion	of	noncalcified	(41%)	plaques.
Finally,	the	relation	between	the	coronary	calcium	score	and	CAD	on	noninvasive	angiog-
raphy	was	evaluated.	In	line	with	the	high	prevalence	of	noncalcified	plaques,	consider-
able	atherosclerosis	was	noted	in	patients	without	(or	minimal)	coronary	artery	calcium.	
These	findings	suggest	that	noninvasive	angiography	with	MSCT	may	provide	additional	
information	to	calcium	scoring	for	detection	of	CAD.	
prevalence of Cad
In	diabetic	patients,	the	diagnosis	of	CAD	is	frequently	missed	or	delayed	since	the	
typical	symptoms	of	myocardial	ischemia	are	often	masked.	Before	symptoms	of	isch-
emia	occur,	diffuse	multi-vessel	atherosclerosis	 is	often	present.	 It	has	been	shown	
that	risk	and	mortality	from	CAD	in	patients	with	type	2	diabetes	are	similar	to	pa-
tients	without	diabetes	and	previous	myocardial	infarction.7 Moreover, the combina-
tion	of	CAD	and	diabetes	strongly	 increases	adverse	outcome	and	underscores	 the	
need	to	develop	practical	approaches	for	detecting	CAD	at	an	early	stage	before	clini-
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cal	complications	have	occurred.	This	approach	may	permit	prevention	of	complica-
tions	and	reduce	morbidity	and	mortality	in	these	patients.
Two	 recent	 studies	 used	 nuclear	 imaging	with	 SPECT	 and	 showed	 a	 prevalence	 of	
(silent)	myocardial	ischemia	ranging	from	18%	to	22%	in	truly	asymptomatic	patients	
with type 2 diabetes.36, 43	 However,	 SPECT	 reflects	 only	 indirectly	 the	 presence	 of	
CAD,	since	it	is	based	on	the	detection	of	coronary	lesions	that	result	in	compromised	
blood	flow	during	stress,	whereas	the	actual	prevalence	of	any	atherosclerosis	in	as-
ymptomatic	 patients	with	 diabetes	mellitus	may	 be	 higher.	 Indeed,	 in	 the	 current	
study	with	MSCT,	CAD	was	observed	 in	80%	of	 asymptomatic	patients	with	 type	2	
diabetes	mellitus.	Furthermore,	the	majority	of	patients	showed	diffuse	involvement	
of all three coronary arteries. The high prevalence of coronary atherosclerosis among 
diabetic	patients	without	clinical	CAD	has	been	defined	previously	in	a	large	autopsy	
cohort of 293 decedents.76	In	line	with	the	current	observations,	coronary	atheroscle-
rosis	was	observed	in	almost	75%	of	individuals	with	50%	having	diffuse	multi-vessel	
CAD.
Noninvasively, calcium scoring has been proposed to determine the prevalence of 
atherosclerosis.	Previous	studies	 in	the	general	population	have	demonstrated	that	
the extent of coronary artery calcium strongly correlates with the overall magnitude 
of	atherosclerotic	plaque	burden	and	subsequent	risk	of	coronary	events.77-79
Figure 4.		Example	of	a	patient	with	noncalcified	atherosclerosis	on	MSCT.	
In	(A)	and	(B)	3D	volume	rendered	reconstructions	are	provided,	showing	the	left	anterior	descending	(LAD)	and	left	circumflex	
(LCx)	coronary	artery	in	(A),	whereas	the	right	coronary	artery	(RCA)	can	be	observed	in	(B).	C-	E)	curved	multiplanar	recon-
structions	of	respectively	the	RCA,	LAD	and	LCx.	In	all	three	coronary	arteries,	atherosclerosis	in	the	absence	of	calcifications	
can	be	observed	(white	arrows).	
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In	the	current	study,	coronary	calcifications	(calcium	score	>10)	were	observed	in	56%	
of	patients.	Moreover,	extensive	calcifications	were	observed	in	19%	of	patients.	These	
observations	are	in	line	with	previous	investigations.49, 80
 
Plaque morphology
In	 addition	 to	 the	 presence	 of	 (significant)	 CAD,	 plaque	 characteristics	were	 also	 as-
sessed	 in	the	current	study.	Analysis	of	 the	relative	proportion	of	nonobstructive	and	
obstructive	plaques	revealed	that	plaques	were	mainly	nonobstructive	(82%).	A	similar	
relation	between	diabetes	and	nonobstructive	plaques	has	been	shown	in	studies	us-
ing invasive coronary angiography.81	It	is	important	to	realize	that	many	of	these	non-
obstructive	lesions	will	not	be	associated	with	stress-inducible	ischemia,	thus	showing	
normal	perfusion	during	stress	nuclear	imaging.	Nonetheless,	plaque	rupture	has	been	
suggested	to	occur	frequently	in	nonobstructive	plaques49, 80-82	and	detection	of	an	in-
creased	nonobstructive	plaque	burden	using	atherosclerosis	imaging	may	therefore	be	
of	clinical	importance	in	asymptomatic	patients	with	diabetes.
With	regard	to	plaque	constitution,	41%	of	the	plaques	were	classified	as	noncalcified	
plaques,	20%	as	mixed	and	39%	as	calcified	plaques.	Recently,	Mollet	et	al	reported	on	
plaque	constitution	in	patients	with	stable	CAD	using	MSCT.	In	this	population,	plaques	
were	noncalcified	in	24%,	while	the	vast	majority	of	lesions	(65%)	were	calcified.79 Ac-
cordingly	asymptomatic	diabetic	patients	appear	to	have	a	higher	prevalence	of	noncalci-
fied	plaques	which	are	mainly	nonobstructive.	These	findings	are	of	clinical	importance,	
since	these	plaques	may	be	vulnerable	to	rupture	and	may	be	related	to	the	high	cardio-
vascular	mortality	and	morbidity	in	diabetic	patients.	Indeed,	in	a	large	study	by	Raggi	et	
al	involving	903	asymptomatic	diabetic	patients,	similar	event	rates	were	observed	at	a	
lower	calcium	score	as	compared	to	non-diabetic	patients,	suggesting	that	noncalcified	
plaques	may	(to	some	extent)	determine	the	event	rate	in	diabetic	patients.78 
 
Value of calcium scoring versus noninvasive angiography to detect CAD
In	a	next	step,	the	relationship	between	calcium	score	and	the	extent	of	CAD	on	MSCT	
was	investigated.	The	prevalence	of	obstructive	CAD	paralleled	the	increasing	calcium	
score,	with	54%	of	patients	with	a	calcium	score	>400	having	at	least	1	significant	steno-
sis.	Nevertheless,	a	calcium	score	<10	was	associated	with	normal	coronary	arteries	on	
MSCT	in	only	45%	of	patients,	whereas	55%	of	patients	still	had	(noncalcified)	athero-
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sclerosis.	These	findings	underscore	the	additional	value	of	noninvasive	angiography	to	
calcium	scoring	for	assessment	of	CAD	using	MSCT.	
Clinical Implications
Identification	of	CAD	in	asymptomatic	patients	with	type	2	diabetes	can	be	of	clinical	
relevance since clinical outcome may considerably improve if aggressive medical ther-
apy	is	initiated	at	an	early	stage.	Screening	of	asymptomatic	diabetic	patients	however,	
is a heavily debated topic.82, 83	Recently,	calcium	scoring	has	been	suggested	as	a	first	
screening	tool	for	CAD	in	asymptomatic	diabetic	patients.43	However,	the	recent	findings	
indicate	that	noncalcified	atherosclerotic	plaques	are	frequently	present,	in	the	absence	
of	coronary	artery	calcium.	Whether	screening	of	asymptomatic	patients	is	useful,	and	
whether calcium scoring with or without MSCT angiography has a role in this process, 
needs to be addressed in large future studies. 
Limitations
Several	limitations	should	be	mentioned.	First,	only	a	limited	number	of	patients	were	
studied and data concerning the prevalence of atherosclerosis as determined by MSCT 
in	 larger	populations	are	needed.	Also,	despite	 the	excellent	diagnostic	accuracy	of	
MSCT,	uninterpretable	segments	due	to	motion	artefacts	remain	problematic.	In	the	
current	study,	3	(4%)	patients	were	excluded	from	analysis	for	this	reason.	Finally,	the	
radiation	 burden	 (10-15	mSv)	 of	MSCT	 remains	 a	 drawback	 of	 this	 imaging	modal-
ity.	However,	a	reduction	in	radiation	burden	is	anticipated	with	the	new	generation	
of	256-slice	MSCT	scanners	and	dose-modulation	strategies	that	are	currently	being	
developed.
Conclusion
MSCT	angiography	detected	a	high	prevalence	of	CAD	in	asymptomatic	patients	with	
type	2	diabetes.	A	 relatively	high	proportion	of	plaques	was	noncalcified	 (41%)	and	
calcified	(39%).	Accordingly,	a	calcium	score	<	10	did	not	exclude	CAD	in	this	particular	
cohort	of	patients	and	appeared	of	limited	value.	MSCT	angiography	may	provide	ad-
ditional	information	over	calcium	scoring	in	asymptomatic	patients	with	diabetes	type	2.	
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abstract
Purpose
The purpose of this study was to evaluate the prevalence of an abnormal stress myocar-
dial	perfusion	study	in	a	cohort	of	truly	asymptomatic	patients	with	type	2	diabetes	mel-
litus using myocardial perfusion imaging by means of single photon emission computed 
tomography	(SPECT).	Secondly,	we	determined	which	clinical	characteristics	may	predict	
an	abnormal	stress	myocardial	perfusion	study	in	this	population.
Methods
A	total	of	120	asymptomatic	patients	 (mean	age	53	±	10	years)	with	 type	2	diabetes	
mellitus	and	one	or	more	risk	factors	for	coronary	artery	disease	were	prospectively	re-
cruited	from	an	outpatient	diabetes	clinic.	All	patients	underwent	myocardial	perfusion	
imaging by means of adenosine 99mTc	sestamibi	SPECT.	Images	were	evaluated	for	the	
presence	of	perfusion	abnormalities	as	well	as	other	nonperfusion	abnormalities	that	
may	indicate	extensive	ischemia,	including	left	ventricular	dysfunction	(defined	as	a	left	
ventricular	ejection	fraction	<45%),	transient	ischemic	dilatation	and	adenosine-induced	
ST-segment	depression.	Multivariable	analysis	was	performed	using	a	backward	selec-
tion	strategy	to	identify	potential	predictors	for	an	abnormal	stress	myocardial	perfusion	
study.	Finally,	all	patients	were	followed	up	for	12	months	to	determine	the	occurrence	
of	 cardiovascular	events:	 (1)	 cardiac	death,	 (2)	nonfatal	myocardial	 infarction,	 (3)	un-
stable	angina	requiring	hospitalization,	(4)	revascularization,	or	(5)	stroke.
Results 
Of	the	120	patients,	40	(33%)	had	an	abnormal	stress	study,	including	myocardial	per-
fusion	abnormalities	 in	30	patients	 (25%).	 In	10	 (8%)	patients,	 indicators	of	extensive	
(possibly	balanced	ischemia)	were	observed	in	the	absence	of	abnormal	perfusion.	The	
multivariable	analysis	identified	current	smoking,	duration	of	diabetes	and	cholesterol/	
high-density	 lipoprotein	 (HDL)	 ratio	 as	 independent	 predictors	 of	 an	 abnormal	 stress	
study.	During	a	 follow-up	period	of	12	months	 six	 (5%)	patients	had	a	 cardiovascular	
event.
Conclusion
The current study revealed a high prevalence of abnormal stress myocardial perfusion 
studies	in	patients	with	type	2	diabetes	mellitus	despite	the	absence	of	symptoms.	In	
contrast	 to	earlier	studies	current	smoking,	duration	of	diabetes	and	cholesterol/HDL	
ratio	were	identified	as	independent	predictors	of	an	abnormal	study.
61
Prevalence and predictors of abnormal MPS
Introduction
Diabetes	mellitus	is	a	devastating	disease	affecting	millions	of	individuals.	Prevalence	of	
the	disease	is	expected	to	grow	exponentially	due	to	aging	of	the	population,	increased	
prevalence	of	obesity,	and	unhealthy	life-styles.	In	patients	with	type	2	diabetes	melli-
tus, cardiovascular diseases are a major cause of mortality and morbidity, with coronary 
artery	disease	(CAD)	being	the	leading	cause	of	death.6 Moreover, atherosclerosis and 
CAD	appear	to	develop	differently	in	patients	with	diabetes	as	compared	to	nondiabetic	
individuals.	 Frequently,	CAD	develops	at	a	 younger	age	and	 shows	 faster	progression	
without the development of symptoms.8, 9	Consequently,	subclinical	or	silent	myocardial	
ischemia	is	frequently	present	in	patients	with	diabetes,	yet	difficult	to	detect	as	a	re-
sults of the absence of symptoms. 
To	improve	identification	of	diabetic	patients	at	high	risk	for	cardiovascular	events,	as-
sessment of myocardial perfusion by means of single photon emission computed tomog-
raphy	(SPECT)	imaging	has	been	proposed.20, 22 Although several studies have described 
the	prevalence	of	myocardial	ischemia	in	type	2	diabetes	mellitus	patients,	only	a	limited	
number	of	studies	have	prospectively	included	truly	asymptomatic	patients	with	diabe-
tes.	These	prospective	studies	have	shown	a	prevalence	of	silent	myocardial	 ischemia	
ranging from 15% to 22%.36, 43	 In	order	 for	screening	to	be	cost-effective,	one	should	
find	strategies	to	“enrich”	the	target	population	of	asymptomatic	patients	with	diabetes.	
Accordingly,	it	has	been	proposed	that	noninvasive	evaluation	should	be	performed	only	
in	a	subset	of	diabetic	patients	with	certain	clinical	characteristics	suggesting	higher	risk	
of	CAD	and	a	 cardiovascular	event,	 thereby	 increasing	 the	yield	of	abnormal	 studies.	
Accordingly,	clinical	predictors	are	needed	to	identify	those	patients	with	a	higher	likeli-
hood of silent myocardial ischemia. 
The purpose of this study was to evaluate the prevalence of an abnormal stress myocar-
dial	perfusion	study	in	a	cohort	of	truly	asymptomatic	patients	with	type	2	diabetes	mel-
litus	using	myocardial	perfusion	imaging	by	means	of	SPECT.	Secondly,	we	determined	
which	clinical	characteristics	may	predict	an	abnormal	stress	myocardial	perfusion	study	
in	this	population	indicative	of	cardiovascular	disease.	
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materials and methods
Patients
A	total	of	120	asymptomatic	patients	with	type	2	diabetes	mellitus	were	included	in	this	
study,	of	whom	100	(83%)	had	also	participated	in	a	previous	study.84	All	patients	were	
referred	from	a	diabetic	outpatient	clinic	to	our	hospital	for	cardiovascular	risk	stratifica-
tion.	The	diagnosis	of	diabetes	was	established	by	the	referring	physician	and	confirmed	
by	patient	history	and/or	the	use	of	insulin	or	oral	hypoglycaemic	agents.1 
Inclusion	criteria	consisted	of	confirmed	type	2	diabetes	mellitus	in	combination	with	
complete	absence	of	angina	or	angina-equivalent	symptoms.	Exclusion	criteria	were:	
known	or	suspected	CAD,	stress	test	or	coronary	angiography	before	referral,	history	
of	 coronary	 revascularization,	 treatment	with	 antianginal	medication,	 electrocardio-
graphic	 evidence	 of	 Q-wave	 myocardial	 infarction,	 ischemic	 ST	 segment	 or	 T-wave	
changes	or	complete	left	bundle	branch	block	and	active	bronchospasm,	excluding	the	
use	of	adenosine.	Asymptomatic	status	was	confirmed	using	the	Rose	questionnaire	
for angina.15 
ECG‑gated SPECT 
Data acquisition
ECG-gated	SPECT	 imaging	was	performed	using	a	2-day	protocol	 (stress	and	rest)	with	
99mTc	sestamibi	(99mTcMIBI).	All	patients	were	instructed	not	to	consume	caffeine-contain-
ing	products	for	24	hour	before	testing.	Adenosine	was	infused	at	a	rate	of	140	µg/kg	body	
weight per minute for 6 minutes with a simultaneous handgrip exercise. Blood pressure 
was measured and recorded at rest and every minute during adenosine infusion and the 
recovery	phase.	Twelve-lead	electrocardiography	(ECG)	was	recorded	each	minute	and	
continuously	monitored	(leads	aVF,	V1	and	V5)	for	the	development	of	arrhythmia	or	ST-
segment	deviation.	At	the	end	of	the	third	minute	of	infusion,	99mTcMIBI	(500	MBq)	was	
injected	intravenously.	Imaging	was	performed	120	minutes	after	radiopharmaceutical	
injection	using	a	triple-head	SPECT	gamma	camera	(GCA	9300/HG;	Toshiba	Corporation,	
Tokyo,	Japan),	using	low-energy,	high	resolution	collimators.	Image	were	acquired	using	
a	circular	360°	orbit,	60	projections	and	40	seconds	per	projection.61, 62	No	attenuation	
correction	was	applied.	The	cardiac	 images	were	processed	 in	 the	usual	manner	and	
short-axis,	horizontal-long	axis	and	vertical-long	axis	views	were	reconstructed.	Patient	
motion	was	evaluated	by	examining	the	raw	cine	images.	
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Data analysis
Reconstructed	short-	and	long-axis	views	as	well	as	polar	map	formats	(normalized	to	
the maximum tracer	activity)	were	used	for	semi-quantitative	visual	interpretation.	The	
myocardium was divided into 17 segments and each segment was evaluated in consen-
sus	by	two	expert	observers	using	a	four-point	scoring	system	(0	>75%	tracer	uptake,	1	
50-75%	tracer	uptake,	2	25-50%	tracer	uptake,	3	<25%	tracer	uptake).66, 85
The	summed	stress	score	(SSS)	and	summed	rest	score	(SRS)	were	obtained	by	summa-
tion	of	the	individual	segmental	scores	in	stress	and	rest,	respectively.	The	summed	dif-
ference	score	(SDS)	was	calculated	by	subtracting	the	SRS	from	the	SSS,	which	represents	
both	the	extent	and	severity	of	perfusion	abnormalities.86
Perfusion	 defects	were	 identified	 on	 the	 stress	 images	 (tracer	 activity	 less	 than	 75%	
of	maximum)	and	divided	into	ischemia	(reversible	defects),	scar	tissue	(fixed	defects)	
or	mixed	(scar	and	ischemia).	Reversible	perfusion	defects,	as	defined	by	SDS	≥2,	were	
graded	as	mild,	 (SDS	2-4)	or	moderate	to	severe	(SDS	≥4).	Fixed	defects	were	consid-
ered	present	 if	 SRS	≥2	and	SDS	<2.	Perfusion	defects	were	allocated	 to	 the	 coronary	
artery	territories	 (left	descending,	 left	circumflex	and	right	coronary	arteries).87 Using 
the	gated	images,	regional	wall	motion	was	analyzed	to	improve	differentiation	between	
true	perfusion	 abnormalities	 and	attenuation	artefacts.	 In	 addition,	 SPECT	data	were	
evaluated	for	other	abnormalities	 indicative	for	 (possibly	extensive)	CAD,	or	balanced	
ischemia.	Left	ventricular	ejection	fraction	(LVEF),	at	rest	and	during	stress,	was	derived	
from	the	end-diastolic	volume	(EDV)	and	end-systolic	volume	(ESV).	Patients	with	resting	
LV	dysfunction	(LVEF	<45%)	were	classified	as	having	an	abnormal	study.36, 88	Also,	SPECT	
images	revealing	increased	radiotracer	lung	uptake	and	transient	ischemic	dilation	(TID)	
(reflected	by	a	ratio	of	stress	and	rest	short-axis	volumes	of	the	LV	larger	than	1.21)	of	
the	LV	were	categorized	as	abnormal.36, 89, 90 Finally,	flat	or	down-sloping	ST-segment	
depression	≥1	mm	at	80	ms	after	the	J-point	in	two	or	more	leads	on	the	ECG	during	
adenosine infusion was also interpreted as an abnormal test result.63 Thus, an abnormal 
vasodilator	stress	SPECT	myocardial	perfusion	imaging	study	was	defined	as;	1	abnormal	
myocardial	perfusion,	2	LVEF	<	45	%,	3	TID,	4	increased	lung	uptake	and	5	ischemic	ST	
depression during adenosine infusion. 
follow-up
Information	during	 12	months	 of	 follow-up	was	 obtained	by	 clinical	 visits	 or	 tele-
phone	interviews.	A	cardiovascular	event	was	defined	as	the	occurrence	of:	(1)	car-
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diac	death,	 (2)	nonfatal	myocardial	 infarction,	 (3)	unstable	angina	 requiring	hospi-
talization,	 (4)	 revascularization,	 or	 (5)	 stroke.	 Cardiac	 death	was	 defined	 as	 death	
caused	by	acute	myocardial	 infarction,	ventricular	arrhythmias,	or	refractory	heart	
failure.	Nonfatal	myocardial	infarction	was	defined	based	on	criteria	of	typical	chest	
pain,	 elevated	 cardiac	 enzyme	 levels,	 and	 typical	 changes	 on	 the	 electrocardio-
gram.91	Finally,	also	the	number	of	diagnostic	conventional	coronary	angiograms	was	
recorded. 
Statistical analysis
Categorical	 baseline	 characteristics	 are	 expressed	 as	 numbers	 and	 percentages,	 and	
compared	between	two	groups	with	the	chi-square	test.	Continuous	variables	are	ex-
pressed	as	mean	(standard	deviation)	and	compared	with	the	two-tailed	t test for inde-
pendent samples.
Uni-	and	multivariable	analysis	of	baseline	characteristics	was	performed	to	identify	po-
tential	predictors	for	an	abnormal	stress	myocardial	perfusion	study.	Odds	ratios	were	
calculated	with	95%	confidence	intervals	as	estimates	of	the	risk	associated	with	a	par-
ticular	variable.	A	backward	selection	strategy	was	used	and	included	all	variables	iden-
tified	in	the	univariable	analysis	with	p	≤0.2.	Statistical	analyses	were	performed	using	
SPSS	software,	version	12.0	(SPSS,	Chicago,	Illinois)	and	p-values	<0.05	were	considered	
statistically	significant.	
results
Patient characteristics
In	total	122	patients	were	referred	prospectively	from	the	outpatient	diabetic	clinic	and	
enrolled	in	the	present	study.	Two	patients	were	excluded	from	the	analysis	due	to	poor	
image	quality.	Thus,	the	final	study	population	included	120	consecutive	asymptomatic	
patients	with	type	2	diabetes.	
Baseline	characteristics	of	the	120	patients	analyzed	are	presented	 in	Table	1.	Briefly,	
the	mean	age	was	53	±	10	years	and	75	patients	(62%)	were	male.	The	mean	duration	of	
diabetes	was	9.5	±	7.3	years.	Oral	anti-diabetic	medication	was	used	by	59%	of	patients,	
whereas	24%	used	insulin.	Overall,	only	23%	of	the	patients	received	aspirin	and	57%	
statin	therapy.	
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table 1.  Patient	characteristics;	comparison	between	patients	with	normal	and	abnor-
mal stress myocardial perfusion studies. 
Variables All patients
n=120
abnormal 
study n=40
normal 
study n=80
P value 
Male 75	(62) 23	(58) 52	(65) 0.42
Female 45	(38) 17	(42) 28	(35) 0.42
Age	(years) 53±10 53±10 53±10 1.00
Diabetes-related	risk	factors
Duration	(years) 9.5±7.3 11.8±8.4 8.3±6.4 0.03
Age	at	time	of	diagnosis	of	diabetes	(years) 43±12 41±13 45±10 0.05
HbA1C 7.3±1.6 7.5±1.6 7.3±1.6 0.39
Treatment
Oral 70	(59) 20	(50) 50	(63) 0.19
Insulin and oral 18	(15) 66	(15) 12	(15) 0.98
Insulin 29	(24) 13	(33) 16	(20) 0.14
Peripheral	vascular	disease	(PVD) 12	(10) 5	(13) 7	(9) 0.52
Peripheral	neuropathy	(PNP) 25	(21) 7	(18) 18	(23) 0.53
Peripheral vascular and neuropathy 17	(14) 9	(23) 8	(10) 0.06
Body	mass	index	(kg/m2) 29.1±5.4 29.0±4.5 29.1±5.7  0.92
Waist	circumference	(cm) 103±14 104±14 102±14 0.66
Hypertension 65	(54) 23	(58) 42	(53) 0.60
Hypercholesterolemia 68	(57) 27	(68) 41	(51) 0.90
Family	history	of	CAD 65	(54) 18	(45) 47	(59) 0.15
Smoking
Past 25	(21) 5	(13) 20	(25) 0.11
Current 27	(23) 16	(40) 11	(14) 0.001
Medication
Aspirin 27	(23) 9	(30) 16	(20) 0.35
ACE	inhibitors 42	(35) 14	(35) 28	(35) 1.0
ARB 27	(23) 14	(25) 17	(21) 0.64
Statins 68	(57) 27	(68) 41	(51) 0.09
Serum markers
Total	cholesterol	(mmol/l) 4.8±1.2 4.5±1.3 4.9±1.1 0.09
LDL	(mmol/l) 3.1±1.1 3.0±1.3 3.1±1.0 0.45
HDL	(mmol/l) 1.4±0.6 1.5±0.5 1.4±0.6 0.48
Triglycerides	(mmol/l) 2.0±1.2 1.8±0.9 2.1±1.4 0.24
Cholesterol/HDL	ratio 3.7±1.3 3.4±1.0 3.9±1.4 0.03
Creatinine	(mmol/l) 77.6±20.1 75.2±20.0 78.8±20.2 0.36
Urine	albumin-creatinine	ratio 11.6±30.2 10.3±26.0 12.4±32.5 0.75
CRP 9.3±9.1 11.1±12.7 8.2±6.1 0.26
ApoA1 1.4±0.2 1.5±0.2 1.1±0.3 0.51
ApoB 0.9±0.3 0.8±0.3 0.9±0.3 0.16
Fibrinogen 3.9±0.9 4.1±1.2 3.8±0.8 0.26
ACE,	angiotensin	converting	enzyme;	Apo,	apolipoprotein;	ARB,	angiotensin	receptor	blocker;	CAD,	coronary	artery	disease;	
CRP,	chain	reactive	protein;	HDL,	high-density	lipoprotein;	LDL,	low-density	lipoprotein.
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prevalence of an abnormal stress myocardial perfusion study 
Perfusion abnormalities
Regional	perfusion	abnormalities	were	present	in	30	patients	(25%).	Of	these	patients	
22	 (73%)	 patients	 showed	 reversible	 defects,	 4	 (13%)	 patients	 had	 fixed	 defects	 and	
4 (13%)	patients	had	partially	reversible	defects.	Ten	patients	(33%)	showed	mild	isch-
emia	(SDS<4),	17	(57%)	showed	moderate	ischemia	(SDS	4-8)	and	3	(10%)	showed	se-
vere	ischemia	(SDS	>8).
The	anatomic	location	of	the	perfusion	defects	was	as	follows:	the	left	anterior	descending	
territory	in	19	patients	(63%),	left	circumflex	territory	in	3	(10%),	and	right	coronary	artery	
territory	in	7	(23%).	In	2	(7%)	patients,	more	than	two	vascular	territories	were	involved.
LVEF and volumes
Data	on	rest	LVEF	and	end-diastolic	volumes	(EDV)	and	end-systolic	volumes	(ESV)	were	
available	in	117	(98%)	patients.	The	mean	LVEF	was	61.4	±	11.4%	with	a	mean	EDV	of	
82.2	±	27.7	ml	and	a	mean	ESV	of	33.1	±	19.4	ml.	Stress	data	regarding	LVEF,	EDV	and	ESV	
were	available	in	92	patients	(77%)	with	a	mean	LVEF	of	59.5	±	11.4%	and	a	mean	EDV	
and	ESV	of	83.6	±	30.2	ml	and	35.6	±	21.7	ml,	respectively,	during	stress.
In	 patients	with	 perfusion	 abnormalities,	mean	 LVEF,	 EDV	 and	 ESV	were	 respectively	
58.0 ± 12.6%, 85.0 ± 29.0 ml and 37.9 ± 22.6 ml at rest and 57.5% ± 12.8%, 90.0 ± 37.0 ml 
and	41.8	±	28.2	ml	during	stress.	Eight	patients	had	LV	dysfunction	at	rest	(LVEF	<45%),	
of	which	4	patients	also	showed	abnormal	perfusion.
Transient ischemic dilatation, increased lung uptake and ST segment ECG changes
Transient	ischemic	dilatation	(TID)	was	noted	in	two	patients,	one	of	which	showed	nor-
mal	perfusion.	 In	none	of	the	patients	was	increased	radiotracer	 lung	uptake	was	ob-
served,	but	adenosine-induced	ST	segment	depression	was	detected	 in	eight	patients	
(7%).	Three	of	these	patients	also	showed	perfusion	abnormalities.	Accordingly,	an	ab-
normal	stress	myocardial	perfusion	study	was	observed	in	40	(33%)	patients.	The	results	
are	summarized	in	Figure	1.
predictors of an abnormal stress myocardial perfusion study 
Baseline	and	clinical	characteristics	of	patients	with	normal	and	abnormal	stress	myo-
cardial	perfusion	studies	are	summarized	in	Table	1.	Patients	with	an	abnormal	stress	
study	had	a	significantly	longer	duration	of	diabetes	and	were	significantly	younger	at	
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the	time	of	diagnosis	(p=0.03	and	p=0.05	respectively)	as	compared	to	patients	with	nor-
mal	stress	tests.	Also,	patients	with	an	abnormal	study	were	significant	more	often	cur-
rent	smokers	and	had	a	lower	cholesterol/	high-density	lipoprotein	(HDL)	ratio	(p=0.001	
and p=0.03,	respectively).	
In	Table	2,	the	univariable	analysis	of	the	clinical	baseline	characteristics	to	predict	an	
abnormal	stress	myocardial	perfusion	study	is	shown.	Subsequently,	multivariable	analy-
sis	was	performed	using	a	backward	selection	strategy	and	included	all	variables	identi-
fied	in	the	univariable	analysis	with	p≤0.2.	As	indicated	in	Table	3,	multivariable	analysis	
demonstrated	 current	 smoking,	duration	of	diabetes	 and	 cholesterol/HDL	 ratio	 to	be	
significant	independent	predictors	of	an	abnormal	stress	myocardial	perfusion	study.
follow-up
During	a	follow-up	period	of	12	months	six	patients	(5%)	had	a	cardiovascular	event.	Five	
patients	underwent	revascularization,	percutaneous	coronary	 intervention	 in	two	and	
coronary	artery	bypass	grafting	in	three.	Finally,	one	patient	had	a	stroke.	In	addition,	
five	patients	underwent	diagnostic	conventional	coronary	angiography	not	followed	by	
intervention.
All	 patients	undergoing	 revascularization	presented	with	abnormal	 SPECT	findings.	 In	
two	patients	with	severe	ischemia	on	SPECT,	coronary	angiography	revealed	significant	
Figure 1.	Distribution	of	stress	myocardial	perfusion	results.
A.	Of	120	patients,	40	had	an	abnormal	stress	myocardial	perfusion	study.	B.	Observations	in	patients	with	abnormal	studies.	
Other,	nonperfusion	abnormalities	that	may	indicate	extensive,	possibly	balanced	ischemia;	TID,	transient	ischemic	dilatation.
LV	dysfunction	 4
TID	 1
ECG	abnormalities	 5
LV	dysfunction	 4
TID	 1
ECG	abnormalities	 3
a b
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table 2. Univariable predictors of an abnormal stress myocardial perfusion study.
Odds ratio 95% confidence interval P value 
Gender	(M/F) 0.73 1.59-0.34 0.42
Age	(years) 1.00 0.96-1.04 1.00
Diabetes-related	risk	factors
Duration	(years) 1.07 1.01-1.13 0.02
Age	at	time	of	diagnosis	of	diabetes	(years) 0.97 0.93-1.00 0.05
HbA1C 1.11 0.87-1.42 0.39
Treatment
Oral 1.67 0.77-3.59 0.19
Insulin and oral 1.02 0.35-2.94 0.98
Insulin 0.53 0.22-1.25 0.15
Peripheral	vascular	disease	(PVD) 0.67 0.20-2.27 0.52
Peripheral	neuropathy	(PNP) 0.73 0.28-1.93 0.57
Peripheral vascular and neuropathy 2.61 0.92-7.40 0.07
Body	mass	index	(kg/m2) 1.00 0.93-1.07 0.92
Waist	circumference	(cm) 1.01 0.98-1.04 0.65
Hypertension 1.22 0.57-2.63 0.61
Hypercholesterolemia 0.09 0.89-4.37 0.09
Family	history	of	CAD 0.57 0.27-1.24 0.16
Smoking
Past 0.43 0.15-1.24 0.12
Current 4.18 1.71-10.26 0.02
Medication
Aspirin 1.52 0.63-3.67 0.36
ACE	inhibitors 1.00 0.45-2.22 1.00
ARB 1.24 0.51-3.02 0.64
Statins 1.98 0.89-4.37 0.09
Serum markers
Total	cholesterol	(mmol/l) 0.75 0.53-1.06 0.10
LDL	(mmol/l) 0.87 0.61-1.24 0.45
HDL	(mmol/l) 1.27 0.66-2.48 0.48
Triglycerides	(mmol/l) 0.81 0.56-1.16 0.25
Cholesterol/HDL	ratio 0.69 0.49-0.97 0.03
Creatinine	(mmol/l) 0.95 0.87-1.02 0.15
Urine	albumin-creatinine	ratio 1.00 0.98-1.01 0.75
CRP 1.04 0.97-1.11 0.29
ApoA1 1.72 0.34-8.53 0.51
ApoB 0.33 0.07-1.55 0.16
Fibrinogen 1.34 0.86-2.06 0.19
ACE,	angiotensin	converting	enzyme;	Apo,	apolipoprotein;	ARB,	angiotensin	receptor	blocker;	CAD,	coronary	artery	disease;	
CRP,	chain	reactive	protein;	F,	female;	HDL,	high-density	lipoprotein;	LDL,	low-density	lipoprotein;	M,	male.
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two-vessel	disease	and	was	 followed	by	percutaneous	coronary	 intervention.	 In	addi-
tion,	three	patients	underwent	coronary	artery	bypass	grafting	following	the	observa-
tion	of	significant	three-vessel	disease	on	conventional	coronary	angiography.	In	these	
patients,	severe	balanced	ischemia	had	been	suspected	based	on	SPECT.	Balanced	isch-
emia	had	also	been	suspected	in	the	additional	five	patients	who	underwent	conven-
tional	coronary	angiography	without	revascularization.	In	these	patients,	no	significant	
stenoses	were	observed.	Of	note,	the	SPECT	study	was	normal	in	the	patient	who	devel-
oped a stroke.
discussion
In	 the	present	 study	33%	of	patients	with	 type	2	diabetes	mellitus	had	an	abnormal	
stress	myocardial	perfusion	study	indicative	for	cardiovascular	disease,	including	perfu-
sion	abnormalities	(25%)	as	well	as	other	relevant	abnormalities	(8%).	In	addition,	the	
variables	current	smoking,	duration	of	diabetes	and	cholesterol/HDL	ratio	were	identi-
fied	as	independent	predictors	of	an	abnormal	stress	myocardial	perfusion	study.
prevalence of abnormal stress myocardial perfusion study indicative for cardiovascular 
disease 
Various	studies	have	evaluated	the	prevalence	of	silent	myocardial	 ischemia	in	both	
retrospective	 and	 prospective	 settings.	 Studies	 using	 nuclear	 imaging	 to	 assess	 the	
prevalence	of	 ischemia	 in	asymptomatic	diabetic	patients	have	shown	perfusion	ab-
normalities	 in	6%	 to	59%	of	patients.19, 25-38	Most	 likely,	 these	widely	differing	esti-
mates	of	CAD	in	asymptomatic	patients	reflect	differences	in	study	design	and	inclu-
sion	criteria.	In	the	investigation	by	Miller	et	al	a	high	prevalence	of	abnormal	stress	
SPECT	 studies	 (59%	of	 patients)	was	 reported.	However,	 in	 this	 retrospective	 study	
also	patients	with	anti-anginal	medication	and	Q	waves	and	ST-T	abnormalities	on	the	
table 3. Multivariable	logistic	regression	analysis
Odds ratio 95% confidence interval P value
Current smoker 7.12 2.51-20.23 <0.001
Cholesterol/HDL	ratio 0.60 0.41-0.89 0.01
Duration	diabetes 1.07 1.01-1.13 0.02
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ECG	were	included,	indicating	a	higher	risk	population.25 In the Milan Study on Athero-
sclerosis	and	Diabetes	(MiSAD)	exercise	electrocardiography	was	used	in	asymptom-
atic	patients	with	diabetes	as	an	initial	test	to	select	candidates	for	stress	myocardial	
perfusion	imaging.	Possibly	because	of	the	low	accuracy	of	exercise	ECG	for	detection	
CAD,	the	overall	prevalence	of	observed	silent	CAD	was	low:	97	(13%)	of	735	enrolled	
patients	had	an	abnormal	exercise	test	that	was	confirmed	in	only	52	(53%	by	myocar-
dial	perfusion	imaging),	yielding	an	overall	prevalence	of	silent	ischemia	of	only	6%.30 
The	patients	enrolled	in	our	study	were	truly	asymptomatic	patients	with	type 2 dia-
betes	without	any	clinical	evidence	of	CAD	and	prospectively	recruited	from	a	single	
diabetes care center. The stress myocardial perfusion study was abnormal in 40 pa-
tients	(33%),	 including	20	patients	(17%)	with	moderate	to	severe	 ischemia.	Slightly	
lower	values	were	reported	in	the	DIAD	trial	by	Wackers	et	al.	The	DIAD	trial	evaluated	
prospectively	silent	myocardial	 ischemia	 in	522	asymptomatic	patients	with	at	 least	
two risk factors, by using gated 99mTc	MIBI	SPECT.36 This study showed a prevalence 
of	22%	abnormal	SPECT	studies,	including	markedly	abnormal	perfusion	images	with	
moderate	or	large	stress	defects	in	33	patients	(6%).
The discrepancy of the prevalence of silent myocardial ischemia between our study 
and	the	DIAD	trial	can	be	explained	by	differences	 in	baseline	characteristics	of	 the	
included	patients.	In	our	study	more	subjects	were	male,	the	age	at	diagnosis	of	diabe-
tes	was	lower	and	consequently	the	duration	of	diabetes	was	longer.	In	addition,	more	
patients	were	 insulin	 dependent	 and	 a	 higher	 percentage	 of	 patients	were	 current	
smokers,	factors	which	are	in	general	associated	with	more	advanced	CAD.	
predictors of an abnormal stress myocardial perfusion study indicative for cardiovas-
cular disease 
In	 the	present	study	current	smoking,	duration	of	diabetes	and	cholesterol/HDL	 ratio	
were	identified	as	independent	predictors	for	an	abnormal	stress	myocardial	perfusion	
study. In contrast, none of the established risk factors could predict abnormal myocardial 
perfusion	in	the	DIAD	trial,	except	for	cardiac	neuropathy.	Also	in	another	prospective	
investigation,	 established	 cardiovascular	 risk	 factors	 failed	 to	predict	myocardial	 isch-
emia.43	Accordingly,	a	large	variation	in	results	exists	among	investigations.	Large	pro-
spective	trials	therefore	are	needed	to	confirm	whether	variables	such	as	duration	of	
diabetes	may	potentially	be	helpful	to	improve	identification	of	asymptomatic	diabetic	
patients	at	higher	risk	for	perfusion	abnormalities	and	possibly	cardiovascular	events.
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Clinical implications
At	present,	screening	 for	CAD	 in	asymptomatic	patients	with	diabetes	 type	2	 is	still	a	
heavily debated topic.82, 83	Nevertheless,	this	population	may	benefit	from	identification	
of silent myocardial ischemia since clinical outcome may be considerably improved by 
initiation	of	aggressive	therapy	at	an	early	stage	as	recently	shown	by	Wackers	et	al.92
However,	 as	 the	 overall	 percentage	 of	 asymptomatic	 diabetic	 patients	with	 ischemia	
appears	 to	be	 low,	selection	criteria	are	needed	to	 identify	patients	at	higher	 risk	 for	
ischemia	and	who	may	benefit	from	myocardial	perfusion	imaging.	Since	in	several	pre-
vious	studies	established	risk	factors	for	CAD	and	clinical	patient	characteristics	 failed	
to	identify	high	risk	patients,	alternative	markers,	such	as	coronary	calcium,	have	been	
proposed. The presence of coronary calcium is a direct marker for coronary atheroscle-
rosis,	and	can	be	relatively	easily	assessed.	In	the	general	population,	several	investiga-
tions	have	demonstrated	a	strong	relation	between	increasing	coronary	calcium	scores	
and a higher prevalence of ischemia as well as coronary events.55, 93 Accordingly, coro-
nary	calcium	may	be	useful	to	select	patients	requiring	further	evaluation	by	means	of	
myocardial	perfusion	imaging.	This	concept	was	recently	evaluated	in	510	asymptomatic	
diabetic	patients	by	Anand	et	al.43	In	this	study	only	patients	with	considerable	calcium	
(reflected	by	a	calcium	score	>100)	were	referred	to	stress	myocardial	perfusion	imag-
ing.	A	random	sample	of	53	patients	without	considerable	calcium	(calcium	score	<100)	
were	also	referred	to	serve	as	a	control	group.	The	extent	of	coronary	calcifications	cor-
related	well	with	 the	 prevalence	 and	 severity	 of	myocardial	 perfusion	 abnormalities.	
Moreover,	patients	with	extensive	calcium	(calcium	score	>400)	were	shown	to	have	a	
high	 likelihood	 (48%)	of	myocardial	 ischemia	while	patients	without	considerable	cal-
cium	(calcium	score	<100)	the	likelihood	of	ischemia	was	low	(18%).	Finally,	the	calcium	
score	was	demonstrated	to	be	superior	to	the	established	risk	factors	in	predicting	silent	
ischemia and cardiac events.
Importantly	however,	severe	calcifications	have	also	been	observed	in	patients	with	nor-
mal myocardial perfusion studies55, 68, and abnormal perfusion studies may occur in the 
absence	of	(extensive)	calcifications.	To	some	extent,	the	presence	of	extensive	noncalci-
fied	atherosclerosis	may	account	for	this	discrepancy.	Indeed,	Scholte	et	al	recently	com-
pared	multislice	computed	tomography	(MSCT)	angiography	to	coronary	calcium	scores	
in	70	asymptomatic	patients	with	type	2	diabetes.	Atherosclerosis	was	present	on	MSCT	
in	55%	of	patients	with	no	or	minimal	calcium,	suggesting	the	presence	of	substantial	
noncalcified	rather	than	calcified	plaque	burden.69	Moreover,	a	subsequent	 investiga-
tion	that	correlated	coronary	calcium	scores,	MSCT	and	myocardial	perfusion	imaging	
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in	a	small	cohort	of	asymptomatic	patients	with	type	2	diabetes	failed	to	demonstrate	
a	consistent	interrelationship	between	these	three	modalities.84 In this study, all three 
tests	were	abnormal	in	only	5%	of	patients.	In	contrast,	in	almost	half	of	patients	with	
abnormal	SPECT	no	significant	abnormalities	were	observed	during	both	coronary	cal-
cium	scoring	and	MSCT.	Accordingly,	it	is	conceivable	that	the	various	imaging	modalities	
that	are	available	reflect	distinctly	different	aspects	of	CAD.	Possibly,	 incorporation	of	
both	predictive	baseline	 characteristics	and	atherosclerotic	markers	 such	as	 coronary	
calcium	score	may	yield	the	most	optimal	algorithm	for	the	identification	of	silent	myo-
cardial	ischemia	in	asymptomatic	patients	with	type	2	diabetes.	
In	such	an	algorithm,	assessment	of	coronary	calcium	could	be	the	initial	test.	In	patients	
with extensive coronary calcium, the likelihood of ischemia is high, regardless of the 
presence	of	additional	risk	factors.43	Consequently,	patients	with	calcium	scores	>400	
should	be	referred	for	evaluation	of	ischemia.	In	contrast,	the	likelihood	of	ischemia	is	
low	in	patients	with	minor	calcifications	(calcium	scores	<100),	and	most	patients	will	
not	require	further	testing.	Indeed,	as	the	expected	prevalence	of	patients	with	ischemia	
is	low,	referral	to	ischemia	testing	will	therefore	probably	not	be	cost-effective.	
However,	patients	with	moderate	calcium	(calcium	scores	between	100	and	400)	repre-
sent	an	uncertain	category	and	possibly,	referral	to	ischemia	testing	should	be	based	on	
the	presence	of	additional	risk	factors	such	as	the	duration	of	diabetes.	Unfortunately,	no	
data	are	currently	available	to	support	this	stepwise	approach.	Large	prospective	studies	
should	address	the	safety,	cost-effectiveness	and	outcome	of	such	proposed	algorithms.
Limitations
Only	a	 limited	number	of	patients	were	included	in	the	present	study.	 In	addition,	no	
comparison	to	other	imaging	modalities,	such	as	coronary	calcium	scoring,	was	system-
atically	available.	With	 regard	 to	data	acquisition,	no	attenuation	correction	was	per-
formed.	This	may	partially	explain	the	higher	prevalence	of	perfusion	abnormalities	in	
comparison	with	other	studies.	However,	only	a	small	proportion	of	the	perfusion	abnor-
malities	were	located	in	the	inferior	region.	Moreover,	the	use	of	gated	image	acquisi-
tion	allowed	systematic	analysis	of	regional	wall	motion,	thereby	improving	differentia-
tion	between	 true	perfusion	abnormalities	 and	attenuation	artefacts.	Although	dura-
tion	of	diabetes	and	cholesterol/HDL	ratio	value	was	demonstrated	to	be	independent	
predictors	for	silent	myocardial	ischemia,	exact	cut-off	values	could	not	be	determined.
Finally,	while	myocardial	 ischemia	due	 to	CAD	 is	 the	main	cause	of	 LV	dysfunction	 in	
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patients	with	diabetes	mellitus	type	2,	diabetic	myocardial	disease	(without	CAD)	is	un-
doubtedly	multifactorial	and	this	may	explain	the	number	of	patients	with	LV	dysfunc-
tion	at	rest.94 
Conclusion
A	high	prevalence	of	abnormal	stress	myocardial	perfusion	studies	indicative	for	cardio-
vascular	disease	in	asymptomatic	patients	with	type	2	diabetes	mellitus	was	observed.	
In	discrepancy	to	earlier	studies	current	smoking,	duration	of	diabetes	and	cholesterol/
HDL	ratio	could	be	identified	as	independent	predictors	of	an	abnormal	stress	myocar-
dial perfusion study.
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Case report
A	43–year	old	man	with	diabetes	type	2	was	referred	for	cardiovascular	risk	assessment	
two years ago. Other risk factors for coronary artery disease included hypercholesterol-
emia, smoking and a family history of coronary artery disease. 
The	patient	was	asymptomatic.	Physical	examination	was	unremarkable;	his	body	mass	
index was 22 kg/m2 and his blood pressure of 125/80 mmHg. Hypercholesterolemia was 
well	regulated	with	statin	administration	(total	cholesterol	3.52	mmol/L,	low-density	li-
poprotein	cholesterol	2.23	mmol/L,	high-density	cholesterol	0.94	mmol/L).	ECG	showed	
normal	sinus	rhythm	and	no	additional	abnormalities	(Figure	1).
Myocardial	perfusion	imaging	(MPI)	was	performed	with	gated	single	photon	emission	
computed	tomography	(SPECT)	using	technetium-99m	sestamibi	(500	MBq).	Pharmaco-
logical	stress	was	performed	using	adenosine;	the	stress	ECG	showed	no	abnormalities.	
On	gated	SPECT,	left	ventricular	ejection	fraction	was	68%	during	stress	as	well	at	rest;	
MPI	showed	no	perfusion	abnormalities	during	stress	or	at	rest	(Figure	2).
In	addition,	no	coronary	calcium	was	observed	during	calcium	scoring	(total	coronary	
calcium	score	0).	However,	contrast-enhanced	multislice	computed	 tomography	coro-
Figure 1. ECG	showing	sinus	rhythm	and	no	abnormalities.
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Figure 2.  SPECT	myocardial	perfusion	 imaging	showing	normal	perfusion	at	stress	and	
rest.	 Short-axis	 (SAX),	 vertical	 long-axis	 (VLA)	 and	 horizontal	 long-axis	 (HLA)	
slices	are	shown.	The	top	rows	are	the	stress	images,	and	the	bottom	rows	are	
the rest images. 
nary	angiography	revealed	the	presence	of	diffuse	nonobstructive	(<50%	luminal	nar-
rowing),	 noncalcified	 plaques	 as	 illustrated	 in	 Figure	 3.	 Risk	 factor	 modification	 was	
advised	(exercise,	stop	smoking)	and	aggressive	medical	therapy	was	initiated	(aspirin,	
statins,	ACE	inhibitor).
Two	 years	 after	 the	 index	 evaluation,	 the	 patient	was	 evaluated	 at	 the	 outpatient	
clinic.	He	was	asymptomatic,	but	the	ECG	revealed	new	development	of	negative	T-
waves	in	leads	II,	III,	aVF,	V5	and	V6	(Figure	4).	Accordingly,	myocardial	perfusion	im-
aging	SPECT	was	repeated	and	showed	a	large	irreversible	defect	in	the	inferolateral	
wall,	with	partial	reversibility	in	the	inferior	wall	(Figure	5).	Resting	echocardiography	
showed	hypokinesia	in	the	inferolateral	regions	with	moderate	(grade	2+)	mitral	re-
gurgitation.
To	evaluate	the	extent	of	infarcted	myocardium,	contrast-enhanced	(gadolinium)	mag-
netic	resonance	imaging	was	performed	(Figure	6)	and	revealed	subendocardial	infarc-
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tion	in	the	inferolateral	wall.	The	resting	cine	MRI	short-axis	slices	confirmed	hypokinesia	
in	the	inferolateral	regions	(online	Movie	1).
On	 the	basis	of	 these	 imaging	 results,	 the	patient	was	 referred	 for	 invasive	 coronary	
angiography, which revealed a proximal occlusion of the right coronary artery with ret-
rograde	filling	from	the	left	anterior	descending	coronary	artery	(online	Movies	2	and	3).	
Accordingly,	the	patient	was	scheduled	for	percutaneous	coronary	intervention.
Screening	of	asymptomatic	patients	with	diabetes	type	2	for	silent	CAD	is	a	heavily	de-
bated topic.95	Despite	early	identification	of	atherosclerosis,	followed	by	risk	factor	mod-
ification	and	aggressive	medical	therapy,	infarction	occurred	2	years	later.
These	findings	 emphasize,	 on	 the	one	hand	 the	need	 for	 risk	 stratification	 (prefer-
ably	with	noninvasive	 imaging)	 in	asymptomatic	diabetic	patients,	but	on	the	other	
hand	that	the	current	imaging	techniques	are	not	perfect	for	prediction	of	events.	We	
have	imaging	techniques	that	provide	highly	accurate	information	on	stress-inducible	
ischemia.	It	is	clear	that	patients	with	ischemia	have	an	increased	risk	for	future	car-
diovascular	 events,	 and	 invasive	 evaluation	 (with	 possible	 intervention)	 is	 needed.	
Figure 3.  Noninvasive coronary angiography with 64-slice computed tomography re-
vealed	 the	presence	of	noncalcified	atherosclerosis	with	predominantly	out-
ward remodelling. In the mid-segment of the right coronary artery a large non-
calcified	 lesion	without	 significant	 stenosis	 (arrow)	was	 detected	 (A).	 Cross-
sectional	 images	 (B,	 enlargement	 C)	 confirmed	 the	 presence	 of	 substantial	
noncalcified	plaque	(arrows)	which	showed	predominantly	outward	remodel-
ling without compromising the vessel lumen.
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This	patient	however	had	normal	myocardial	perfusion	imaging	results	while	at	stress	
and rest.
More	 recently,	 techniques	 have	 become	 available	 that	 permit	 early	 identification	 of	
atherosclerosis	 (calcium	scoring),	and	also	provide	preliminary	 information	on	plaque	
composition	 (multislice	 computed	 tomography	 angiography).	 In	 this	 patient,	 calcified	
plaques	were	not	present,	but	noncalcified	lesions	were	observed.	Recent	preliminary	
data	indicate	that	noncalcified	plaques	are	associated	with	acute	coronary	syndromes	
and	 suggest	 a	 relatively	 high	 vulnerability	 of	 these	 plaques.96, 97	 These	 noncalcified	
plaques	were	the	only	substrate	underlying	the	recent	myocardial	infarction.	This	high-
lights	the	potential	value	of	modern	imaging	technology,	but	at	the	same	time,	illustrates	
that	better	understanding	of	plaque	vulnerability	is	needed	to	further	develop	imaging	
for	optimal	risk	stratification	in	asymptomatic	diabetic	patients.
Figure 4. 	An	ECG	obtained	after	2	years	reveals	new	negative	T	waves	in	leads	II,	III,	aVF,	
V5	and	V6.
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Figure 5.		Repeat	 SPECT	myocardial	 perfusion	 imaging	was	 performed	 two	 years	 after	
the	index	SPECT	(Figure	2)	was	obtained.	An	irreversible	defect	is	shown	in	the	
inferolateral	region	(thick	arrows),	whereas	reversibility	is	demonstrated	in	the	
inferior	wall	(thin	arrows).
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Figure 6.		Contrast-enhanced	magnetic	resonance	imaging;	short-axis	slices	are	shown.	
Evidence	of	subendocardial	scar	tissue	is	observed	(arrows).
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abstract
Background
The	presence	of	 subclinical	 left	ventricular	 (LV)	dysfunction	 in	 asymptomatic	patients	
with type 2 diabetes has been previously described. However, whether there is a link 
between	subclinical	LV	dysfunction	and	subclinical	coronary	atherosclerosis	is	unknown.	
Accordingly,	the	aim	of	the	present	study	was	to	evaluate	whether	subclinical	LV	systolic	
dysfunction	 is	 independently	 related	 to	 subclinical	 coronary	 atherosclerosis	 in	 type	2	
diabetic	patients	and	if	it	could	provide	incremental	information	over	baseline	charac-
teristics	to	identify	high	risk	patients.	
Methods
A	total	of	234	asymptomatic,	type	2	diabetes	mellitus	patients	without	overt	LV	systolic	
dysfunction	and	80	controls	matched	by	age,	gender,	LV	ejection	fraction	and	cardiovas-
cular	risk	factors	underwent	coronary	artery	calcium	(CAC)	scoring	and	2-dimensional	
(2D)	echocardiography.	LV	global	longitudinal	strain	(GLS)	was	assessed	using	automated	
function	imaging	(AFI).	
Results
Patients	with	coronary	atherosclerosis	(CAC>0)	(n=139),	had	more	impaired	GLS	as	com-
pared	 to	patients	without	 coronary	 atherosclerosis	 (CAC=0)	 (n=95)	 (-18.0	 ±	 2.8 % vs. 
-16.3 ± 3.0 %, p	<0.001).	At	multivariate	analysis,	male	gender,	hypertension,	hypercho-
lesterolemia	and	GLS	were	independently	associated	with	coronary	atherosclerosis.	The	
addition	of	GLS	to	other	selected	independent	clinical	variables	significantly	improved	
the	ability	to	predict	coronary	atherosclerosis	in	these	patients	(c2 =	58.92;	p	=	0.001).
Conclusion
As	compared	to	patients	without	coronary	atherosclerosis,	diabetic	patients	with	coro-
nary	atherosclerosis	showed	a	more	impaired	GLS.	The	presence	of	subclinical	LV	systolic	
dysfunction	provides	significant	incremental	value	for	the	identification	of	patients	hav-
ing coronary atherosclerosis.
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Introduction
Cardiovascular	complications,	including	coronary	artery	disease	(CAD),	are	the	leading	
causes of morbidity and mortality in individuals with type 2 diabetes.6 The poor clinical 
outcome	of	patients	with	diabetes	underscores	the	need	to	develop	practical	approach-
es	for	detecting	CAD	at	an	early	stage	for	early	initiation	of	appropriate	treatment,	which	
potentially	may	affect	favourably	an	otherwise	poor	outcome.57	However,	the	detection	
of	CAD	in	patients	with	diabetes	remains	challenging	because	CAD	is	often	asymptom-
atic.	Noninvasive	assessment	of	the	coronary	artery	calcium	(CAC)	score,	by	means	of	
electron-beam	computed	tomography	or	multislice	computed	tomography	(MSCT),	non-
invasive imaging of the coronary arteries, by means of MSCT coronary angiography, and 
myocardial perfusion imaging, by means of single photon emission computed tomog-
raphy	(SPECT),	have	been	recently	proposed	to	improve	identification	of	asymptomatic	
diabetic	patients	at	high-risk	for	cardiovascular	events.36, 43, 84 
Recently,	subtle	abnormalities	of	 left	ventricular	(LV)	systolic	 function	have	been	re-
ported	 in	 patients	with	 type	 2	 diabetes	 using	 automated	 function	 imaging	 (AFI),	 a	
novel method based on 2-dimensional speckle-tracking echocardiography.98 However, 
in	asymptomatic	diabetic	patients	the	relation	between	subclinical	LV	systolic	dysfunc-
tion	and	the	presence	of	coronary	atherosclerosis	is	still	unclear.	Accordingly,	the	pur-
pose	of	the	present	study	was	to	evaluate	whether	subclinical	LV	systolic	dysfunction	
is independently related to coronary atherosclerosis and if it could provide incremen-
tal	 information	 over	 baseline	 characteristics	 for	 the	 identification	 of	 asymptomatic	
diabetic	patients	having	CAD.	AFI	was	used	to	identify	the	presence	of	subclinical	LV	
systolic	dysfunction,	while	the	presence	of	coronary	atherosclerosis	was	assessed	by	
means of CAC scoring.
methods
Patient population
A	total	of	289	consecutive	asymptomatic	outpatients	with	type	2	diabetes	underwent	
CAC	scoring	for	screening	of	CAD.	Two-dimensional	echocardiography	was	performed	
in	all	patients	on	the	same	day.	Patients	with	angina	or	angina-equivalent	symptoms,	
history	of	CAD,	 cardiomyopathy,	 significant	 (moderate	or	 severe)	valvular	heart	dis-
ease,	congenital	heart	disease,	rhythm	other	than	sinus	and	conduction	abnormalities	
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were	excluded.	In	addition,	patients	were	excluded	in	case	of	suboptimal	echocardio-
graphic	window.	Asymptomatic	status	was	confirmed	using	the	Rose	questionnaire	for	
angina.15	History	of	CAD	was	defined	as	the	presence	of	previous	acute	coronary	syn-
dromes,	percutaneous	or	surgical	coronary	revascularization	or	angiographically	docu-
mented	coronary	stenosis	≥50%	luminal	diameter.67 Hypertension was considered if 
systolic	blood	pressure	was	≥140	mmHg	or	diastolic	blood	pressure	was	≥90	mmHg,	
and	if	patients	were	on	antihypertensive	treatment,	regardless	of	their	blood	pressure	
values.	Hypercholesterolemia	was	defined	by	a	total	cholesterol	level	>5.0	mmol/L	or	
use	of	cholesterol	lowering	medication.	In	addition,	80	subjects	without	diabetes	were	
included in the present study as control group. The subjects of the control group were 
matched	by	age,	gender,	LV	ejection	fraction	(LVEF)	and	Framingham	risk	score	accord-
ing	to	Wilson	et	al.60	The	aforementioned	exclusion	criteria	were	also	applied	for	the	
control	group.	Control	 individuals	underwent	CAC	scoring	and	2D	echocardiography	
on the same day. 
Coronary artery calcium score, data acquisition and analysis
CAC	scoring	was	performed	using	a	64-slice	MSCT	scanner	(Aquilion	64,	Toshiba	Medical	
Systems,	Tokyo,	Japan).	For	this	purpose,	a	nonenhanced	low	dose	ECG-gated	scan	was	
performed	with	prospective	triggering	at	75%	of	the	R-R	interval.	Scan	parameters	were	
as	follows:	collimation	4	x	3.0	mm,	gantry	rotation	time	0.5	second,	tube	current	200-
250	mA	and	tube	voltage	120	kV.	CAC	score	was	determined	by	an	experienced	observer	
using	dedicated	software	 (Vitrea	2,	Vital	 Images,	Minnetonka,	Minnesota,	USA).	Total	
CAC	score	was	calculated	for	each	patient	using	the	Agatston	method.99 The presence of 
coronary	atherosclerosis	was	defined	as	a	CAC	score	>0.
Two‑dimensional echocardiography, data acquisition and analysis
Two-dimensional	echocardiography	was	performed	with	the	patient	 in	 the	 left	 lateral	
decubitus	position	using	a	commercially	available	system	(Vivid	7,	General	Electric	Ving-
med,	Milwaukee,	Wisconsin,	USA)	equipped	with	a	3.5-MHz	 transducer.	 Standard	M-
mode,	2-dimensional	images	and	Doppler	and	colour-Doppler	data	were	acquired	from	
the	parasternal	and	apical	views	(4-,	2-	and	3-chamber)	and	digitally	stored	in	cine-loop	
format.	Analyses	were	performed	offline	using	Echo	PAC	version	7.0.0	(GE	Healthcare,	
Horten,	Norway).	LV	diameters,	end-diastolic	 thickness	of	the	 interventricular	septum	
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and the posterior wall were measured on the parasternal long-axis M-mode recordings. 
LV	end-systolic	and	end-diastolic	volumes	were	assessed	and	LVEF	was	calculated	from	
the	apical	4-	and	2-chamber	views	using	the	Simpson’s	rule.100	Subsequently,	LV	mass	
was	determined	using	the	formula	by	Devereux	et	al	and	normalized	for	body	surface	
area	(LV	mass	index,	g/m2).101	Based	on	the	recommendations	of	the	American	Society	
of	Echocardiography,	 transmitral	and	pulmonary	vein	flows	were	derived	with	pulsed-
wave	Doppler	tracings.102	In	addition,	early	(E)	and	late	(A)	diastolic	waves,	deceleration	
time	(DT)	of	E	wave	and	pulmonary	vein	systolic	(PVs)	and	diastolic	(PVd)	velocities	were	
obtained.	Diastolic	function	was	then	classified	as	normal,	when	the	E/A	ratio	= 0.9-1.5, 
DT = 160-240	ms	and	PVs	≥	PVd.103	The	LV	global	 left	ventricular	 strain	 (GLS)	was	as-
sessed	offline	(Echo	PAC	version	7.0.0)	using	AFI	as	previously	described.14, 104	The	soft-
ware	analyzes	motion	by	tracking	speckles	 (natural	acoustic	markers)	 in	 the	2D	ultra-
sonic	image.	The	frame-to-frame	changes	of	the	speckles	are	used	to	derive	motion	and	
velocity.	For	this	purpose,	one	single	cardiac	cycle	is	needed	from	each	LV	apical	view	
(apical	long-axis,	4-	and	2-chamber	views).	Mean	frame	rate	of	the	obtained	images	was	
70	fps	(range	40-100	fps).
First,	 the	end-systolic	 frame	is	defined	 in	the	apical	 long-axis	view.	The	closure	of	the	
aortic	valve	is	marked	and	the	software	measures	the	time	interval	between	R	wave	and	
aortic	valve	closure.	This	interval	is	used	as	a	reference	for	the	4-	and	2-chamber	view	
loops.	After	defining	the	mitral	annulus	and	the	LV	apex	with	3	index	points	at	the	end-
systolic frame in each apical view, the automated algorithm traces 3 concentric lines on 
the endocardial border, the mid-myocardial layer and epicardial border, including the 
entire	myocardial	wall.	The	tracking	algorithm	follows	the	endocardium	from	this	single	
frame throughout the cardiac cycle, and allows for a further manual adjustment of the 
region of interest to ensure that all myocardial regions are included throughout the car-
diac	cycle.	The	LV	is	divided	in	6	segments	in	each	apical	view	and	the	tracking	quality	is	
validated for each segment. 
Finally,	the	automated	algorithm,	using	a	17-segment	model,	provides	the	peak	systolic	
longitudinal	strain	for	each	LV	segment	in	a	“bull‘s	eye”	plot,	with	the	average	value	of	
peak	systolic	longitudinal	strain	for	each	view	and	the	averaged	GLS	for	the	entire	left	
ventricle.	 In	general,	LV	GLS	values	are	presented	as	negative	values;	a	more	negative	
value indicates a larger extent of longitudinal strain. The intra- and interobserver agree-
ment	for	GLS	measurements	has	been	reported	previously,	with	an	intraclass	correlation	
coefficient	of	0.95	for	intra-observer	comparisons	and	0.92	for	inter-observer	compari-
sons.
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Statistical analysis
The	study	population	was	divided	according	to	the	absence	or	presence	of	coronary	ath-
erosclerosis.	Continuous	variables	are	expressed	as	mean	and	standard	deviation	(SD)	and	
categorical	variables	are	expressed	as	numbers	and	percentages.	Differences	in	continu-
ous	and	categorical	variables	between	patients	with	and	without	coronary	atherosclerosis	
were	assessed	using	the	Student	t-test	and	the	chi-square	test,	respectively.	Comparisons	
among groups were performed using the one-way analysis of variance test with Bonfer-
roni	 post-hoc	 analysis.	Univariable	 and	multivariable	 logistic	 regression	 analysis	 (enter	
model)	were	performed	to	evaluate	the	association	between	the	presence	of	coronary	
atherosclerosis	and	baseline	clinical	(age,	gender,	coronary	risk	factors,	diabetes-related	
risk	factors	and	complications)	and	echocardiographic	(LV	mass	index,	LVEF,	presence	of	
diastolic	dysfunction	and	GLS)	characteristics.	Only	significant	(p	<0.05)	univariable	pre-
dictors	were	entered	as	covariates	in	the	multivariate	model.	Odds	ratios	and	95%	confi-
dence	intervals	were	calculated.	In	order	to	determine	the	potential	incremental	value	of	
LV	GLS	over	the	other	selected	independent	predictors	of	coronary	atherosclerosis,	the	
chi-square	distribution	of	the	multivariable	model	was	compared	with	chi-square	distri-
bution	of	the	same	model	without	LV	GLS,	applying	the	model	chi-square	step.
In	addition,	the	optimal	cut-off	value	for	LV	GLS	to	predict	coronary	atherosclerosis	 in	
asymptomatic,	type	2	diabetes	patients	was	determined	by	receiver	operating	charac-
teristic	 (ROC)	 curve	analysis.	 The	optimal	 cut-off	value	was	defined	as	 the	value	 that	
provided	the	maximal	sensitivity	and	specificity	to	distinguish	between	asymptomatic,	
type	2	diabetic	patients	with	and	without	coronary	atherosclerosis.
All	statistical	tests	were	2-sided	and	a	p	value	<0.05	was	considered	statistically	signifi-
cant.	Statistical	analysis	was	performed	using	the	SPSS	software	package	(SPSS	15.0,	Chi-
cago,	Illinois,	USA).
results
Patient characteristics
From	the	initial	cohort	of	289	patients,	35	(12%)	had	suboptimal	echocardiographic	win-
dow,	precluding	reliable	AFI	analysis,	and	were	not	eligible	for	the	study.	Consequently,	234	
patients	were	included	in	the	final	analysis.	Baseline	and	echocardiographic	characteris-
tics	of	the	overall	study	population	and	of	patients	with	and	without	coronary	atheroscle-
rosis	are	summarized	in	Table	1.	The	mean	age	was	52	±	11	years	and	134	(57%)	patients	
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table 1.  Clinical	and	echocardiographic	characteristics	of	the	study	population	in	rela-
tion	to	coronary	atherosclerosis
overall Coronary atherosclerosis p value
n=234 CaC score = 0
 (n=95)           
CaC score > 0
(n=139)
Age	(years) 52 ± 11 46 ± 11 56 ± 10 <0.001
Male	gender,	n	(%) 134	(57) 42	(44) 92	(66) 0.01
Hypertension,	n	(%)* 133	(57) 34	(36) 37	(58) <0.001
Smoking,	n	(%) 54	(23) 18	(19) 36	(26) 0.22
Hypercholesterolemia,	n	(%)	# 143	(61) 44	(46) 99	(71) <0.001
Positive	family	history,	n	(%) 113	(48) 43	(45) 70	(50) 0.44
Diabetes-related	risk	factors
Diabetes	duration	(years) 13 ± 11 10 ± 8 14 ± 12 <0.001
Age	at	time	of	diagnosis	DM	(years) 40 ±15 36 ± 13 42 ± 15 0.08
HbA1C	(%) 7.8 ± 1.7 7.7 ± 1.6 7.9 ± 1.7 0.57
Treatment,	n	(%)
Oral 89	(38) 35	(37) 54	(39) 0.76
Insulin 97	(42) 35	(37) 54	(39) 0.66
Insulin and oral agent 42	(18) 15	(16) 27	(19) 0.48
Retinopathy,	n	(%) 48	(21) 11	(12) 37	(27) 0.005
Nephropathy 32	(14) 9	(9) 23	(17) 0.12
PVD,	n	(%) 33	(14) 11	(12) 22	(16) 0.36
PNP,	n	(%) 89	(38) 23	(24) 66	(48) <0.001
Body	mass	index	(kg/m2) 28 ± 6 28 ± 6 28 ± 5 0.73
Waist	circumference	(cm) 100 ± 14 98 ± 14 101 ±14 0.14
Medication,	n	(%)
Aspirin 53	(23) 11	(12) 42	(30) 0.001
ACE-inhibitors 70	(30) 12	(13) 58	(42) <0.001
Statins 118	(50) 31	(33) 87	(63) <0.001
Serum markers
Total	cholesterol	(mmol/l) 4.7 ± 1.1 4.6 ± 1.0 4.8 ± 1.2 0.12
LDL	(mmol/l) 3.0 ± 1.0 2.9 ± 1.0 3.0 ± 1.0 0.39
HDL	(mmol/l) 1.4 ± 0.6 1.4 ± 0.5 1.4 ± 0.6 0.55
Cholesterol/HDL	ratio 3.6 ± 1.3 3.5 ± 1.2 3.8 ± 1.3 0.07
Triglycerides	(mmol/l) 1.7 ± 1.1 1.6 ± 1.1 1.8 ± 1.2 0.13
were	male.	Almost	half	of	the	patients	were	on	insulin	therapy.	In	the	total	population,	
average	CAC	score	was	319	±	901	(range	0-8730).	CAC	was	absent	in	95	(41%)	patients.	In	
the	remaining	139	(59%)	patients,	an	average	CAC	score	of	537	±	1120	was	observed	with	
41	(29%)	and	19	(14%)	patients	having	a	CAC	score	>400	or	>1000,	respectively.	
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overall Coronary atherosclerosis p value
n=234 CaC score = 0
 (n=95)           
CaC score > 0
(n=139)
Two-dimensional echocardiography
LV	ejection	fraction	(%) 68 ± 10 68 ± 9 68 ± 11 0.90
LV	enddiastolic	volume	(ml) 118 ± 29 117 ± 25 119 ± 32 0.72
LV	endsystolic	volume	(ml) 39 ± 17 38 ± 14 39 ± 19 0.69
E	wave	(m/sec) 0.71 ± 0.18 0.75 ± 0.21 0.69 ± 0.16 0.06
A	wave	(m/sec) 0.69 ± 0.19 0.66 ± 0.18 0.72 ± 0.19 0.04
E/A 1.08 ± 0.35 1.20 ± 0.41 1.00 ± 0.29 <0.001
DT	E	Wave	(msec) 179 ± 55 175 ± 46 181 ± 61 0.38
PVs	(m/sec) 0.52 ± 0.11 0.52 ± 0.11 0.52 ±0.12 0.87
PVd	(m/sec) 0.41 ± 0.10 0.43 ± 10 0.40 ± 0.10 0.05
PV	s/d 1.30 ± 0.35 1.26 ± 0.32 1.34 ± 0.36 0.08
E’	(cm/sec) 6.37 ± 2.13 7.05 ± 2.34 5.89 ± 1.83 <0.001
E/E’ 12.56 ± 6.73 12.16 ± 6.67 12.84 ± 6.78 0.45
LV	diastolic	dysfunction,	n	(%) 158	(68) 53	(23) 105	(45) 0.002
LV	mass	index	(g/m2) 83 ± 22 80 ± 19 85 ± 24 0.07
LV	GLS	(%) -17.0 ± 3.0 -18.0 ± 2.8 -16.3 ± 3.0 <0.001
A,	atrial;	ACE,	angiotensin	converting	enzyme;	DM,	diabetes	mellitus;	DT,	deceleration	time;	E,	early;	E’,	early	prime;	GLS,	
global	longitudinal	strain;	HDL,	high	density	lipoprotein;	LDL,	low	density	lipoprotein;	LV,	left	ventricular;	PNP,	polyneuropathy;	
Pv,	pulmonary	vene;	PVD,	peripheral	vessel	disease.	
* Blood pressure >140/90	mm	Hg	or	treatment	with	antihypertensive	medication,	#total	cholesterol	level	>5.0	mmol/L	or	use	
of	cholesterol	lowering	medication
Table1.  continued
Regarding	 the	 echocardiographic	 characteristics,	 the	 LVEF	 was	 within	 normal	 limits	
(68 ± 10%)	and	the	LV	mass	index	was	83 ± 22 g/m2.	The	mean	GLS	was	-17.0 ± 3.0%.
Diastolic	dysfunction	was	observed	in	158	(68%)	patients.
Comparison between patients with and without coronary atherosclerosis
Clinical data
Clinical	and	echocardiographic	characteristics	of	the	study	population	are	presented	in	
Table	1.	As	compared	to	patients	without	coronary	atherosclerosis	(n=95),	patients	with	
coronary	atherosclerosis	(n=139)	were	significantly	older	and	had	a	longer	duration	of	
diabetes	(p	<0.001	for	both	comparisons);	 in	addition,	patients	with	coronary	athero-
sclerosis	 had	 more	 frequently	 hypertension,	 hypercholesterolemia,	 retinopathy	 and	
polyneuropathy	(p	<0.01	for	all	comparisons).	
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Figure 1.		Scatter-plot	illustrating	the	individual	values	of	LV	GLS	in	asymptomatic,	type 2 
diabetic	patients	with	and	without	coronary	atherosclerosis	 (defined	by	CAC	
score).	Diabetic	patients	with	CAC>0	had	significantly	more	impaired	LV	GLS	as	
compared	to	diabetic	patients	with	CAC=0.
CAC,	coronary	artery	calcium;	GLS,	global	longitudinal	strain;	LV,	left	ventricular
Two-dimensional echocardiography
No	difference	in	LVEF	was	observed	between	patients	with	and	without	coronary	athero-
sclerosis.	However,	in	patients	with	coronary	atherosclerosis,	impaired	GLS	was	observed	
as	compared	to	patients	without	coronary	atherosclerosis	(-16.3±3.0%	vs.	-18.0±2.8%;	
p <0.001)	(Figure	1).	In	addition,	the	prevalence	of	diastolic	dysfunction	was	significantly	
higher	among	patients	with	coronary	atherosclerosis	(45%	vs.	23%;	p=0.002).	
Comparison between patients with diabetes mellitus and control patients 
The	patients	with	type	2	diabetes	were	compared	with	a	control	group	(n=80)	matched	
by	age,	gender,	LVEF	and	Framingham	risk	score	according	to	Wilson	et	al	(Table	3).105 
The	controls	were	divided	into	two	groups	according	to	the	CAC	score:	41	patients	had	
CAC	=0,	39	patients	had	CAC	>	0.	The	controls	with	CAC	=	0	showed	the	most	preserved	
values	of	LV	GLS	(-19.4	±	1.8	%)	whereas	the	patients	with	diabetes	and	CAC	score	>	0	
had	the	most	impaired	LV	GLS	values	(-16.3	±	3.0	%;	ANOVA	p	<	0.001)	(Table	4).	
Predictors of coronary atherosclerosis
The	results	of	 the	univariate	and	multivariate	 logistic	regression	analysis	performed	to	
identify	potential	predictors	of	coronary	atherosclerosis	are	provided	in	Table	2.	At	univar-
p <0.001
-18.0 ± 2.8% -16.3 ± 3.0%
CAC=0 CAC>0
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table 2.		Univariable	and	multivariable	logistic	regression	analysis	to	determine	indepen-
dent predictors for coronary atherosclerosis
univariable Multivariatble
or (95% Ci) p value or (95% Ci) p value
Age	(years) 1.10	(1.06-1.13) <0.001 1.04	(0.91-1.18) 0.61
Male 2.47	(1.45-4.22) 0.001 2.70	(1.36-5.36) 0.005
Hypertension 4.44	(2.54-7.75) <0.001 2.58	(1.30-5.13) 0.007
Smoking 1.51	(0.73-2.86) 0.21 - -
Family	history	of	CAD 1.23	(0.73-2.07) 0.44 - -
Hypercholesterolemia 2.94	(1.70-5.09) <0.001 2.41	(1.26-4.63) 0.016
Diabetes	duration	(years) 1.04	(1.01-1.08) 0.003 1.10	(0.96-1.25) 0.17
Age	at	time	of	diagnosis	DM	(years) 1.03	(1.01-1.04) 0.006 1.10	(0.92-1.20) 0.45
HbA1C	(%) 1.088	(0.93-1.28) 0.31 - -
Retinopathy	 2.77	(1.33-5.76) 0.006 1.80	(0.67-4.90) 0.24
Nephropathy 1.90	(0.84-4.30) 0.13 - -
PVD 1.44	(0.66-3.12) 0.36 - -
PNP 2.83(1.59-5.03) <0.001 1.69	(0.82-3.50) 0.16
LV	mass	index	(g/m2) 1.01	(1.00-1.02) 0.07 - -
LV	ejection	fraction	(%) 1.00	(0.97-1.03) 0.91 - -
Diastolic	dysfunction 2.45	(1.40-4.28) 0.002 0.71	(0.33-1.51) 0.37
LV	GLS	(%) 1.23	(1.11-1.30) <0.001 1.20	(1.07-1.36) 0.003
CAD,	coronary	artery	disease;	CI,	confidence	interval;	DM,	diabetes	mellitus;	GLS,	global	longitudinal	strain;	LV,	left	ventricular;	
OR,	odds	ratio;	PNP,	peripheral	neuropathy;	PVD,	peripheral	vessel	disease.
table 3.		Comparison	 of	 age,	 gender,	 LV	 ejection	 fraction	 and	 Framingham	 risk	 score	
between	the	control	group	and	the	study	population.
Control group
(n=80)
Diabetes study population 
(n=234)
p value
Age	(years) 54 ± 8 52 ± 11 0.15
Male	(%) 37	(46%) 134	(57) 0.09
LV	ejection	fraction	(%) 66 ± 5 68 ± 10 0.21
Framingham	risk	score 11 ± 6 12 ± 9 0.12
LV,	left	ventricular
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iate	analysis	age,	male	gender,	hypertension,	hypercholesterolemia,	duration	of	diabetes,	
age	at	time	of	diagnosis,	retinopathy,	peripheral	vascular	disease,	peripheral	neuropathy,	
diastolic	dysfunction	and	GLS	were	significantly	 related	 to	coronary	atherosclerosis.	At	
multivariate	analysis,	male	gender	(OR	=	2.70;	95%	CI	1.36-5.36;	p=0.005),	hypertension	
(OR	=	2.58;	95%	CI	1.30-5.13;	p=0.007,	hypercholesterolemia	(OR	=	2.30;	95%	CI	1.17-
4.54;	p=0.016)	and	GLS	(OR	=	1.20;	95%	CI	1.07-1.36;	p=0.003)	were	independent	factors	
associated	with	coronary	atherosclerosis.	As	shown	in	Figure	2,	adding	GLS	to	the	other	
selected	independent	variables	significantly	improved	the	ability	to	predict	coronary	ath-
erosclerosis.	Finally,	ROC	curve	analysis	was	performed	to	obtain	a	cut-off	value	of	LV	GLS	
to	identify	asymptomatic	type	2	diabetic	patients	at	a	high	risk	of	having	coronary	ath-
erosclerosis.	A	cut-off	value	of	-17.5%	predicted	the	presence	of	coronary	atherosclerosis	
with	a	sensitivity	and	specificity	of	62%	for	both	(area	under	the	curve:	0.65)	(Figure	3).
discussion
The	results	of	the	present	study	can	be	summarized	as	follow:	1)	as	compared	to	diabetic	
patients	without	atherosclerosis,	diabetic	patients	with	coronary	atherosclerosis	showed	an	
impaired	GLS,	even	though	LVEF	was	still	preserved	(reflecting	the	presence	of	subclinical	
LV	systolic	dysfunction)	2)	the	presence	of	subclinical	LV	systolic	dysfunction	provides	sig-
nificant	incremental	value	for	the	identification	of	patients	having	coronary	atherosclerosis.
Coronary atherosclerosis and subclinical LV systolic dysfunction in diabetes mellitus
In	diabetic	patients,	the	diagnosis	of	CAD	is	frequently	missed	or	delayed	since	the	typi-
cal	symptoms	of	myocardial	 ischemia	are	often	masked.	Before	symptoms	of	 ischemia	
table 4. Comparison	of	LV	GLS,	between	age,	sex	and	Framingham	risk	score	matched	
controls	and	the	diabetic	study	population.
Control group
(n=80)
Diabetes study population
(n=234)
p value
CAC	score	=	0	
(n=41)
CAC	score	>	0
(n=39)
CAC	score	=	0
(n=95)											
CAC	score	>	0
(n=139)
LV	GLS	(%) -19.4 ± 1.8# -17.8 ± 1.6 -18.0 ± 2.8 -16.3 ± 3.0* 0.001
# p	<	0.02	versus	the	other	groups,	*	p=	0.032	versus	diabetes	and	CAC	score	=	0
CAC,	coronary	artery	calcium;	GLS,	global	longitudinal	strain;	LV,	left	ventricular
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Figure 3.		ROC	 curve	 analysis,	 showing	 the	optimal	 cut-off	 value	 for	 LV	GLS	 to	 predict	
coronary atherosclerosis.
AUC	=	area	under	the	curve
Figure 2.		Bar	graph	illustrating	the	incremental	value	of	LV	global	longitudinal	strain	(GLS)	
by	automated	function	imaging	to	predict	coronary	atherosclerosis.	The	addi-
tion	of	GLS	to	a	model	including	baseline	clinical	characteristics	(male	gender,	
hypertension	and	hypercholesterolemia)	results	in	incremental	risk	stratifica-
tion	of	type	2	diabetic	patients	for	having	coronary	atherosclerosis.
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occur,	diffuse	multi-vessel	atherosclerosis	is	frequently	present.	It	has	been	shown	that	
risk	and	mortality	from	CAD	in	patients	with	type	2	diabetes	are	similar	to	patients	with-
out	diabetes	and	previous	myocardial	 infarction,	 indicating	increased	event	risk	 in	dia-
betic	patients.7 In	addition,	CAD	is	one	of	the	main	causes	of	overt	LV	dysfunction	and	
heart	failure	in	this	group	of	patients.106	Accordingly,	early	identification	of	coronary	
atherosclerosis	 in	 asymptomatic	diabetics	may	be	beneficial,	 allowing	timely	detec-
tion	of	patients	at	increased	risk,	and	appropriate	selection	of	further	diagnostic	and	
therapeutic	procedures.	 In	 the	present	 study,	noninvasive	assessment	of	CAC	score	
was	performed	 in	a	 large	cohort	of	asymptomatic	patients	with	type	2	diabetes	 for	
CAD	screening	purpose;	moreover,	conventional	transthoracic	echocardiography	and	
speckle-tracking echocardiography were performed to evaluate the presence of dia-
stolic	and	subclinical	systolic	dysfunction,	 respectively.	The	relationship	between	LV	
dysfunction	 and	 subclinical	 coronary	 atherosclerosis	 was	 then	 evaluated.	 Previous	
studies	in	the	general	population	have	demonstrated	that	the	extent	of	CAC	strongly	
correlates	with	 the	 overall	magnitude	 of	 atherosclerotic	 plaque	 burden.107, 108 The 
extent	of	CAC	 is	affected	by	age,	gender,	and	traditional	cardiovascular	 risk	 factors.	
A	threshold	value	of	400	as	the	cut-point	for	high	risk	for	obstructive	CAD	has	been	
found in previous studies.109	However,	such	scores	are	very	rare	in	men	<60	years	old	
and	almost	nonexistent	in	women	<65	years	old.	In	screening	for	a	disease	as	preva-
lent	as	CAD,	such	stringent	criteria	for	a	positive	scan	may	not	be	appropriate	when	
screening	asymptomatic	individuals.In	line	with	previously	published	studies,	diastolic	
dysfunction	was	 frequently	 observed	 in	 diabetic	 patients	 (68%)110-116;	 of	 note,	 the	
prevalence	of	diastolic	dysfunction	was	higher	in	diabetics	with	as	compared	to	those	
without	coronary	atherosclerosis	(45%	versus	23%).	More	interestingly,	GLS	(i.e.	ac-
tive	 myocardial	 deformation),	 assessed	 by	 speckle-tracking	 echocardiography,	 was	
impaired	in	diabetic	patients	with	as	compared	to	those	without	coronary	atheroscle-
rosis	(-16.3	±	3.0%	vs.	-18.0	±	2.8%),	reflecting	the	presence	of	subclinical	LV	systolic	
dysfunction.	GLS,	indeed,	was	found	to	be	independently	related	to	the	presence	of	
coronary	atherosclerosis,	and	provided	significant	incremental	value	over	other	base-
line	patient	characteristics	for	the	identification	of	patients	having	CAD.
Previous	 studies	 have	 underscored	 the	 presence	 of	 subclinical	 LV	 dysfunction	 in	
a	symptomatic	 patients	with	 type	 2	 diabetes.117-119 The underlying pathophysiology 
of	 diabetic	 cardiomyopathy	 includes	 several	 processes	 that	 act	 synergistically	 and	
hyperglycemia	 is	considered	as	the	central	 factor	that	 triggers	several	adaptive	and	
maladaptive	responses.120 These responses lead to accelerated apoptosis of the myo-
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cardial	fibers,	myocardial	fibrosis	and	increased	content	of	collagen.	Particularly,	the	
deposits	of	collagen	are	thought	to	contribute	to	arterial	and	myocardial	stiffness	and	
endothelial	 dysfunction.	 The	 subendocardial	 fibers,	 oriented	 longitudinally,	 are	 the	
first	to	be	involved	in	these	processes	and,	therefore,	subclinical	LV	systolic	dysfunc-
tion	 can	 be	 identified	with	 the	 assessment	 of	 LV	 GLS.	 A	 reduced	 GLS	 indicates,	 at	
these	early	 stages,	 an	 impairment	of	 the	 subendocardial	 shortening.	 In	 addition	 to	
these	mechanisms,	atherosclerotic	plaques	formation	may	further	negatively	impact	
on	LV	longitudinal	function.	However,	the	relation	between	subclinical	LV	dysfunction	
and	asymptomatic	coronary	atherosclerosis	was	not	yet	investigated	in	this	group	of	
patients.	The	findings	of	the	present	study	extend	the	available	knowledge,	suggesting	
a	link	between	subclinical	LV	systolic	dysfunction	and	asymptomatic	coronary	athero-
sclerosis.	 Small	 vessel	micro-embolization,	 endothelial	 dysfunction	 or	 chronic	 isch-
emia may indeed induce subclinical myocardial damage. This may lead to decreased 
GLS	of	 the	 longitudinal	 fibers,	which	 are	more	 susceptible	 to	 ischemia	 and	 explain	
the	observations	by	the	current	study.121	Interestingly,	similar	data	have	been	previ-
ously	 reported	by	other	authors	 in	different	 study	populations,	partially	 supporting	
the	present	findings.	Stein	and	co-workers,	for	instance,	observed	a	relation	between	
subclinical	 LV	 impairment	 (evaluated	 by	tissue-Doppler	 imaging)	 and	 coronary	 ath-
erosclerosis	(evaluated	by	coronary	angiography	and/or	 intravascular	ultrasound)	 in	
26	asymptomatic	patients	with	type	1	diabetes.122	Edvarsen	et	al	investigated	the	re-
lation	between	regional	coronary	calcium	score	and	regional	 left	ventricular	systolic	
strain	(assessed	by	tagged	magnetic	resonance	imaging)	in	509	asymptomatic	patients	
without	 history	 of	 CAD	and	with	normal	 LVEF.123	 Although	 the	patients	were	older	
and	had	 lower	CAC	scores	as	compared	to	our	population,	an	 independent	relation	
between	impairment	of	regional	LV	systolic	function	and	coronary	atherosclerosis	was	
observed.
Clinical implications
The	 results	 of	 the	present	 study	 indicate	 that	 LV	GLS	may	 allow	 the	 identification	of	
subclinical	systolic	dysfunction	in	diabetic	patients,	possibly	related	to	the	presence	of	
subclinical	coronary	atherosclerosis.	As	mentioned	before,	the	poor	clinical	outcome	in	
patients	with	type	2	diabetes	underscores	the	need	to	develop	practical	approaches	for	
detecting	coronary	atherosclerosis	at	an	early	stage	for	early	 initiation	of	appropriate	
treatment.
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To	improve	the	identification	of	diabetic	patients	at	high	risk	of	cardiovascular	events,	
SPECT	 myocardial	 perfusion,	 CAC	 score	 and	 MSCT	 coronary	 angiography	 has	 been	
proposed.36, 43, 84, 124	However,	 these	 techniques	may	be	 limited	available	and	associ-
ated	with	 non-negligible	 radiation	 exposure,	 especially	 taking	 into	 account	 that	 peri-
odical	screening	exams	are	often	performed	in	the	diabetic	population.	Possibly,	routine	
screening	for	subclinical	LV	dysfunction	with	2D	speckle-tracking	echocardiography	can	
be	the	first	line	approach	to	identify	those	patients	with	higher	likelihood	of	coronary	
atherosclerosis	who	need	further	clinical	explorations.
Conclusion
Subclinical	LV	systolic	dysfunction	is	independently	related	to	the	presence	of	subclini-
cal	coronary	atherosclerosis	in	patients	with	type	2	diabetes.	In	addition,	subclinical	LV	
systolic	dysfunction	has	significant	incremental	value	over	other	baseline	patient	charac-
teristics	to	predict	coronary	atherosclerosis.
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abstract
Purpose
The purpose of this study was to evaluate the prevalence of cardiac autonomic neuropa-
thy	(CAN)	in	a	cohort	of	truly	asymptomatic	patients	with	type	2	diabetes	mellitus	using	
heart	 rate	 variability	 (HRV)	 and	 123I-metaiodobenzylguanidine	 (123I-mIBG)	 myocardial	
scintigraphy.
Methods
88	asymptomatic	patients	with	 type	2	diabetes	mellitus	were	prospectively	 recruited	
from	an	outpatient	diabetes	clinic.	 In	patients	with	normal	myocardial	perfusion	CAN	
was	assessed	by	HRV	and	123I-mIBG	myocardial	scintigraphy.	Two	or	more	abnormal	tests	
were	defined	as	CAN	positive	 (ECG-based	cardiac	autonomic	neuropathy)	and	one	or	
less	as	CAN	negative.	CAN	assessed	by	123I-mIBG	scintigraphy	was	defined	as	abnormal	
if:	heart/mediastinum	ratio<1.8,	washout>25%,	or	total	defect	score>13.
Results 
The	prevalence	of	CAN	in	asymptomatic	patients	with	type	2	diabetes	and	normal	myo-
cardial	perfusion	assessed	by	HRV	and	123I-mIBG	scintigraphy	was	respectively,	27%	and	
58%.	Furthermore,	 in	almost	half	of	patients	with	normal	HRV,	123I-mIBG	scintigraphy	
showed CAN.
Conclusion
The	current	study	revealed	a	high	prevalence	of	CAN	in	patients	with	type	2	diabetes	
mellitus.	Secondly,	disagreement	between	HRV	and	 123I-mIBG	scintigraphy	 for	 the	as-
sessment of CAN was observed.
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Introduction
Diabetes	mellitus	is	an	increasing	health	care	problem.2, 16	Cardiovascular	complications	
including	coronary	artery	disease	(CAD),	are	the	most	common	causes	of	mortality	and	
morbidity	in	patients	with	type	2	diabetes	mellitus.7	Because	patients	with	diabetes	mel-
litus	 type	2	often	 suffer	 from	CAD	without	 symptoms,	 risk	 stratification	 is	 needed	 to	
identify	patients	at	high	risk	for	CAD.	In	the	DIAD	(Detection	of	silent	myocardial	Isch-
emia	in	Asymptomatic	Diabetic	subjects)	study	the	overall	prevalence	by	single	photon	
emission	computed	tomography	 (SPECT)	of	silent	myocardial	 ischemia	was	22%.36 Al-
though	traditional	risk	factors	failed	to	predict	silent	myocardial	ischemia,	cardiac	auto-
nomic	neuropathy	(CAN)	assessed	by	heart	rate	variability	(HRV),	was	a	strong	predictor	
for	silent	myocardial	 ischemia	 in	this	study.	Furthermore,	 it	 is	known	that	CAN	is	one	
of	the	most	common	diabetes-associated	complications	and	has	been	associated	with	
increased risk of mortality and major cardiovascular events.125-129 However, although 
CAN	assessed	by	HRV	is	a	sensitive	method	to	detect	neuropathy,	it	is	less	accurate	in	de-
tecting	sympathetic	dysfunction.130	The	sympathetic	cardiac	innervation	can	nowadays	
be assessed directly and noninvasively with 123I-mIBG	myocardial	scintigraphy	in	many	
clinical disorders, including diabetes.131-135 
How	HRV	and	123I-mIBG	myocardial	scintigraphy	compare	in	asymptomatic	patients	with	
diabetes	is	unknown.	The	current	observational	study	evaluated	the	prevalence	of	CAN	
according	to	HRV	versus	123I-mIBG	myocardial	scintigraphy.	
methods
Patient population
All	patients	were	referred	from	an	outpatient	diabetic	clinic	to	our	institution	for	risk	strat-
ification.	This	included	adenosine	stress	SPECT	myocardial	perfusion	imaging	to	assess	
myocardial	ischemia	and	HRV	to	assess	CAN.	The	diagnosis	of	diabetes	was	established	
by	the	referring	physician	and	confirmed	by	patient	history	or	the	use	of	medication	such	
as insulin or oral hypoglycaemic agents.1	Inclusion	criteria	consisted	of	confirmed	type	2	
diabetes	mellitus	in	combination	with	complete	absence	of	angina	or	angina-equivalent	
symptoms.	Asymptomatic	 status	was	 confirmed	using	 the	Rose	questionnaire	 for	 an-
gina.15	Exclusion	criteria	were:	known	CAD;	stress	test	or	coronary	angiography	before	
referral,	history	of	coronary	revascularization,	treatment	with	anti-anginal	medication,	
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electrocardiographic	evidence	of	Q-wave	myocardial	infarction,	ischemic	ST-segment	or	
T-wave	changes	or	complete	left	bundle	branch	block	and	active	bronchospasm,	exclud-
ing	the	use	of	adenosine	as	stressor	for	SPECT	myocardial	perfusion	imaging.	In	patients	
with	 normal	myocardial	 perfusion	 (stress	 and	 rest)	 123I-mIBG	myocardial	 scintigraphy	
was	performed	to	evaluate	the	prevalence	of	sympathetic	CAN	compared	to	the	preva-
lence	of	CAN	assessed	by	HRV.
Adenosine stress SPECT myocardial perfusion imaging
Data	 acquisition	 and	 analysis	 were	 performed	 as	 described	 before.84	 Briefly,	 ECG-
gated	 SPECT	 imaging	 was	 performed	 using	 a	 2-day	 protocol	 (adenosine	 and	 rest)	
with	technetium-99m	sestamibi	(99mTcMIBI).	Twelve-lead	electrocardiography	(ECG)	
was	 recorded	 each	minute	 and	 continuously	monitored	 (leads	 aVF,	 V1	 and	V5)	 for	
the	 development	 of	 arrhythmia	 or	 ST-segment	 deviation.	 Imaging	 was	 performed	
120	minutes	after	tracer	injection	using	a	triple-head	SPECT	camera	(GCA	9300/HG,	
Toshiba	Corporation,	Tokyo,	Japan)	using	low-energy,	high	resolution	collimators.	Im-
age	acquisition	was	performed	using	a	circular	360°	orbit,	60	projections	and	40	sec-
ond/projection61, 62	No	attenuation	correction	was	applied.	The	cardiac	images	were	
processed	in	the	usual	manner	and	short-axis,	horizontal	and	vertical	long-axis	views	
were	reconstructed.	The	adenosine	stress	SPECT	myocardial	perfusion	imaging	study	
was	considered	normal	in	case	of	1)	both	SRS	and	SDS	<2,	2)	resting	LVEF	≥45%,	and	3)	
absence	of	increased	lung	uptake,	TID	or	flat	or	down	sloping	ST-segment	depression	
≥	1mm	at	80	ms	after	the	J-point	in	two	or	more	leads	on	the	ECG	during	adenosine	
infusion. 
Cardiovascular autonomic reflex tests
Data acquisition
To	assess	cardiovascular	autonomic	neuropathy	(CAN),	heart	rate	variability	(HRV)	was	
measured	during	the	following	4	cardiovascular	reflex	tests	and	recorded	with	the	aid	of	
a	Holter	ECG	.136, 137 
1. HRV	at	rest	over	150	consecutive	beats,	
2. HRV	during	deep	breathing	at	6	cycles	per	minute	over	120	consecutive	beats,	
3. HRV	during	Valsalva	manoeuvre,	
4. Immediate	heart	rate	response	to	standing	from	the	recumbent	position.
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A	final	test	measured	the	difference	in	systolic	blood	pressure	between	supine	and	up-
right	position.	No	patients	were	 receiving	drugs	 influencing	HRV,	 such	as	neuroleptic	
drugs	 or	 clozapine.	 Antihypertensive	medications	 such	 as	 angiotensin	 converting	 en-
zyme	(ACE)-	inhibitors	and	angiotensin	receptor	blockers	(ARB)	were	stopped	one	week	
before	HRV	measurements.138, 139
Data analysis
All	Holter	ECG	recordings	were	analyzed	by	two	experienced	observers	unaware	of	the	
clinical	history	of	the	patients.	In	case	of	disagreement,	a	joint	reading	was	performed	
and	a	consensus	decision	was	reached.	For	the	evaluation	of	HRV	at	rest,	coefficient	of	
variation	(CV)	was	used.140	HRV	during	deep	breathing	was	evaluated	by	calculating	the	
E-I	ratio	(ratio	of	the	mean	longest	to	shortest	R-R	interval	during	respectively	inspira-
tion	and	expiration).141	 The	 ‘Valsalva	 ratio’	was	 calculated	as	 the	 ratio	of	 the	 longest	
R-R	interval	following	release	to	the	shortest	R-R	interval	during	the	maneuver.142 Im-
mediate	heart	rate	response	to	standing	up	was	calculated	as	the	‘30-15	ratio’,	defined	
as	the	longest	R-R	interval	of	beats	20-40	divided	by	the	shortest	R-R	interval	of	beats	
5-25	with	beat	one	being	the	first	one	during	the	process	of	getting	up.	The	shortest	R-R	
interval	came	always	prior	to	the	longest	R-R	interval	within	the	calculation	of	the	‘30-
15	ratio’.	Age	related	normal	ranges	were	used	for	evaluation	of	these	4	cardiovascular	
reflex	tests.143	Patients	were	excluded	from	analysis	when	either	one	or	more	recordings	
of	HRV	during	Holter	monitoring	consisted	of	too	few	consecutive	beats	for	interpreta-
tion	or	 in	case	of	extra	systoles	 impairing	 interpretation.	A	decrease	of	systolic	blood	
pressure	equal	to	or	greater	than	30	mmHg	within	2	minutes	after	standing	was	defined	
as an abnormal heart rate response.144
Thus,	CAN	assesses	by	HRV	was	classified	according	to	the	number	of	abnormal	cardio-
vascular	reflex	tests.	Two	or	more	abnormal	tests	were	defined	as	CAN	positive	(ECG-
based	cardiac	autonomic	neuropathy)	and	1	or	less	as	CAN	negative.145, 146
 
123i-mIBG myocardial scintigraphy imaging protocol
Data acquisition
Patients	were	instructed	not	to	take	tricyclic	antidepressants	drugs,	sympathetic	agents,	
or other drugs known to interfere with mIBG	uptake.	Thyroid	uptake	of	unbound	123I was 
blocked	with	sodium	iodine	solution	given	orally	60	minutes	before	123I-mIBG injection.	
185	MBq	of	123I-mIBG (GE	Healthcare,	USA)	was	injected	in	60	seconds	intravenously	at	
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rest.	Fifteen	minutes	post	injection	anterior	planar	images	of	the	chest	were	acquired	
and	stored	 in	a	256	x	256	matrix.	Thereafter,	a	360°	SPECT	study	was	acquired	using	
a	double-head	gamma	camera	(GCA	9300/HG,	Toshiba	Corporation,	Tokyo,	Japan)	(4˚/
step,	35	sec/projection,	128	x	128	matrix).	Repeat	planar	and	SPECT	studies	were	ac-
quired	at	approximately	4	hours	post-injection.	All	camera	heads	were	equipped	with	
low-energy	high-resolution	collimators	and	all	acquisitions	were	performed	with	a	15%	
energy	window	centered	at	the	159	keV	photopeak	of	123I.
Data analysis and image interpretation 
Planar images
Early	(15	min	post-injection)	and	late	(4-hour	delayed)	planar	images	were	processed	
to	determine	 the	heart-to-mediastinum	ratio	 (HMR).	The	planar	mIBG	 images	were	
analyzed	using	 regions	of	 interest	 (ROI)	 to	 calculate	 the	uptake	 ratios	 and	washout	
percentages.	Therefore,	a	ROI	was	drawn	manually	over	the	 left	ventricle.	A	second	
rectangular	ROI	over	the	upper	mediastinum	and	opposite	arm	were	used	as	a	refer-
ence	background	region.	The	HMR	of	average	counts	per	pixel	was	calculated	for	the	
early	 and	 delayed	 images.	 After	 correcting	 for	 the	 physical	 decay	 of	 123I, early and 
delayed	HMR	values	were	then	used	to	compute	the	myocardial	washout	ratio	(WR)	
of mIBG	as	follows:
WR=	[early	heart	counts-early	mediastinum	counts]	–	[delayed	heart	counts-delayed	
mediastinum	counts]	/	[early	heart	counts-early	mediastinum	counts]	x	100%.
Since	most	available	evidence	supports	the	use	of	the	delayed	MIBG	images	(and	the	
derived	HMR	and	WR)	for	risk	stratification,	abnormal	delayed	HMR	and	WR	were	de-
fined	as	lower	than	1.8	and	higher	than	25%,	respectively.147, 148
SPECT	images
Polar	map	formats	 (normalized	to	100%)	were	used	for	semi-quantitative	and	visu-
al	 interpretation.	 The	 delayed	myocardial	 SPECT	 images	were	 divided	 into	 17	 seg-
ments and each segment was evaluated in consensus by two expert observers, using 
a	4-point	scoring	system	(0:	>70%	tracer	uptake,	1:	50-70%	tracer	uptake,	2:	30-50%	
tracer	uptake,	3:	<30%	tracer	uptake).66, 85 As a result, the summed score for each 
study	could	theoretically	range	from	0	to	51	(17	x	3).	The	total	defect	score	(TDS)	was	
calculated	as	the	sum	of	all	defect	scores.	The	TDS	was	converted	to	percentage	of	the	
total	denervated	myocardium.	The	percentage	denervation	in	the	LV	was	calculated	
as	follows:	(TDS/	51	[maximum	score	=17x3]	x	100.	Based	on	the	study	by	Kasama	et	
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al,	a	TDS	>18	was	considered	abnormal;	when	corrected	for	a	4-point	scoring	system	
(as	used	in	the	current	study),	a	TDS	>13	would	be	considered	abnormal.149 Next, the 
location	of	defects	was	evaluated,	and	categorized	as	inferior,	apical,	lateral,	anterior	
or	 septal.	 In	 addition,	 patients	were	 categorized	 as	 having	 1	 defect	 allocated	 to	 1	
region	(see	above),	having	≥2	defects,	or	diffusely	reduced	MIBG	uptake.	Thus,	CAN	
assessed by 123I-mIBG	scintigraphy	was	defined	as	abnormal	if:	HMR<1.8,	WO>25%,	
or	TDS>13.
Statistical analysis
Categorical	baseline	characteristics	were	expressed	as	numbers	and	percentages.	Con-
tinuous	 variables	were	expressed	as	mean	 (±	 standard	deviation).	 Statistical	 analyses	
were	performed	using	SPSS	software	(version	12.0,	SPSS	Inc,	Chicago,	Il,	USA)	and	SAS	
software	(The	SAS	system,	release	6.12,	Cary,	NC, USA:	SAS	Institute	Inc.).	A	P-value	<0.05	
was	considered	as	statistically	significant.
results
Patient characteristics
From	the	clinical	registry,	110	consecutive	patients	with	normal	SPECT	perfusion	studies	
were	identified	and	available	for	123I-mIBG	scintigraphy.	Of	these,	22	(20%)	patients	were	
excluded	due	to	incomplete	datasets	(n=13)	or	poor	MIBG	image	quality	(n=9).
Thus,	the	final	patient	population	consisted	of	88	patients	(56	men,	age	53	±	10	years).	
The	patient	characteristics	are	shown	in	Table	1.	The	mean	duration	of	diabetes	was	9.8	
±	8.2	years.	Most	of	the	patients	were	on	oral	anti-diabetic	therapy	(61%).	ACE	inhibi-
tors/ARB	was	used	in	35%	and	21%	of	patients.	Twenty-eight	patients	had	complications	
of diabetes, such as peripheral neuropathy and/or peripheral vascular disease.
 
Cardiac autonomic neuropathy assessed by hrV
Of	the	88	patients,	CAN	was	classified	according	to	the	number	of	abnormal	cardiovas-
cular	reflex	tests.	Thirty	(34%)	of	these	patients	had	≥1	abnormal	cardiovascular	reflex	
test.	Twenty-four	(27%)	patients	were	considered	to	have	≥2	abnormal	tests	and	were	
categorized	as	CAN	positive.
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table 1.  Patient	characteristics	of	88	asymptomatic	patients	with	diabetes	type	2.	Data	
between parentheses indicate percentages.
Variables Patients n=88
Male 56(64)
Age	(years) 53±10
Diabetes-related	risk	factors
Duration	(years) 9.8±8.2
Age	at	time	of	diagnosis	of	diabetes	(years) 44±12
HbA1C 7.4±1.6
Treatment
Oral/Insulin 54(61)/21(24)
Oral and Insulin 11(13)
Peripheral vascular disease/peripheral neuropathy 9(10)/19(22)
Peripheral vascular and neuropathy 11(13)
Body	mass	index	(kg/m2) 29.2±5.7
Waist	circumference	(cm) 103±15.0
Hypertension 				47(53)
Hypercholesterolemia 46(52)
Family	history	of	CAD 52(59)
Current Smoking 12(14)
Medication
Aspirin 18(21)
ACE	inhibitors/ARB 31(35)/18(21)
Statins 45(51)
Total	cholesterol	(mmol/l) 4.9±1.1
LDL	(mmol/l) 3.2±.1.1
HDL	(mmol/l) 1.4±0.6
Cholesterol/HDL	ratio 3.8±1.3
Triglycerides	(mmol/l) 2.0±1.2
Creatinine	(mmol/l) 78.5±20.0
Urine	albumin-creatinine	ratio 12.4±32.8
CRP	(mg/l) 8.3±5.8
Apolipoprotein	A1	(g/l) 1.4±0.30
Apolipoprotein	B	(g/l) 0.9±0.30
Fibrinogen	(g/l) 3.9±0.90
ACE,	angiotensin	converting	enzyme;	ARB,	angiotensin	receptor	blockers;	CAD,	coronary	artery	disease;	CRP,	chain	reactive	
protein;	HDL,	high-density	lipoprotein;	LDL,	low-density	lipoprotein.	
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Cardiac autonomic neuropathy assessed by 123i-mibg 
Of	the	88	patients,	37	patients	 (42%)	had	a	normal	123I-mIBG	study.	 In	the	remaining	
51	patients	(58%),	the	123I-mIBG	study	was	abnormal.	Of	these	51	patients,	22	patients	
(43%)	 had	 1	 criterium	 for	 an	 abnormal	 123I-mIBG	 study;	 the	 remaining	 30	 patients	
(57%)	had	≥2	criteria.	In	the	total	88	patients,	36	(41%)	patients	had	a	HMR<1.8	(mean	
1.62±0.13)	and	32	(36%)	patients	had	a	WO>25%	(mean	34±	8).	A	TDS>13	(mean	43±18)	
was	observed	in	25	(28%)	patients.	
Location of 123i-mibg defects on speCt
Thirty-nine	patients	(44%)	had	no	defects	on	the	delayed	123I-mIBG	images.	The	majority	
(n=22,	25%)	of	the	innervation	defects	were	located	in	the	inferior	wall.	Seven	patients	
showed	defects	in	the	apex,	whereas	3	patients	had	defects	in	the	anterior	wall.	Eight	
patients	had	diffuse	diminished	tracer	uptake	over	the	entire	LV	and	9	patients	had	de-
fects	in	more	than	2	regions.	In	the	25	patients	with	a	TDS>13	the	location	of	the	defects	
were	as	follows:	inferior	wall	n=7,	apex	n=4,	diffuse	diminished	n=7	and	≥	2	regions	n=6.
Cardiac autonomic neuropathy assessed by 123i-mibg versus hrV
The	agreement	and	disagreement	between	HRV	and	123I-mIBG	for	the	assessment	of	CAN	
is	shown	in	Figure	1.	Of	the	64	patients	without	CAN	according	to	HRV,	35	patients	(55%)	
had a normal 123I-mIBG	study.	Of	the	24	patients	with	CAN	according	to	HRV,	22	(92%)	
had an abnormal 123I-mIBG	study.	 In	particular,	15	 (63%)	patients	had	HMR<1.8	 (mean	
1.57±0.16),	13	(54%)	patients	had	a	WO>25%	(mean	35±10)	and	12	(50%)	patients	had	a	
TDS>13	(mean	51±24).	12	patients	(50%)	had	≥2	criteria	for	an	abnormal	123I-mIBG	study.
However,	in	the	remaining	29	patients	(45%)	with	normal	HRV,	123I-mIBG	scintigraphy	was	
abnormal.	In	particular,	twenty-one	patients	(72%)	had	a	HMR<1.8	(mean	1.66±0.10),	18	
patients	(62%)	had	a	WO>25%	(mean	34±7)	and	13	patients	(45%)	had	a	TDS>13	(mean	
26±11).	15	patients	(52%)	had	≥2	criteria	for	an	abnormal	123I-mIBG	study.	
discussion
In	the	present	study,	the	prevalence	of	CAN	in	asymptomatic	patients	with	type	2	diabe-
tes	and	normal	myocardial	perfusion	was	assessed	by	HRV	and	123I-mIBG	scintigraphy;	
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Figure 1.  Agreement	and	disagreement	between	HRV	and	123I-mIBG	scintigraphy	for	the	
assessment of cardiovascular autonomic neuropathy
CAN,	cardiac	autonomic	neuropathy;	HRV,	heart	rate	variability.
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Figure 1. Agreement and disagreement between HRV and 123I-mIBG scintigraphy for the assessment 
of cardiovascular autonomic neuropathy 
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the	prevalence	of	CAN	was	27%	according	to	HRV	and	58%	on	123I-mIBG	scintigraphy.	Im-
portantly,	in	almost	50%	of	the	patients	with	normal	HRV,	123I-mIBG	scintigraphy	showed	
CAN,	suggesting	 that	123I-mIBG	 imaging	may	be	more	sensitive	 for	 the	assessment	of	
CAN	than	HRV.	
CAN	 is	 one	of	 the	most	 important	 complications	of	 diabetes	mellitus.	 It	 results	 from	
damage	to	the	autonomic	nerve	fibers	innervating	the	heart	and	blood	vessels,	which	
causes	abnormalities	in	heart	rate	control	and	impairs	vascular	dynamics.	Clinical	mani-
festations	of	CAN	include	exercise	intolerance,	intra-operative	cardiovascular	instability,	
orthostatic	hypotension,	asymptomatic	ischemia	and	painless	myocardial	infarction.150 
Furthermore,	CAN	is	associated	with	poor	outcome	related	to	ventricular	arrhythmias	
and sudden cardiac death.125-129 151	In	clinical	practice,	CAN	is	generally	assessed	using	
HRV.	When	CAN	has	progressed	significantly,	it	may	result	in	a	reduction	of	HRV.152 Mea-
suring	the	HRV	has	shown	to	be	a	simple,	noninvasive	method	to	evaluate	the	sympa-
theticovagal	balance	at	the	sinoatrial	level	and	can	identify	patients	at	elevated	risk	for	
cardiac arrhythmias and sudden death.153, 154 
Therefore,	assessing	HRV	is	potentially	important	in	the	management	of	patients	with	
diabetes.	In	the	current	study,	a	series	of	simple	bedside	tests	that	are	fairly	sensitive	in	
detecting	CAN	were	used.126	In	1976	already,	Ewing	et	al	published	the	results	of	37 dia-
betic	patients	with	 symptoms	and	clinical	 features	 suggestive	of	autonomic	neuropa-
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thy who were followed for 33 months.125 The authors concluded that simple autonomic 
function	 tests	 provided	 significant	 prognostic	 information,	with	 abnormal	 tests	 being	
associated	with	a	high	mortality.	These	results	were	confirmed	 in	a	 larger	population	
(n=605)	of	the	Hoorn	study	with	a	follow-up	period	of	9	years.127 Mortality during the 
follow-up	was	17%	 (n=101	patients);	 patients	with	diabetes	 and	 impaired	autonomic	
function	had	a	twofold	mortality	risk.
123I-mIBG	is	an	analog	of	the	false	neurotransmitter	guanethidine.	It	is	taken	up	by	ad-
renergic neurons in a similar fashion to norepinephrine and does not undergo intracellu-
lar	metabolism.	When	labelled	with	123I,	it	can	be	used	to	visualize	adrenergic	receptors	
in	the	myocardium	using	scintigraphic	imaging.155 At present, cardiac 123I-mIBG	imaging	
has	mainly	been	used	 for	prognostification	of	patients	with	heart	 failure.	 In	a	pooled	
analysis,	including	almost	1800	patients	derived	from	8	studies,	a	decreased	late	H/M	
ratio	or	increased	myocardial	123I-mIBG	washout	was	associated	with	a	worse	outcome	
compared	to	patients	with	normal	123I-mIBG	scintigraphy	parameters.156	In	patients	with	
diabetic	neuropathy	and/or	CAN,	Ziegler	et	al	 investigated	prospectively	 the	effect	of	
glycemic	control	on	myocardial	sympathetic	innervation	using	123I-mIBG	scintigraphy,	at	
baseline and at 4 year follow-up.157	Among	the	patients	with	a	poorly	controlled	HbA1c,	
(mean	≥7.6%)	123I-mIBG	uptake	deteriorated	after	4	years.	
Conversely, Schnell and co-workers reported that global and regional 123I-mIBG	uptake	
in	22	asymptomatic	patients	with	type	1	insulin-dependent	diabetes	did	neither	signifi-
cantly regress nor progress on average 123I-mIBG	uptake	over	3	year	follow-up.	These	re-
sults suggested hat CAN seemed to be a persistent phenomenon in intensive treated dia-
betic	patients.158	Recently,	Nagamachi	et	al	 investigated	retrospectively	the	 long-term	
(mean	7.2	±	3.2	years)	prognostic	value	of	123I-mIBG	scintigraphy	for	both	cardiac	events	
and	mortality	in	144	patients	with	type	2	diabetes	and	normal	myocardial	perfusion.131 
A	decreased	delayed	H/M	ratio	(<1.7)	was	an	independent	predictor	of	long-term	mor-
tality.	A	combination	of	123I-mIBG	scintigraphy	parameters	(delayed	H/M	ratio	<1.7,	WR	
>25%)	and	HRV	was	independently	predictive	of	cardiac	events.	
Previous data have suggested that 123I-mIBG	scintigraphy	may	be	more	sensitive	than	
HRV	for	detection	of	CAN	in	diabetic	subjects.137, 157 Schnell and colleagues demonstrat-
ed	that	14	(93%)	of	15	diabetic	patients	without	CAN	according	to	HRV	had	an	abnormal	
123I-mIBG	study.137 
The	role	of	CAN	in	asymptomatic	diabetic	patients	has	been	described	by	Valensi	et	al.159 
In	this	study,	75	patients	with	at	 least	two	cardiovascular	risk	factors,	were	evaluated	
for	silent	myocardial	ischemia	and	CAN	with	a	3-7	years	follow-up	period.	Eleven	(15%)	
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patients	had	a	major	cardiovascular	event	and	multivariate	analysis	demonstrated	that	
CAN	was	a	better	predictor	of	major	cardiac	events	than	silent	myocardial	ischemia.	Fur-
thermore,	Langer	et	al	investigated	CAN	according	to	HRV	and	123I-mIBG	scintigraphy	in	
23	normal	subjects	and	65	asymptomatic	patients	with	diabetes	type	2	and	silent	myo-
cardial ischemia.160 The authors showed that 123I-mIBG	uptake	was	largely	diminished	
in	diabetic	patients,	especially	in	those	with	clinically	detectable	CAN;	moreover	diffuse	
abnormalities	in	123I-mIBG	uptake	were	observed	in	patients	with	silent	myocardial	isch-
emia. 
In	 the	present	 study,	we	performed	a	 systematic,	head-to-head	comparison	between	
HRV	and	 123I-mIBG	 scintigraphy	 in	 88	 asymptomatic	patients	with	 type	2	diabetes	 to	
evaluate	the	presence	of	CAN.	The	current	study	has	included	much	more	patients	than	
the	previous	studies,	but	although	the	inclusion	criteria	were	different,	our	results	are	
in	 line	with	 previous	 reports	 observing	 a	 significantly	 higher	 proportion	 of	 CAN	with	
123I-mIBG	scintigraphy	compared	to	HRV.137, 161, 162	The	fact	that	more	patients	exhibit	
abnormalities	in	123I-mIBG	imaging	as	compared	to	HRV,	underscores	the	suggestion	that	
abnormalities	 in	cardiac	 sympathetic	 innervation	occur	prior	 to	ECG-based	 (HRV)	car-
diac	autonomic	dysfunction.137	An	alternative	explanation	is	that	123I-mIBG	scintigraphy	
mainly	reflects	sympathetic	innervation,	whereas	HRV	may	be	more	related	to	parasym-
pathetic	function.163 It remains to be determined which of these two parameters may be 
more useful to predict long-term outcome.
While	HRV	and	other	traditional	parameters	provide	an	impression	of	global	innervation	
abnormalities,	123I-mIBG	scintigraphy	with	SPECT	provides	 information	on	regional	 in-
nervation.	The	findings	in	the	current	study	indicated	that	regional	abnormalities	occur	
often	in	patients	with	asymptomatic	diabetes.	Other	studies	using	123I-mIBG	scintigraphy,	
in	populations	with	varying	cardiovascular	diseases,	have	also	shown	regional	innerva-
tion	abnormalities.137, 161, 162, 164	For	example,	Langer	et	al	evaluated	65	diabetic	patients	
and	noted	significantly	impaired	123I-mIBG	uptake	in	the	inferior	wall	and	apex.160 Ad-
ditional	studies	have	shown	that	abnormalities	in	CAN	tend	to	occur	first	in	the	inferior	
regions of the myocardium and then progressively spread to adjacent segments.165, 166 
It	may	well	are	that	these	regions	of	reduced	innervation	may	be	more	prone	to	cardiac	
arrhythmias, but this remains to be determined. 
It is noteworthy that reduced 123I-mIBG	uptake	has	also	been	reported	(to	a	lesser	ex-
tent)	in	normal	subjects	and	was	related	to	attenuation	artefacts;	although	we	did	not	
correct	for	attenuation	in	the	current	study,	only	individuals	with	normal	SPECT	perfu-
sion	studies	were	included,	which	reduces	the	likelihood	of	attenuation	artefacts.167
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Clinical implications
Diabetic	CAN	 is	 a	 serious	and	common	complication	of	diabetes.	 It	 is	 related	 to	an	 in-
creased	risk	of	cardiovascular	mortality	and	morbidity.	Therefore,	early	detection	of	CAN	
in	diabetic	patients	is	of	importance	for	appropriate	risk	stratification.	Of	all	established	
diabetes-related	and	cardiac	risk	factors	in	patients	with	asymptomatic	diabetes,	poor	gly-
cemic control is of great importance in the development and progression of CAN.157, 165 
At	 the	same	time,	poor	glycemic	control	 is	associated	with	poor	outcome.168 Accord-
ingly,	early	detection	of	CAN	is	of	utmost	importance.	As	observed	in	the	current	study,	
123I-mIBG	scintigraphy	appears	more	sensitive	than	HRV	to	detect	CAN	in	asymptomatic	
diabetic	 patients,	without	myocardial	 perfusion	 abnormalities;	 identification	of	 these	
patients	may	permit	risk	factor	modification,	and	intensive	medical	treatment,	aiming	
at	better	glycemic	control,	which	in	turn	may	favourably	affect	outcome.169-172 Indeed, 
several	 studies	have	 shown	 that	 improvement	of	 CAN	 (as	 evidenced	by	HRV)	 can	be	
achieved by weight loss with regular exercise.173, 174	Furthermore,	progression	of	CAN	
can also be delayed by intensive medical therapy, thereby reducing the risk of premature 
mortality.175
Conclusion
The	poor	long-term	prognosis	of	asymptomatic	diabetic	patients	and	CAN	justifies	early	
risk	stratification.	In	the	current	head-to-head	comparison	between	123I-mIBG	scintigra-
phy	and	HRV,	123I-mIBG	scintigraphy	identified	significantly	more	patients	with	CAN	as	
compared	 to	HRV.	These	findings	 suggest	 that	 123I-mIBG	myocardial	 scintigraphy	may	
be	 suited	 for	early	detection	of	CAN.	Prospective	studies	are	needed	 to	evaluate	 the	
prognostic	value	of	123I-mIBG	myocardial	scintigraphy	in	asymptomatic	diabetic	patients.
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summary
Diabetes	mellitus	 (DM)	 is	 an	endocrine	disease	and	primarily	defined	by	 the	 level	of	
hyperglycaemia.	The	prevalence	of	this	disease	is	high	and	is	still	increasing.	Ninety	per-
cent	of	all	diabetic	patients	have	DM	type	2.	Cardiovascular	disease	is	one	of	the	most	
important	complications	of	DM,	and	 the	prognosis	of	patients	with	DM	 is	mainly	de-
pendent	on	the	presence	of	coronary	artery	disease	(CAD).	In	patients	with	DM	type	2,	
CAD	is	often	in	an	advanced	state	but	asymptomatic.	These	asymptomatic	patients	with	
DM	type	2	have	an	increased	risk	for	cardiovascular	morbidity	and	mortality,	and	early	
identification	of	these	patients	is	important.	In	this	thesis,	we	evaluated	the	value	of	dif-
ferent	cardiac	imaging	techniques	for	risk	stratifying	in	asymptomatic	patients	with	DM	
type	2.	The	general	introduction	of	this	thesis	(chapter 1)	provides	an	overview	of	the	
prevalence	of	DM,	its	complications	and	the	background	of	different	noninvasive	imag-
ing	modalities	that	are	used	for	risk	stratifying	these	patients.	Moreover,	the	outline	and	
the aims of this thesis are described. In chapter 2,	we	focused	on	the	potential	role	of	
stress	myocardial	perfusion	imaging	(MPI)	and	computed	tomography	coronary	artery	
calcium	(CAC)	scoring	as	two	complementary	approaches	for	screening	asymptomatic	
patients	with	DM	type	2.	Recent	studies	suggested	a	relatively	low	prevalence	of	silent	
CAD	as	evidenced	by	abnormal	MPI.	However,	with	increasing	severity	of	CAC	scores,	the	
prevalence	and	severity	of	stress-induced	MPI	abnormalities	increased.	We	proposed	an	
algorithm	for	the	screening	of	asymptomatic	diabetic	patients,	in	which	depending	on	
the	CAC	score	and	specific	patient	characteristics,	stress	MPI	may	be	justified.	In	chapter 
3, we	prospectively	assessed	for	the	presence	of	silent	CAD	in	asymptomatic	patients	
with	DM	 type	 2	 by	 single	 photon	 emission	 computed	 tomography	 (SPECT)	MPI,	 CAC	
scoring,	and	multislice	computed	tomography	(MSCT)	coronary	angiography.	We	con-
cluded	that	different	imaging	modalities	visualized	different	aspects	of	silent	coronary	
atherosclerosis.	 Anatomical	 evidence	 of	 coronary	 atherosclerosis	 (as	 determined	 by	
CAC	and	MSCT)	occurred	more	frequently	than	functional	evidence	of	ischemia	(stress	
SPECT).	However,	 clinically	 significant	manifestations	of	 CAD	were	observed	 in	 about	
one-quarter	 to	one-fifth	of	patients	by	each	 imaging	modality,	either	separately	or	 in	
combination.	 The	 purpose	 of	 the	 study	 in	 chapter 4 was to evaluate the prevalence 
of	CAD	as	well	as	plaque	morphology	in	asymptomatic	patients	with	DM	type	2	using	
MSCT.	 In	 addition,	 the	 relation	between	CAC	 score	 and	MSCT	findings	was	explored.	
MSCT	coronary	angiography	detected	a	high	prevalence	of	CAD	(80%),	of	which	a	rela-
tively	high	proportion	of	plaques	were	noncalcified	(41%).	Importantly,	a	CAC	score	<10	
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AU	did	not	exclude	the	presence	of	CAD	in	these	patients.	In	chapter 5, the prevalence 
of	an	abnormal	stress	MPI	by	means	of	SPECT	in	a	cohort	of	truly	asymptomatic	patients	
DM	type	2	was	evaluated.	We	also	determined	which	clinical	characteristics	may	predict	
an	abnormal	stress	myocardial	perfusion	study	in	this	population.	The	study	revealed	a	
high	prevalence	(33%)	of	abnormal	stress	MPI	studies.	In	contrast	to	previous	studies,	
current	smoking	status,	duration	of	DM	type	2	and	cholesterol/HDL	ratio	were	identified	
as independent predictors of an abnormal stress MPI study. In chapter 6, we described a 
case	report	of	a	patient,	who	suffered	a	silent	myocardial	infarction,	despite	early	identi-
fication	of	coronary	atherosclerosis,	followed	by	risk	factor	modification	and	aggressive	
medical therapy. The aim of the study described in chapter 7 was to evaluate whether 
subclinical	 left	ventricular	 systolic	dysfunction	was	 independently	 related	 to	 coronary	
atherosclerosis	and	if	it	provided	incremental	information	over	baseline	characteristics	
to	identify	patients	with	coronary	atherosclerosis.	Compared	to	patients	without	athero-
sclerosis,	 diabetic	 patients	 with	 coronary	 atherosclerosis	 showed	 an	 impaired	 global	
left	 ventricular	 strain.	 The	 presence	of	 subclinical	 left	 ventricular	 systolic	 dysfunction	
provided	significant	 incremental	value	 for	 the	 identification	of	patients	with	coronary	
atherosclerosis. The purpose of the study in chapter 8 was to evaluate the prevalence 
of	cardiac	autonomic	neuropathy	(CAN)	in	patients	with	DM	type	2,	using	heart	rate	vari-
ability	(HRV)	and	123I-metaiodobenzylguanidine	(123I-mIBG)	myocardial	scintigraphy.	The	
study	revealed	a	high	prevalence	of	CAN	in	patients	DM	type	2.	In	addition,	123I-mIBG	
scintigraphy	was	more	sensitive	than	HRV	for	the	assessment	of	CAN.
Conclusions and future perspectives
In	this	thesis,	we	evaluated	several	different	cardiac	imaging	techniques	for	risk	stratify-
ing	asymptomatic	patients	with	DM	type	2.	We	concluded	that	different	 imaging	mo-
dalities	 visualized	 different	 aspects	 of	 silent	 coronary	 atherosclerosis,	 and	 anatomic	
presence	of	coronary	atherosclerosis	by	CAC	and	MSCT	occurred	more	frequently	than	
functional	evidence	of	ischemia	by	stress	MPI	SPECT.
Secondly,	a	relatively	high	proportion	(40%)	of	the	plaques	identified	was	noncalcified	
calcified,	and	a	CAC	score	<10	AU	did	not	exclude	atherosclerosis.	
Moreover,	several	independent	predictors	for	an	abnormal	stress	MPI	were	identified.	
Furthermore,	 in	asymptomatic	patients	with	DM	type	2	and	coronary	atherosclerosis,	
subclinical	 left	ventricular	dysfunction	 reflected	by	an	 impaired	global	 left	ventricular	
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strain	proved	to	be	of	incremental	value	for	identifying	coronary	atherosclerosis.	Finally,	
123I-mIBG	myocardial	scintigraphy	seemed	to	be	a	more	sensitive	method	to	detect	dia-
betic	cardiovascular	autonomic	neuropathy	compared	to	heart	rate	variability.
The	prognostic	value	of	all	these	cardiac	imaging	techniques	for	risk	stratification	of	as-
ymptomatic	patients	with	DM	 type	2	will	 be	determined	 in	 future	 follow-up	 studies.	
However,	one	has	to	realize	that	all	these	different	cardiac	imaging	techniques,	visualize	
different	aspect	of	cardiac	disease.	Of	course,	also	the	costs	of	all	these	techniques	must	
be	taken	into	account.	The	challenge	is	to	risk	stratify	diabetic	patients	to	identify	those	
at	 increased	risk	for	cardiovascular	morbidity	and	mortality.	For	this	purpose,	 integra-
tion	of	the	different	imaging	modalities	may	be	most	beneficial.	If	eventually,	adequate	
treatment	of	that	patient	will	indeed	lead	to	an	improved	outcome,	must	be	clarified	in	
future studies.
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Diabetes	 mellitus	 (suikerziekte)	 is	 een	 stofwisselingsziekte,	 die	 gekenmerkt	 wordt	
door te hoge waardes van het suikergehalte in het bloed. Het is een veel voorkomend 
ziektebeeld	 en	 de	 prevalentie	 neemt	 nog	 steeds	 toe.	Het	merendeel	 (90%)	 van	 de	
patiënten	met	diabetes	mellitus	heeft	diabetes	mellitus	type	2,	ook	wel	ouderdoms-
suiker	 genoemd.	Hart-	 en	 vaatziekten	 zijn	 de	belangrijkste	 gevolgen	 van	dit	 ziekte-
beeld.	De	 levensverwachting	van	patiënten	met	diabetes	mellitus	wordt	 vooral	 be-
paald	door	aderverkalking	van	de	kransslagaders	 (coronairlijden).	Coronairlijden	bij	
patiënten	met	diabetes	mellitus	verloopt	vaak	zonder	symptomen	(asymptomatisch).	
Het	 identificeren	van	deze	asymptomatische	patiënten	met	diabetes	mellitus	 is	be-
langrijk, omdat er voor hen een verhoogd risico bestaat op het krijgen van hart- en 
vaatziekten.	Diverse	beeldvormingstechnieken	van	het	hart,	kunnen	gebruikt	worden	
voor	deze	 risicostratificatie.	 In	dit	 proefschrift	wordt	de	 rol	 bestudeerd	 van	diverse	
beeldvormingstechnieken,	die	gebruikt	kunnen	worden	voor	risicostratificatie	in	een	
groep	van	asymptomatische	patiënten	met	diabetes	mellitus	type	2.	 In	hoofdstuk 1 
van	 dit	 proefschrift	 wordt	 een	 overzicht	 gegeven	 van	 de	 prevalentie	 van	 diabetes	
mellitus	 type	2,	de	gevolgen	hiervan	en	achtergrondinformatie	over	de	verschillen-
de	beeldvormingstechnieken	die	gebruikt	worden	voor	risicostratificatie	 in	deze	pa-
tiëntengroep.	hoofdstuk 2	beschrijft	de,	 in	de	 literatuur	gevonden,	prevalentie	van	
zuurstoftekort	 (ischemie)	 van	 de	 hartspier	 (myocard)	 tijdens	 inspanning,	 gemeten	
met	behulp	van	myocardperfusie	 scintigrafie.	Met	deze	 techniek	wordt	met	behulp	
van	radioactief	materiaal,	de	zuurstofopname	van	de	hartspier	tijdens	rust	en	inspan-
ning	in	beeld	gebracht.	Dit	is	een	indirecte maat voor de ernst van het coronairlijden. 
Coronairlijden kan direct	 in	beeld	gebracht	worden	met	de	multislice	 computer	 to-
mografie	 (MSCT)	 scan.	Hierbij	wordt	o.a.	gebruik	gemaakt	van	de	calciumscore.	De	
calciumscore is een maat is voor verkalking van de kransslagaders. Uit bestudering van 
de	 literatuur,	 blijkt	 dat	myocardischemie,	 gemeten	met	perfusiescintigrafie,	 relatief	
weinig	voorkomt.	Echter,	de	prevalentie	van	myocardischemie	blijkt	toe	te	nemen,	in-
dien	de	patiënt	een	hogere	calciumscore	heeft.	Naar	aanleiding	van	deze	bevindingen	
wordt	een	algoritme	voor	het	screenen	van	asymptomatische	patiënten	met	diabetes	
mellitus type 2 voorgesteld. hoofdstuk 3	beschrijft	een	groep	patiënten,	waarin	met	
behulp	van	myocardperfusie	scintigrafie,	de	calciumscore	en	niet-invasieve	coronair	
angiografie	verschillende	aspecten	van	coronairlijden	in	kaart	werden	gebracht.	Ana-
tomisch bewijs voor coronairlijden met de calciumscore en niet-invasieve coronair 
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angiografie,	bleek	vaker	voor	te	komen	dan	myocardischemie	tijdens	inspanning.	Kli-
nisch relevant coronairlijden werd met de 3 verschillende technieken apart of gecom-
bineerd	in	20	tot	25%	gezien.	Het	doel	van	het	onderzoek	beschreven	in	hoofdstuk 4 
was	om	met	behulp	van	de	MSCT	scan	allereerst	de	prevalentie	van	coronairlijden	te	
onderzoeken	in	asymptomatische	patiënten	met	diabetes	mellitus	type	2.	Vervolgens	
is	de	samenstelling	van	de	atherosclerotische	plaques	die	tot	een	vernauwing	leiden	
in	de	kransslagaders	bestudeerd.	Daarnaast,	 is	de	relatie	tussen	de	calciumscore	en	
de	samenstelling	van	de	vernauwing	geëvalueerd.	Er	bleek	sprake	te	zijn	van	een	hoge	
prevalentie	(80%)	van	coronairlijden	in	deze	specifieke	groep	van	patiënten.	Een	rela-
tief	hoog	percentage	(41%)	van	de	vernauwingen	bleek	geen	kalk	te	bevatten.	Belang-
rijk om te noemen is, dat een lage calciumscore, een vernauwing van de kransslagader 
niet	altijd	uitsloot.	
hoofdstuk 5	 beschrijft	een	 studie,	waarbij	de	prevalentie	van	een	afwijkende	myo-
cardperfusie	scintigrafie	werd	onderzocht.	Vervolgens	is	er	ook	gekeken	of	er	bepaalde	
patiënten	kenmerken	konden	worden	vastgesteld,	die	voorspellend	waren	voor	een	
afwijkende	myocardperfusie	scintigrafie.	 In	deze	patiëntengroep,	bleek	er	een	hoge	
prevalentie	te	zijn	van	afwijkende	perfusie	scans.	In	tegenstelling	tot	eerdere	studies	
bleek	roken,	de	duur	van	diabetes	mellitus	en	de	verhouding	cholesterol/HDL	onaf-
hankelijke	voorspellers	te	zijn	voor	een	afwijkend	onderzoek.	hoofdstuk 6	beschrijft	
een	casus,	waarbij	ondanks	het	vroegtijdig	vaststellen	van	coronairlijden,	adequate	
aanpak	 van	 de	 risicofactoren	 en	 het	 instellen	 van	medicatie,	 een	hartinfarct	wordt	
doorgemaakt	 zonder	klachten.	 In	hoofdstuk 7 worden de resultaten gepresenteerd 
van	metingen	van	de	 linker	kamerfunctie	van	het	hart	met	ultrageluid	(echo).	 In	de	
patiënten	werd	met	behulp	van	echocardiografie,	vervorming	(strain)	van	de	linker	ka-
mer	hartspier	gemeten.	Het	bleek	dat	in	patiëntengroep	met	diabetes	mellitus	type	2	
en	coronairlijden,	de	strain	verlaagd	is	ten	opzichte	van	de	groep	patiënten	zonder	co-
ronairlijden. In hoofdstuk 8	werd	geïnventariseerd,	wat	de	prevalentie	van	autonome	
dysfunctie	van	het	hart	in	de	patiëntengroep	is.	Autonome	dysfunctie	betekent	dat	de	
zenuwen,	die	het	hart	aansturen,	niet	goed	functioneren.	Dit	kan	worden	vastgesteld	
door	het	meten	van	de	variatie	in	hartritme	en	in	beeld	worden	gebracht	met	behulp	
van 123I- gelabeld mIBG.	Ondanks	het	feit	dat	autonome	dysfunctie	van	het	hart	vaak	
wordt gemeten, leek 123I-mIBG	scintigrafie	een	gevoeligere	methode	te	zijn,	voor	het	
vastleggen	van	autonome	dysfunctie	van	het	hart	bij	asymptomatische	patiënten	met	
diabetes mellitus type 2.
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Conclusies en toekomstperspectief
In	dit	proefschrift	werd,	met	behulp	van	verschillende	beeldvormingstechnieken	van	het	
hart,	getracht	om	tot	een	inschatting	van	het	risico	van	asymptomatische	patiënten	met	
diabetes	mellitus	 type	2	 te	 komen.	Uit	het	onderzoek	bleek	onder	meer,	dat	 in	deze	
patiëntengroep	met	de	verschillende	beeldvormingstechnieken,	verschillende	aspecten	
van	asymptomatisch	coronairlijden	 in	kaart	konden	worden	gebracht.	Anatomisch	be-
wijs	 voor	 coronairlijden	 (calciumscore	en	niet-invasieve	 angiografie)	bleek	 vaker	 voor	
te	 komen	dan	 functioneel	bewijs	 van	 coronairlijden	 (myocardperfusie	 scintigrafie).	 Er	
kon	worden	geconstateerd,	dat	in	80%	van	deze	patiëntenpopulatie,	met	de	MSCT	scan	
anatomisch	bewijs	voor	coronairlijden	werd	gezien.	In	40%	van	de	kransslagaders	met	
atherosclerose,	werden	niet-verkalkte	vernauwingen	gezien.	Belangrijk	om	te	vermel-
den	hierbij	is,	dat	een	lage	calciumscore,	coronairlijden	niet	altijd	uitsloot.
Daarnaast	is	het	mogelijk	geweest	om	onafhankelijke	factoren	te	identificeren	voor	een	
afwijkend	myocard	perfusiescintigrafie	onderzoek.	Met	behulp	van	het	meten	van	de	
strain	 van	 de	 linker	 kamerfunctie,	 konden	 binnen	 deze	 patiëntengroep,	 de	 patiënten	
met	 coronairlijden	worden	 geïdentificeerd.	 Tenslotte,	 bleek	 dat	 123I-mIBG	 scintigrafie	
een	gevoeligere	methode	was	voor	het	opsporen	van	autonome	dysfunctie	van	het	hart,	
dan	het	meten	van	de	variabiliteit	 in	het	hartritme.	De	voorspellende	waarde	van	bo-
vengenoemde	beeldvormingstechnieken	voor	het	inschatten	op	een	cardiaal	risico	van	
asymptomatische	patiënten	met	diabetes	mellitus	type	2,	zal	moeten	worden	bepaald	in	
follow-up	studies.	Men	dient	zich	echter	wel	realiseren,	dat	elke	beeldvormingstechniek	
een	specifiek	aspect	van	het	hart	in	kaart	brengt.	Hierbij	moet	uiteraard	ook	rekening	
worden	gehouden	met	de	kosten	die	elk	onderzoek	met	zich	meebrengt.	Mogelijk	is	in-
tegratie	van	de	diverse	beeldvormingstechnieken	de	beste	strategie.	Uiteindelijk	zal	met	
een combinatie van de bovengenoemde beeldvormingstechnieken die	patiënt	moeten	
worden	geïdentificeerd,	die	een	aanzienlijk	hoger	risico	op	een	toekomstig	myocardin-
farct	heeft.	
Of	uiteindelijk	adequate	behandeling	van	die	patiënt	 tot	een	verbeterde	uitkomst	 zal	
leiden,	moet	worden	verhelderd	in	toekomstige	studies.
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Dankwoord
Op	de	allereerste	plaats	wil	ik	alle	patiënten	bedanken	die	vanuit	van	het	Medisch	Cen-
trum	Haaglanden	 (Diabetes	Zorg	Haaglanden)	werden	verwezen	naar	het	 LUMC	voor	
diagnostiek	naar	stille	myocardischemie.	Zij	waren	gemotiveerd	en	bereid	om	meerdere	
malen	vanuit	Den	Haag	en	omstreken	naar	Leiden	te	reizen	en	diverse	onderzoeken	te	
ondergaan.	Dit	was	 niet	mogelijk	 geweest	 zonder	 de	uitstekende	 samenwerking	met	
collega	Antje	Kharagjitsingh,	internist	in	het	Diabetes	Centrum.	Hoewel	we	elkaar	niet	
vaak	hebben	gezien,	was	het	contact	via	de	email	uitstekend	en	heeft	dit	tot	een	mooi	
onderzoek	geleid.
Multimodality	imaging	is	alleen	mogelijk	met	meerdere	afdelingen	en	mensen.	Zonder	
iemand te kort te doen, wil ik een aantal mensen persoonlijk bedanken.
De	collega’s	van	de	afdeling	Hartziekten.	De	echolaborantes	en	de	secretaresses	van	de	
functie	afdeling	en	polikliniek	voor	het	plannen	van	de	echo’s	en	poli	afspraken.
De	medewerkers	van	SEAL,	 in	het	bijzonder	Arie	Maan,	hartelijk	dank	voor	het	analy-
seren van de Holters en het begeleiden van de studenten.
De	studenten	Jurriaan	Kok	en	Mieke	Bus,	voor	het	begeleiden	van	de	patiënten	door	het	
ziekenhuis	en	het	uitvoeren	van	de	hartritme	variabiliteit	onderzoeken	bij	de	patiënten.
Alle	medewerkers	van	de	afdeling	Nucleaire	Geneeskunde.	De	secretaresses,	voor	de	
planning	van	de	diverse	onderzoeken.	De	nucleair	geneeskundigen	en	laboranten	voor	
de	prettige	samenwerking	tussen	de	afdeling	Hartziekten	en	de	Nucleaire	Geneeskunde.
De	paranimfen,	Hans-Marc	Siebelink	en	Márton	Vidra	wil	ik	hartelijk	danken	voor	hun	
steun	en	hulp	tijdens	het	promotietraject.
Edgar	en	Thea,	als	schoonouders	van	een	Hollander	valt	het	voor	jullie	niet	altijd	mee.	
Echter,	jullie	zuidelijke	liefde	voor	ons	en	de	kinderen	is	geweldig.
Madelon	en	Rob,	hoewel	economen	niet	veel	begrijpen	van	de	manier	van	werken	van	
medici	en	vice	versa,	vind	ik	het	fijn	dat	jullie	er	vandaag	bij	zijn.	
Lieve	pap	en	mam,	jullie	hebben	me	altijd	onvoorwaardelijk	met	liefde	gesteund	en	ge-
holpen	met	alles	wat	ik	doe.	Hopelijk	kunnen	jullie	ook	vandaag	weer	trots	zijn.
Lieve	Cacha,	 traditiegetrouw	 staat	het	belangrijkst	 van	een	proefschrift	op	de	 laatste	
regels.	Het	viel	niet	altijd	mee,	alles	bij	elkaar.	Tweemaal	verhuizen,	verbouwen,	drie	
kinderen,	twee	banen	en	dienstroosters	en	ja,	ook	nog	een	proefschrift.	Echter,	samen	
met	jou,	Julie,	Beer	en	Faye	ben	ik	het	gelukkigst.	Daarom	stelde	ik	het	schrijven	wel	eens	
uit.	Want	er	is	maar	één	ding	belangrijk	in	mijn	leven	en	dat	zijn	jullie.	
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De	auteur	van	dit	proefschrift	werd	geboren	op	11	december	1968	te	Mook	en	Mid-
delaar.	Na	het	behalen	 van	het	VWO	examen	 in	 1987	aan	het	Bonhoeffer	College	 te	
Castricum	startte	hij	met	de	studie	Tandheelkunde.	Een	jaar	later	begon	hij	met	de	studie	
Geneeskunde	aan	de	Vrije	Universiteit	te	Amsterdam,	waar	hij	in	1995	het	artsexamen	
behaalde.	Tijdens	de	opleiding	geneeskunde	verrichtte	hij	wetenschappelijk	onderzoek	
op	het	gebied	van	de	cardiologie	in	Mainz,	Duitsland,	bij	Prof.dr.	R.	Erbel	en	in	New	York,	
Verenigde	Staten,	bij	Dr.	 J.	Machac.	De	vooropleiding	 interne	geneeskunde	werd	ver-
richt	 in	het	Gooi-Noord	ziekenhuis	te	Blaricum	(1998-2000,	opleider	Dr.	P.	Niermeyer)	
en	de	opleiding	tot	cardioloog	in	het	Onze	Lieve	Vrouwe	Gasthuis	te	Amsterdam	(2001-
2003,	opleider	Dr.	G.J.	Laarman)	en	het	Leids	Universitair	Medisch	Centrum	(2004-2005,	
opleider	Prof.dr.	E.E.	van	der	Wall).	Sinds	2005	is	hij	staflid	van	de	afdeling	Hartziekten	
van het Leids Universitair Medisch Centrum met als aandachtsgebied niet-invasieve car-
diale	beeldvorming	(echocardiografie	en	nucleaire	cardiologie).	Het	promotieonderzoek	
werd	verricht	in	de	periode	2005-2009	op	de	afdeling	Hartziekten	van	het	LUMC.	

